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NIDOVIRUSES AS EMERGING PATHOGENS: IMPACT AND CHALLENGES
Emerging infections are a major cause of morbidity and mortality world-wide, and 
many pandemics and outbreaks have had an enormous medical, societal and economic 
impact [1]. Emerging infectious diseases are defined by their appearance in a popula-
tion for the first time, or by an existing disease that rapidly increases in incidence or 
geographic range [2]. One of the best-known human pathogens is influenza A virus, 
which is responsible for the seasonal flu epidemics causing approximately 250,000 to 
500,000 deaths annually [3]. In addition, highly pathogenic strains do emerge regularly. 
Examples were the viruses causing the 1918 Spanish Flu, the 1957 Asian flu, the 1968 
Hong Kong flu and the 2009 swine flu pandemics, which highlighted the severity and 
global effects that virus outbreaks can have on society. Human immunodeficiency virus 
(HIV) is a well-known example of a virus that had a disastrous impact on society and 
still is a major health problem in developing countries, causing an estimated 1.7 billion 
deaths in 2011 [4]. In addition, hepatitis C virus (HCV) infection has been called the silent 
epidemic since about 130 million individuals worldwide are estimated to be chronically 
infected, and more than 350,000 people die each year from HCV-related liver disease. 
About 27% of all cases of liver cirrhosis and hepatocellular carcinomas are attributed to 
HCV infection [5].
Between November 2002 and July 2003, an outbreak of a previously unknown severe 
acute respiratory syndrome (SARS) occurred in Southern China and Hong Kong. Acceler-
ated by air travel, the disease rapidly spread to several parts of the world and nearly 
became a pandemic. SARS-coronavirus (SARS-CoV) was identified as the causative agent 
of this zoonotic infection [6-8], for which >8,000 cases and 774 deaths were reported 
worldwide [9]. Although in death toll not comparable to influenza, HIV or HCV, the 2003 
SARS-CoV outbreak caused worldwide unrest and had a serious impact on global econ-
omy (estimated losses $ 30-100 billion; [10]). SARS-CoV initially causes lower respiratory 
tract disease, which can lead to a progressive and potentially lethal atypical pneumonia 
with clinical symptoms that include fever, malaise, lymphopenia, and in some cases also 
diarrhoea. Two years after the outbreak, horse-shoe bats were identified as the likely 
source of the SARS virus, which is believed to have been transferred to humans via the 
civet cat as intermediate host [11, 12]. Apparently, adaptation to the human host pre-
dominantly required a small number of mutations in the receptor-binding domain of 
the SARS-CoV spike (S) protein, which mediates cell binding and entry [13]. Therefore, 
the re-emergence of SARS-CoV or zoonotic transfer of other animal coronaviruses to 
humans remains a serious public health concern.
Almost a decade after the SARS-CoV outbreak the fear for the emergence of the 
next highly pathogenic coronavirus has become a painful reality. In June 2012 a novel 







[14], was isolated from a 60 year-old Saudi Arabian male who died from acute respira-
tory distress syndrome (ARDS) and multiple organ failure, including renal failure [15, 
16]. MERS-CoV can cause a lower respiratory tract infection with symptoms that include 
coughing and high fever. Up to August 2013, 94 confirmed MERS-CoV cases have been 
recorded, of which 46 were fatal [17], and new cases continue to be reported regularly. 
The majority of fatalities involved patients with underlying diseases, and the reported 
case fatality rate of about 50% might be an overestimation (due to underreporting of 
milder or asymptomatic cases). Initially, most MERS-CoV cases were attributed to iso-
lated zoonotic transmissions, although the evidence for human-to-human transmission 
is increasing as several (secondary) MERS-CoV infections have now been documented, 
involving patients that had not travelled to the Arabian Peninsula. A number of small 
clusters of MERS have been reported in the UK, Jordan, Italy, Tunisia, Saudi-Arabia and 
France. However, transmission seems inefficient and does not appear to have extended 
beyond these small clusters that, thus far, have all occurred in health care settings or 
among close family contacts. Although the hunt for the natural reservoir of the virus is 
still ongoing, the close relatedness to multiple bat coronaviruses and the ability of the 
virus to efficiently replicate in bat cell lines make bats the most likely natural animal res-
Fig. 1 –  RNA polymerase-based nidovirus phylogenetic tree. To infer phylogenetic relationships be-
tween nidoviruses, partially constrained trees were calculated using the nidovirus-wide conserved RNA-
dependent RNA polymerase (RdRp) domain. Picornaviruses were used as a domain-specific out group. 
Courtesy of Dr. Chris Lauber and Prof. Alexander E. Gorbalenya, Leiden University Medical Center, The 
Netherlands. Reprinted with permission from [26].
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ervoir [16, 18]. However, other animals, like camels, have been mentioned as potential 
(intermediate) host or reservoir as well. 
Besides the highly pathogenic SARS-CoV and MERS-CoV, which received consider-
able scientific and media attention over the past decade, two established human 
coronaviruses - HCoVs OC43 and 229E - have been known since the 1960s. These viruses 
cause mild respiratory disease and, after rhinoviruses, are a leading cause of common 
colds (10-30% of the cases) [19-21]. More recently, two additional coronaviruses have 
been discovered in humans, HCoV-NL63 [22] and HCoV-HKU1 [23]. Interestingly, recent 
findings suggest that all established human coronaviruses originate from zoonotic 
transfer from bats [24]. 
Coronaviruses are not only known as important human pathogens, also a number of 
severe veterinary diseases have been linked to coronavirus infection. This is illustrated 
by the recent emergence of a novel variant of porcine epidemic diarrhoea virus, which is 
closely-related to a strain that caused a large outbreak killing almost one million piglets 
in China in 2010. Mortality among pigs younger than four weeks has commonly been 
over 50% and more than 100 cases have been reported since May 2013 in the USA alone 
[25].
The coronaviruses, together with arteri-, mesoni- and roniviruses, are grouped in 
the order Nidovirales (Fig. 1). Besides coronaviruses, this order includes the distantly 
related arterivirus family, which includes some serious veterinary pathogens. Porcine 
reproductive and respiratory syndrome virus (PRRSV), for example, has emerged as the 
most prevalent swine disease in the world, causing an estimated annual loss of $664 
million in the USA alone [27]. The arterivirus EAV, besides being an equine pathogen, 
has been extensively used as a model virus to study nidovirus molecular biology and 
virus-host interactions.
The economic impact of nidovirus infections, the recent emergence of highly 
pathogenic zoonotic coronaviruses, the concerns that new coronaviruses will emerge 
in the future and the lack of effective antiviral strategies make it painfully clear that 
our preparedness and options to treat or prevent diseases caused by these viruses are 
very limited. This highlights the urgency of advancing our knowledge on (the replica-
tion of ) these viruses, which should ultimately contribute to the development of (broad 
spectrum) antiviral strategies to combat infections by known nidoviruses and those that 
might emerge in the future. 
THE NIDOVIRUS REPLICATIVE CYCLE
Nidoviruses belong to the positive-stranded RNA (+RNA) viruses and their genome acts 







Fig. 2 – EAV and SARS-CoV genome organisation. (A, B) Nidovirus genome structure and expression 
strategy, illustrated using EAV (A) and SARS-CoV (B). The open reading frames in the viral genome are indi-
cated at the top of each schematic. Note that the arterivirus and coronavirus genomes are drawn to differ-
ent scales. The names of the replicase gene and structural protein genes are given (see also [41]). Below the 
genome organisation, the structural relationships of the genome and sg mRNAs are depicted. The leader 
sequence and Transcription Regulatory Sequences (TRSs) are indicated as blue and orange boxes, respec-
tively. The ribosomal frameshifting (RFS) element found in the genome-length mRNA1 is indicated and 
green lines mark the translated region of each mRNA, whereas translationally silent regions are indicated 
by red lines. Only the translated ORFs are shown for each mRNA. Reprinted with permission from [40]. (C) 
Domain organisation of the EAV and SARS-CoV replicase pp1ab. Arrows represent sites in pp1ab that are 
cleaved by papain-like proteases (orange and blue) or chymotrypsin-like protease (main protease; MP). The 
cleavage products, the location and names of domains that have been identified are highlighted. They in-
clude diverse domains with conserved Cys and His residues (C/H), putative transmembrane domains (TM), 
domains with conserved features (AC, X and Y), and domains that have been associated with proteolysis 
(PL1, PL2, and MP), RNA-dependent RNA synthesis (RdRp), helicase, exonuclease (ExoN), uridylate-specific 
endoribonuclease, methyl transferase (MT) and cyclic phosphodiesterase activities. Please note that SARS-
CoV and EAV polyproteins are drawn to different scales. Reprinted with permission from [37]. 
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cell’s translational machinery. A typical feature of nidoviruses, and all other +RNA viruses 
(reviewed in [28]), is that their replication takes place in the cytoplasm of the infected 
cell, in association with modified intracellular membranes that presumably form a plat-
form for the assembly of the +RNA viral replication complexes (RCs) that engage in RNA 
synthesis [29-36]. 
Compared to other +RNA viruses, most nidoviruses have exceptionally large ge-
nomes (from 20 to over 30 kilobases (kb)), but arteriviruses form a special lineage (Fig. 
1) with genomes of about 13-16 kb in length [37, 38]. Nidoviruses have a characteristic 
polycistronic genome organisation and employ a unique mechanism of discontinuous 
RNA synthesis to express the ORFs located downstream of the replicase ORF1ab (see Fig. 
2). They generate a nested set (‘nidus’ is Latin for nest) of subgenomic (sg) mRNAs encod-
ing these structural and accessory proteins. The sg mRNAs are 3’ co-terminal but they 
also contain a common 5’ leader sequence. The leader and “body” segments of the sg 
RNAs are joined during discontinuous negative strand RNA synthesis, which produces a 
sg-length template for each of the sg mRNAs [39, 40]. 
The nidovirus replicative cycle (see Fig. 3) starts with the translation of the viral 
genome by host ribosomes, which results in the expression of two large replicase poly-
proteins (pp1a and pp1ab). Translation of the larger pp1ab from open reading frame 1ab 
(ORF1ab) involves a -1 ribosomal frameshift (RFS) near the 3’ end of ORF1a, a regulatory 
mechanism that probably evolved to ensure lower expression levels of ORF1b-encoded 
proteins compared to ORF1a-encoded nsps [42-44]. To derive the mature replicase 
proteins, the two polyproteins are subsequently processed by virally-encoded papain-
like accessory proteases (PLP1 and/or PLP2) and a chymotrypsin-like main protease 
(MP; also referred to as 3C-like protease) into 13 to 16 non-structural proteins (nsps; or 
collectively referred to as ‘the replicase’) [45-47]. A schematic overview of the EAV and 
SARS-CoV replicase is given in Fig. 2. These replicase subunits contain a variety of (en-
zymatic) activities and functions required for viral RNA synthesis and capping [45, 46], 
like helicase and RNA-dependent RNA polymerase (RdRp) functions. The presence of an 
endoribonuclease, located  in arterivirus nsp11 and coronavirus nsp15, is a conserved 
feature of vertebrate nidoviruses [48], while an exoribonuclease domain was identified 
in most nidoviruses, with the exception of arteriviruses [49]. The latter was postulated to 
promote the fidelity of RdRp-mediated RNA synthesis, since in the case of coronaviruses 
inactivation of ExoN activity resulted in a ~15-fold increase of the error rate during 
viral genome replication. Consequently, this activity was postulated to contribute to a 
primitive form of RNA proofreading [50, 51], although the mechanistic details of ExoN 
function remain to be elucidated.
Nidoviruses encode their own RdRp which is crucial for viral RNA synthesis, as the 
host cell only contains DNA-dependent RNA polymerases that are responsible for the 







and other replicase proteins, together with recruited host cell proteins, form membrane-
associated replication/transcription complexes (RTCs; [52, 53]), which localise to virus-
induced replication structures in the perinuclear region of the infected cell [29-36]. 
Nidovirus infection causes the extensive remodelling of intracellular membranes 
into a structure that has been described as a reticulovesicular network (RVN) of modi-
fied endoplasmic reticulum (ER), which is continuous with its membrane donor and 
includes double-membrane vesicles (DMVs). EAV DMVs are ~100 nm in size, while for 
coronaviruses much larger DMVs have been reported with a diameter of up to 300 nm. 
Fig. 3 - Schematic overview of the nidovirus replicative cycle. Following entry by receptor-mediated 
endocytosis and release of the genome into the cytosol, genome translation yields the pp1a and pp1ab 
replicase polyproteins. Following polyprotein cleavage by multiple internal proteases, the viral nsps as-
semble into a replication/transcription complex (RTC) that engages in minus-strand RNA synthesis. Both 
full-length and subgenome (sg)-length minus strands are produced, with the latter templating the syn-
thesis of sg mRNAs required to express the structural protein genes in the 3′-proximal quarter of the ge-
nome. Ultimately, novel genomes are packaged into nucleocapsids that become enveloped by budding 
from smooth intracellular membranes, after which the new virions leave the cell by following the exocytic 
pathway. See text for more details. Reprinted with permission from [41].
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In the case of coronaviruses, also convoluted membranes (CM) and vesicle packets, ap-
parently arising from the merger of DMVs, were described. On the basis of ultrastructural 
studies, including electron tomography, all these membrane structures were concluded 
to be derived from and continuous with the ER [29, 30]. Nevertheless, other studies have 
suggested late endosomes and autophagosomes [32, 54], or EDEMosomes [55] to be 
the source of these membranes. The membrane association of nidovirus RTCs likely 
provides a scaffold for their assembly, might constitute a suitable environment for RNA 
synthesis, or could play a role in evading the innate immune response [29, 30, 52, 53]. 
Although the role(s) of cellular membranes in nidovirus replication remain(s) far from 
understood, they may shield the viral RNA, in particular double-stranded RNA (dsRNA) 
that is formed as an intermediate of viral replication, from detection by innate immune 
sensors [30]. The modified membrane structures might also play a role in increasing the 
local concentration of (membrane-associated) proteins and other components required 
for efficient replication [56]. The membrane-associated RTCs synthesise a full-length 
negative-stranded RNA that serves as template for genome synthesis. In addition, 
discontinuous RNA synthesis generates a set of negative-stranded sg-length templates 
[39], which serve as templates for sg mRNA synthesis (Fig. 2). Encapsidation of the 
newly synthesised genome by the nucleocapsid (N) protein and assembly by budding 
of nucleocapsids into the lumen of pre-Golgi (ERGIC) compartments is followed by the 
release of infectious virus into the extracellular space via the exocytic pathway [57-59].
NIDOVIRUS-HOST INTERACTIONS
+RNA viruses interact with the infected host cell at many levels during their replicative 
cycle. Thus far, a handful of host cell proteins with a role in virus replication have been 
identified [60-65]. Host factors play a role in virtually all steps of the nidovirus life cycle, 
including viral entry, gene expression, RNA synthesis and virus release. Moreover, host 
factors are targeted or hijacked to modulate host gene expression and antiviral defenc-
es, to create a more suitable environment for viral replication. The interaction with the 
infected host also plays a decisive role in pathogenesis and the outcome of infection. 
This paragraph presents a brief overview of some of the host factors and processes that 
are involved in or affected by nidovirus infection.
The effect of nidovirus infection on the host cell’s translation machinery
Several +RNA viruses were reported to interfere with host protein synthesis to limit the 
translation of cellular mRNAs and favour the synthesis of viral proteins, resulting in the 
most favourable conditions for viral replication and the production of infectious progeny 







cycle, as well as for the host cell to be able to respond to infection by mounting an anti-
viral (innate) immune response. In eukaryotic cells, translation is initiated by formation 
of the heterotrimeric eIF2 complex, which is composed of the regulatory α-subunit, the 
tRNA-binding β-subunit, and a GTP-binding γ-subunit. The eIF2 complex is responsible 
for loading of the 40S subunit with Met-tRNAi, followed by the recruitment of the cap-
binding complex eukaryotic translation initiation factor 4F (eIF4F) to this pre-initiation 
complex. The 43S complex than serves as a scaffold for the binding of several additional 
proteins, including eIF3, to the capped 5’ end of the mRNA. Upon this activation step, the 
43S pre-initiation complex attaches to the mRNA and scans in the 5’ to 3’ direction for 
a translation initiation codon. At this point, the 60S subunit joins and protein synthesis 
starts (reviewed in [67]). Poly(A)-binding protein (PABP), which binds to the poly(A)-tail 
of mRNAs, is also involved in stimulating protein synthesis. 
The eIF2 complex is inactivated by phosphorylation of its alpha subunit (eIF2α). This 
step can be carried out by four mammalian kinases in response to various (external) trig-
gers. These are the PKR-like endoplasmic reticulum kinase (PERK), eukaryotic translation 
initiation factor 2-α kinase 4 (also known as GCN2), heme-regulated inhibitor (HRI), and 
double-stranded RNA-activated protein kinase (PKR). The latter is a serine/threonine 
protein kinase that is activated by dsRNA, a hallmark of viral infection. PKR is a key player 
in the innate immune response to virus infection by inducing upregulation of antiviral 
gene expression, including the production of interferons (IFNs). 
Viruses have evolved various strategies to counteract PKR-mediated antiviral immune 
signalling [68]. Coronaviruses appear to modulate the cellular translation machinery to 
their own benefit, as for example infectious bronchitis virus (IBV) appears to (weakly) 
antagonise the antiviral activity of PKR through two independent mechanisms: a block 
of PKR activation was observed and the expression of growth arrest and DNA-damage-
inducible 34 protein (GADD34) was induced in infected cells [69]. Both processes reduce 
phosphorylation of eIF2α in IBV-infected cells [69]. Also transmissible gastroenteritis virus 
(TGEV) has been reported to modulate the host cell’s translation machinery through its 
protein 7, which regulates the dephosphorylation of eIF2α through an interaction with 
protein phosphatase 1 (PP1). PP1 is a key regulator of the host antiviral response and its 
inhibition by TGEV protein 7 leads to a reduction in cytopathicity [70]. The S proteins of 
both SARS-CoV and IBV were found to physically interact with eIF3F, to modulate host 
translation, and the expression of pro-inflammatory cytokines interleukin 6 (IL-6) and 
IL-8 at a later stage of infection [71]. Therefore, this interaction may play an important 
regulatory role in coronavirus pathogenesis.
The SARS-CoV N protein was shown to associate with EF1α to block protein transla-
tion and cell proliferation, and SARS-CoV nsp1 was identified as a eukaryotic translation 
inhibitor that represses multiple steps of translation initiation. SARS-CoV nsp1 does so 
by inhibiting 48S initiation complex formation and interfering with the conversion of 
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the 48S complex into the 80S initiation complex [72]. In addition, the multifunctional 
SARS-CoV nsp1 is also able to directly bind the 40S subunit to inhibit its function in 
translation [73]. This nsp1-40S subunit complex is furthermore able to induce cleavage 
of cellular mRNA to reduce cellular translation to an even larger extent [74]. 
Taken together, modulation of host protein synthesis through different and often 
multiple mechanisms has a profound effect on the cell and ‘viral translation modulators’ 
likely contribute to coronavirus pathogenicity.
Nidovirus-induced rearrangement of host cell membranes 
As outlined above, a common characteristic of +RNA viruses is the fact that their replica-
tion takes place in the cytoplasm of the infected cell and is intimately associated with 
virus-induced membrane structures (reviewed in [28, 56, 75]). In general, virus-induced 
membrane alterations can be divided into two different types of structures: single-
membrane invaginations with negative membrane curvature and positively curved 
convoluted tubular–vesicular membrane networks. For a recent review, see [28]. In the 
case of membrane invaginations, the replication machinery is located on the inside of 
the invagination and the replication compartment is connected to the cytoplasm by 
an opening wide enough to allow the in-flow of nucleotides and export of synthesised 
RNA. Examples are the structures induced by Dengue virus (DENV), West Nile virus, 
Flock House virus and Semliki Forest virus, for which RNA synthesis appears to take 
place within membrane invaginations originating from either the ER [76, 77], the outer 
mitochondrial membrane [78], or the plasma membrane [79].
In tubular-vesicular replication structures, the viral replicase is (for most viruses) 
assumed to be localised to the external membranous surface facing the cytoplasm. 
Viruses like poliovirus and HCV induce complex networks of modified membranes, such 
as protrusions originating from cis-Golgi membranes or the ER that transform from 
single-membrane tubular compartments into double-membrane structures [80, 81]. 
Also nidoviruses belong to the group that induces the formation of tubular-vesicular 
replication structures [29-31]. For nidoviruses, however, convincing evidence about 
the exact localisation of viral RTCs is still lacking. Within the RVN of SARS-CoV-infected 
cells, dsRNA was particularly found inside DMVs while the majority of the viral replicase 
subunits colocalised with the CMs [30]. Furthermore, DMVs in SARS-CoV-infected cells 
appear to be sealed, which poses the question how export of newly synthesised RNA 
from the interior of DMVs is organised [30].  
This division according to membrane alterations induced may reflect an evolutionary 
divergence between +RNA virus groups and suggests that the mechanisms of mem-







Nidovirus-induced cell cycle deregulation
The cell cycle is a series of highly regulated events that lead to cell division, and the pro-
cess can be divided into four distinct phases: G1, S, G2, and M. The first three phases are 
collectively referred to as the interphase, and the M phase stands for mitosis, the actual 
cell division [82]. The regulation of the cell cycle involves processes that are crucial to the 
survival of a cell, as well as the prevention of uncontrolled cell division. The molecular 
events that control the cell cycle are ordered, directional and highly regulated by cyclin-
dependent protein kinases (CDKs). Passage through the cell cycle requires activation of 
the different CDKs by e.g. cyclin regulatory subunits. To promote cell cycle progression 
towards the replication of DNA, CDK/cyclin complexes phosphorylate proteins which 
triggers and activates DNA replication [83].
Like many other viruses (reviewed in [84]), nidoviruses have been shown to exten-
sively manipulate and arrest cell cycle progression to benefit from the physiological 
state of the cell when it is arrested in that specific phase. For example, IBV-infected 
cells were shown to go into cell cycle arrest in the S phase, by activating the cellular 
DNA damage response [85]. This is beneficial to virus replication since factors that 
are normally needed for DNA replication and are upregulated in the S phase, are now 
recruited to the cytoplasm by the virus. For example, DDX1, a cellular RNA helicase 
of the DExD/H family, interacts with coronavirus nsp14 [86] and was reported to be 
hijacked to enhance efficient coronavirus replication. Bhardwaj et al. have shown that 
coronavirus nsp15 interacts with retinoblastoma protein (pRb) and thereby inhibits the 
function of this protein, resulting in the enhanced expression of genes that are normally 
repressed by pRb and in an increased proportion of cells in the S phase of the cell cycle 
[87]. Similar effects have been observed in MHV-infected cells, which showed decreased 
hyper-phosphorylation of pRb, an event that is necessary for the progression from the 
G1 towards the S phase [88, 89].
Nidoviruses modulate host innate immune responses
During infection, there is a continuous interplay between the virus and the infected host. 
Cells respond to infection by mounting an antiviral response, which in the case of +RNA 
viruses is often triggered by the dsRNA molecules that are formed as intermediates 
during viral RNA replication. These dsRNA molecules are foreign to the cell and can be 
recognised by the intracellular sensors of the Rig-I-like receptor (RLR) family, like retinoic 
acid-inducible gene 1 (RIG-I) and melanoma differentiation-associated protein 5 (MDA-
5) (reviewed in [90]). Activation of these sensors eventually leads to the activation of 
transcription factor IFN-regulatory factor 3 (IRF3). This transcription factor upregulates 
the expression of IFN-β, which in turn activates the JAK-STAT signalling cascade that 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































results in an antiviral state of the infected cell and neighbouring cells. ISGs were shown 
to target virtually all steps in the viral cycle in order to restrict viral replication [91]. 
Innate immune signalling pathways are extensively regulated by ubiquitination. A 
number of proteins involved in signal transduction – e.g. RIG-I, TANK-binding kinase 
1 (TBK1), and TNF receptor-associated factor 3 (TRAF3) – were recently shown to be 
activated by Lys63-linked ubiquitination [92]. Notably, ubiquitin-mediated regulation 
offers excellent possibilities for negative feedback and viral immune evasion, since 
ubiquitination can be reversed by deubiquitinating enzymes (DUBs). Viruses have 
evolved a multitude of mechanisms to evade or counteract the innate immune response 
(reviewed in [93]). Like many other +RNA viruses, nidoviruses express several proteins 
that have been implicated in immune evasion. First of all, the coronavirus papain-like 
protease 2 domain (PL2pro) [94-97] and the TGEV PL1pro domain [98] within nsp3 were 
shown to harbour deubiquitination (DUB) activity. This DUB activity may remove ubiqui-
tin from innate immune signalling factors to suppress the induction of an antiviral state, 
and indeed was shown to reduce IFN signalling [96, 99]. A similar DUB activity has been 
described for the arteriviruses EAV and PRRSV. The PLP2 domain in nsp2 has potent in 
vitro DUB activity [100, 101], and compared to wt EAV, infection with an EAV mutant that 
lacks this DUB activity resulted in an increased innate immune response [102].
A multitude of SARS-CoV nsps, structural and accessory proteins [103] and also many 
other nidovirus proteins have been implicated in blocking IFN-mediated signalling 
through a variety of mechanisms. Besides inhibition of cellular mRNA translation (see 
above), SARS-CoV nsp1 was shown to block IFN signalling by reducing the amount of 
phosphorylated STAT1 (p-STAT1) in infected cells [104]. In addition, the SARS-CoV ORF6 
protein [105, 106] and PRRSV nsp1β [107, 108] were shown to block p-STAT1 import 
into the nucleus, and this block was suggested to reduce the expression of genes that 
affect virus-induced pathogenesis. Similar observations regarding the blocking of IFN 
signalling were made for the ORF3b protein of SARS-CoV [106] and SARS-like CoVs [109], 
SARS-CoV nsp7, nsp15, and N protein [110], albeit that the mechanism by which these 
proteins block IFN signalling is not fully understood. 
TBK1 was shown to be a target of both MHV PLP2 [95, 111] and the SARS-CoV 
membrane (M) protein [112]. MHV PLP2 deubiquitinates and binds TBK1, as well as IRF3, 
and SARS-CoV M protein binds TRAF1 to prevent binding of TRAF1 to TBK1 and eventu-
ally to prevent nuclear translocation of this complex to block IRF3-mediated signalling. 
SARS-CoV PLpro was shown to interact with IRF-3, to inhibit phosphorylation and nuclear 
translocation of IRF-3, thereby disrupting the activation of type I IFN responses [113].
Host factors directly involved in viral RNA synthesis
Another class of host factors involved in viral replication are the RNA-binding proteins. 
The 3’ and 5’ end of viral RNA genomes contain key regulatory elements for their replica-
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tion [114], and albeit that the precise role of host factors interacting with these signals is 
in general poorly understood,  RNA-binding proteins have been identified as frequently 
used enhancers of viral RNA synthesis. A summary of proteins that are known to bind 
nidovirus RNAs is listed below (Table 1).
DIRECT-ACTING AND HOST-DIRECTED ANTIVIRALS FOR INHIBITING 
NIDOVIRUS INFECTION
Antiviral research efforts have resulted in prophylactic or therapeutic possibilities, in-
cluding vaccines and antiviral drugs, to combat the diseases caused by a small number 
of human pathogens. Despite these efforts, HCV is the only +RNA virus for which specific 
antiviral drugs have currently been approved. Antiviral drugs can be divided into direct-
acting antivirals (DAA) and host-directed antivirals (HDA). Most antivirals are DAAs and 
inhibit essential processes in the viral replicative cycle. However, when using DAAs 
antiviral drug resistance is a serious problem, in particular when combating RNA viruses, 
due to their high mutation rate and potential for rapid adaptation. Thus, the possibility 
to target host factors rather than viral proteins is receiving increasing attention as an 
alternative approach (reviewed in [130, 131]). In contrast to DAA-based therapy, the use 
of drugs targeting host factors should not lead to drug resistance.
The previous paragraphs summarised how nidoviruses have evolved multiple 
mechanisms to hijack or manipulate cellular components and pathways to promote 
their efficient replication. Insight into these virus-host interactions does not only yield 
valuable information on the molecular details of the nidovirus replicative cycle, but can 
also be a starting point for the development of antiviral strategies. However, one should 
keep in mind that targeting host factors can have cytotoxic or other undesirable side-
effects. Below, first the application of some of the more classical antiviral approaches 
to the inhibition of nidoviruses will be discussed, and subsequently the possibilities, 
advantages and disadvantages of targeting host factors will be evaluated.
Neutralising antibodies and viral entry or fusion inhibitors
The early stages of nidovirus infection can be blocked by virus neutralisation or by in-
terfering with viral entry into host cells. Coronavirus entry is mediated by an interaction 
of the S protein with its entry receptor, which is the angiotensin converting enzyme 2 
(ACE2) for SARS-CoV. During the early phase of the SARS-CoV outbreak, convalescent 
plasma, obtained from recovered SARS patients, was transferred to newly infected SARS 
patients, which resulted in a significant drop in viral load and a higher discharge rate 
from the hospital. This demonstrates that neutralising antibodies can protect against 







blood from persons that have recovered from SARS is needed. To circumvent this, re-
combinant human antibodies against the SARS-CoV S protein – using human antibodies 
might reduce the side effects in patients – have been made, and were shown to block 
the S-ACE2 interaction (reviewed in [134]). For example, Ter Meulen et al. and Van den 
Brink et al. have shown that anti-SARS-CoV S antibodies neutralise SARS-CoV in cell 
culture and in a ferret animal model. Prophylactic administration of (a combination of ) 
these human monoclonal antibodies reduced replication of SARS-CoV in the lungs of 
ferrets, completely prevented the development of SARS-CoV-induced lung pathology 
and abolished virus shedding [135-137].
Another class of compounds that block viral entry are inhibitors of vacuolar (or endo-
somal) acidification, like ammonium chloride and the FDA-approved anti-malaria drug 
chloroquine. These compounds, in cell culture and in animal models, has been shown to 
block the entry of nidoviruses [138-143], including SARS-CoV [144].
Since SARS-CoV is an enveloped virus, fusion of the viral envelope with cellular 
membranes is needed for entry into host cells. Virus binding is mediated by the interac-
tion of the receptor binding domain in the S1 region of the S protein with the ACE2 
receptor. The S2 region contains heptad repeat 1 (HR1) and HR2 domains, which play 
an important part in SARS-CoV fusion with target cells. Binding of the receptor-binding 
domain (RBD) of S1 to the receptor ACE2 triggers a conformational change of the S2 
region from a pre-fusion form to a fusogenic form, resulting in insertion of the putative 
fusion peptide into the target cell membrane and association of HR1 and HR2 domains 
to form a six-helix bundle fusion core structure. This brings the viral envelope and target 
cell membrane into close proximity for fusion [145].
Many laboratories have tried to develop strategies that block this fusion step. These 
include inhibitors, e.g. peptides that block the interaction between HR1 and HR2 to 
prevent the formation of a fusogenic complex or by blocking S protein oligomerisation 
(reviewed in [145]).
Viral protease inhibitors
Viral proteases play a crucial role in the processing of polyproteins into active viral repli-
case subunits, a strategy that is employed by many viruses. Therefore, proteases are clas-
sical targets for the development of antiviral therapies, e.g. against human pathogens 
like HCV and HIV-1 (for recent reviews, see [146, 147]).
Nidovirus proteases, like the main protease that mediates many steps in polyprotein 
processing, have crucial roles in the viral replication cycle. For this reason, these prote-
ases are interesting drug targets and many research groups have attempted to identify 
or develop protease inhibitors that are either SARS-CoV nsp5-specific or broadly active 
against coronavirus main proteases. Several small-molecule inhibitors or peptide-like 
protease inhibitors have been reported to effectively block protease activity in vitro and 
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infection in cell culture at concentrations in the low-micromolar range [148-152]. The 
SARS-CoV papain-like protease (PLpro) was shown to also harbour immune evasion prop-
erties (see above) by inhibiting IRF3-mediated signalling [113]. The compound GRL0617 
yielded promising results regarding its inhibitory effect on SARS-CoV replication, pre-
sumably by targeting this function of PLpro [153]. These developments make it clear that 
targeting nidovirus proteases may be an interesting strategy to block viral replication.
Inhibitors of the viral polymerase and other viral proteins
A unique feature of +RNA viruses, including nidoviruses, is the synthesis of new viral 
RNA from an RNA template, which is performed by a virus-encoded RdRp. Thus, target-
ing the viral polymerase is a straightforward approach for antiviral therapy. A first class 
of RdRp inhibitors are the nucleoside analogues, which are incorporated into the newly 
synthesised viral RNA and abrogate RNA synthesis or lead to the accumulation of a lethal 
number of mutations. In view of the lack of known inhibitors of coronavirus replication, 
Ribavirin, a well-known nucleoside analogue, was used during the 2003 SARS outbreak, 
since this purine analogue showed potent, broad antiviral activity against several other 
+RNA viruses like HCV [154]. However, there is conflicting data on the effectiveness of 
Ribavirin against SARS-CoV infection in cell culture [155-157] and in vivo [157, 158]. Fur-
thermore, treatment of infected cells with a combination of Zn2+ and the zinc-ionophore 
pyrithione was shown to block replication of SARS-CoV and EAV, possibly by impairing 
RdRp activity [159]. Recently, Liu et al. showed that peptides that target the PRRSV poly-
merase can block replication, which suggests that peptides that target nidovirus nsps 
could form the basis for antiviral strategies [160].
The viral helicase has been shown to play an important role in the nidovirus replica-
tive cycle, and therefore is another interesting target for antiviral therapy. Several studies 
identified antivirals that are directed to the SARS-CoV helicase and inhibited SARS-CoV 
replication in cell culture. A screen by Kao et al. identified HE602 as a potent SARS-CoV 
helicase inhibitor, and this compound reduced SARS-CoV plaque formation with an IC50 
of 6 µM. Tanner et al. identified bananins as SARS-CoV helicase inhibitors [161]. These 
compounds block SARS-CoV replication with an IC50 of less than 10 µM without any 
cytotoxicity at high concentrations. Yang et al. showed that bismuth complexes effec-
tively block SARS-CoV replication by inhibiting both the unwinding and ATPase activi-
ties of the SARS-CoV helicase [162, 163]. Later on, several other helicase inhibitors, like 
Myricetin and Scutellarein (IC50s of 2.71 and 0.86 µM, respectively), were identified [164]. 
These inhibitors specifically block the ATPase function of the helicase. SSYA10-001 and 
aryl diketo acids block the helicase unwinding activity [165], however these compound 
were not tested in cell culture, so their effect on virus replication remains to be analysed. 
Furthermore, Liu et al. showed that several helicase-directed peptides could be used as 







A few small molecules were reported to inhibit the MT activity of SARS-CoV nsp16, 
such as S-adenosyl-l-homocysteine, Sinefungin [166] and aurintricarboxylic acid [167]. 
Furthermore, two peptides were identified that inhibit the methlytranferase activity of 
SARS-CoV nsp16 [168]. 
The only coronavirus structural protein of which the function can thus far be blocked 
by small-molecule inhibitors is the envelope (E) protein, which mediates viral assembly 
and morphogenesis. Hexamethylene amiloride was recently shown to inhibit HCoV-
229E and MHV replication by blocking E protein function, suggesting that the nidovirus 
E protein could be used as drug target as well [169].
Antisense morpholino oligomers and RNAi approaches to block nidovirus 
replication
A different class of molecules that can block virus replication are peptide-conjugated 
antisense phosphorodiamidate morpholino oligomers (P-PMOs). These molecules, 
which are resistant to cellular nucleases, are designed to target viral genome sequences 
and inhibit viral gene expression by a steric blockade. Two P-PMOs targeting the SARS-
CoV leader TRS region in the 5’ untranslated region appeared most effective, however 
after several passages escape mutants were observed [170]. Nevertheless, the use of 
these P-PMOs in an animal model for MHV showed the potency of these molecules in 
vivo [171]. Another study by Ahn et al. showed that an antisense nucleic acid oligomer 
that prevented the -1 RFS suppressed SARS-CoV replication in cell culture [172]. These 
P-PMOs have also been shown to block arterivirus replication. P-PMOs that are directed 
to the 5’UTR of the EAV genome showed a significant block in virus amplification in the 
low micromolar range [173]. PRRSV replication in cell culture appeared also sensitive to 
treatment with P-PMOs that are directed towards the 5’UTR of the viral genome [174-
176]. PRRSV-infected piglets showed reduced viremia, and elevated levels of antiviral 
genes in P-PMO-treated piglets, suggesting that using these P-PMOs could be consid-
ered as PRRSV control strategy [177].
Through a mechanism known as RNA interference (RNAi), small interfering RNA 
(siRNA) molecules can target complementary (viral) mRNA strands for degradation, and 
can thus specifically target viral mRNAs in infected cells. The ability of siRNAs to inhibit 
viral gene expression offers a mechanism that can be exploited for novel therapeutics. 
In vitro experiments have shown for multiple nidoviruses that blocking infection using 
RNAi might also be a viable approach [178-182]. Although currently not applicable in 
humans, the use of RNAi in animal models has shown some potential to combat +RNA 
viruses that cause respiratory disease (reviewed in [183, 184]), including SARS-CoV [185, 
186]. However, several hurdles have to be taken, since targeting of specific tissues and 
reaching effective levels of siRNAs are still challenges that have to be addressed. 
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Currently, most assays using antisense oligonucleotides (P-PMOs or siRNAs) have 
been applied to directly target nidovirus replication, however these molecules can 
also be used to target host factors that are involved in virus replication. As mentioned 
before, targeting host factors might cause a higher barrier for the development of viral 
resistance, although the chance of developing side effects might also increase upon 
depletion of host factors.
Corticosteroids and IFN as immunomodulatory antiviral agents
The use of the immunomodulatory corticosteroids to treat SARS patients is controversial 
and remains debated. Administration of high doses of corticosteroids to SARS patients, 
mostly in combination with Ribavirin, hardly showed any effect and serious side-effects, 
including progressive viral infection, have been observed (reviewed in [187]).
In this respect, the antiviral effect of the immunomodulatory agent IFN is more prom-
ising. IFN was shown to trigger the innate immune response by the transcription of ISGs 
that have a role in combating virus infection. ISG expression results in an antiviral state 
of infected and neighbouring non-infected cells, to limit virus replication and spread 
[91]. IFN is a registered drug for the treatment of HCV, and is also explored as antiviral 
agent for nidoviruses (in particular for SARS-CoV and MERS-CoV). Treatment with type I 
IFNs inhibits coronavirus replication in cell culture [188-192] and, for example, protected 
type I pneumocytes against SARS-CoV infection in macaques [190]. This inhibition was 
observed despite the immune evasive properties of the SARS-CoV ORF6 protein that in-
hibits IFN signalling by blocking the nuclear translocation of p-STAT1, which is essential 
for transcriptional activation of downstream antiviral genes. Despite the potency of IFN 
as antiviral agent, HCV treatment with IFN triggered the development of side effects like 
fatigue, malaise, apathy, and cognitive changes in several patients [193].  
Concluding remarks
This paragraph summarises (potential) antiviral strategies for the treatment of infections 
with nidoviruses, in particular SARS-CoV. Most strategies are aimed towards targeting 
the virus directly, and in many cases, replication was effectively blocked in cell culture. 
Currently, intervention strategies for nidoviruses in humans have not been approved 
yet, and some of the abovementioned approaches might form a basis for the devel-
opment of such strategies. As mentioned before, there is a high risk of development 
of resistance when the viral structural proteins or replicase subunits are targeted, as 
exemplified by the development of escape mutants by only a few mutations upon using 
e.g. neutralising antibodies [194]. Multiple studies have identified host factors that are 
involved in nidovirus replication (reviewed in [65]), and these might be suitable targets 







single-DAA treatments would argue for the development of HDAs and combination 
therapies using both DAAs and HDAs as an effective intervention strategy.
OUTLINE OF THIS THESIS
In this thesis, the interplay between nidoviruses and the infected host cell was investi-
gated, to better understand virus replication and hopefully provide additional starting 
points for the development of antiviral strategies. Chapter 2 describes the partial purifi-
cation of active EAV RTCs from infected cells and the development of an in vitro assay for 
EAV RNA synthesis. Arterivirus RNA-synthesising activity was shown to depend on intact 
membranes, and isolation of RTCs by using differential centrifugation showed that viral 
RNA synthesis is dependent on a cytosolic host protein with a mass between 59 and 70 
kDa, which does not cosediment with the RTC. 
In chapter 3, the in vitro assay described in chapter 2 was used to identify the im-
munosuppressant drug cyclosporin A (CsA) as an inhibitor of EAV RNA synthesis. This 
chapter also shows that CsA blocks replication of EAV and the swine arterivirus PRRSV in 
cell culture. Cyclophilin A (CypA) appears to be an important host factor for EAV replica-
tion since its depletion reduced the production of EAV progeny. 
CsA may be a nidovirus-wide inhibitor of replication since this compound also 
blocked coronavirus replication. Chapter 4 describes that SARS-CoV, HCoV-229E, and 
mouse hepatitis virus (MHV) replication in cell culture is effectively blocked by CsA treat-
ment. However, knockdown of either CypA or CypB did not reduce SARS-CoV replication, 
leaving the possibility that CsA blocks replication of different nidoviruses via different 
mechanisms. 
Chapter 5 describes an siRNA library screen that aimed to identify cellular kinases 
and signalling pathways involved in the SARS-CoV replicative cycle. In total, ninety 
antiviral and forty proviral hits were found. Two factors that were identified as hits in 
the primary screen – PKR as antiviral and COPB2 as proviral factor – were validated in 
follow-up experiments. Depletion of PKR resulted in enhanced SARS-CoV replication 
and increased release of SARS-CoV progeny. COPB2 knockdown severely reduced SARS-
CoV replication and release of virus progeny, and implicated COP-I coated vesicles in 
virus replication. The identification of proviral and antiviral factors in the siRNA screen 
enhances our understanding of the replication of SARS-CoV and coronaviruses in gen-
eral, and may define novel targets for coronavirus antiviral therapy. 
We also investigated (chapter 6) the replication characteristics of the recently identi-
fied MERS-CoV, including the kinetics of viral RNA synthesis and viral progeny release, 
and demonstrated that viral RNA synthesis is associated with the virus-induced mem-
brane structures.
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Furthermore, we describe an assay to measure MERS-CoV-induced cytopathology 
and its application to the screening for compounds that block MERS-CoV infection. 
CsA was identified as a potential anti-MERS-CoV compound in this assay. In addition, 
treatment with pegylated IFN-α (PEG-IFN) significantly inhibited infection, and MERS-
CoV was shown to be much more sensitive to PEG-IFN treatment than SARS-CoV, an 
observation that may have implications for the treatment of MERS-CoV infection. Finally, 
chapter 7 summarises the findings that are described in this thesis.
Chapter 2
The in vitro RNA synthesizing activity of the 
isolated arterivirus replication/transcription 
complex is dependent on a host factor
Martijn J. van Hemert, Adriaan H. de Wilde, 
 Alexander E. Gorbalenya, and Eric J. Snijder




The cytoplasmic replication of positive-stranded RNA viruses is associated with charac-
teristic, virus-induced membrane structures that are derived from host cell organelles. 
We used the prototype arterivirus, equine arteritis virus (EAV), to gain insight into the 
structure and function of the replication/transcription complex (RTC) of nidoviruses. 
RTCs were isolated from EAV-infected cells and their activity was studied using a newly 
developed in vitro assay for viral RNA synthesis, which reproduced the synthesis of both 
viral genome and subgenomic mRNAs. A detailed characterization of this system and its 
reaction products is described. RTCs isolated from cytoplasmic extracts by differential 
centrifugation were inactive unless supplemented with a cytosolic host protein factor, 
which - according to subsequent size fractionation analysis - has a molecular mass in 
the range of 59-70 kDa. This host factor was found to be present in a wide variety of 
eukaryotes. Several EAV replicase subunits cosedimented with newly made viral RNA in 
a heavy membrane fraction that contained all RNA-dependent RNA polymerase activ-
ity. This fraction contained the characteristic double membrane vesicles (DMVs) that 
were previously implicated in EAV RNA synthesis and could be immunolabeled for EAV 
nonstructural proteins (nsps). Replicase subunits directly involved in viral RNA synthesis 
(nsp9 and nsp10) or DMV formation (nsp2 and nsp3) exclusively cosedimented with the 
active RTC. Subgenomic mRNAs appeared to be released from the complex, while newly 
made genomic RNA remained more tightly associated. Taken together, our data strongly 
support a link between DMVs and the RNA-synthesizing machinery of arteriviruses.







Positive-strand RNA viruses form the largest group of animal viruses and include many 
important human pathogens, like poliovirus, hepatitis A and C virus, dengue virus, 
yellow fever virus, West Nile virus and various human coronaviruses. Although these 
viruses differ in many aspects of their biology, including genome size, organization, and 
expression strategy, they are united by the fact that their RNA genome is replicated by 
cytoplasmic enzyme complexes. These complexes are associated with virus-induced 
membrane structures that are derived from host cell organelles (for reviews see [75, 
195, 196]). Such membrane structures might function as scaffold for the replication 
machinery, provide a suitable microenvironment for viral RNA synthesis, serve to recruit 
membrane-bound host proteins, and/or provide protection against the host cell’s antivi-
ral responses (e.g. RNA degradation or responses triggered by the double-stranded (ds) 
RNA intermediates of viral RNA synthesis). 
Nidoviruses (corona-, roni-, and arteriviruses) have exceptionally large polycistronic 
RNA genomes and employ a unique transcription mechanism to produce a nested set of 
subgenomic (sg) mRNAs. Therefore, among positive-strand RNA viruses, nidovirus RNA 
synthesis is considered to be of unparalleled complexity [37, 196]. In nidovirus-infected 
cells, newly synthesized viral RNA and many replicase subunits were found to colocalize 
in discrete foci in the perinuclear region [32, 33, 35, 197-208]. Electron microscopy of this 
area revealed the presence of large numbers of typical paired membranes and double 
membrane vesicles (DMVs) [31, 32, 35, 201, 208-212]. For the coronaviruses mouse hepa-
titis virus (MHV) and SARS-coronavirus (SARS-CoV) and the arterivirus equine arteritis 
virus (EAV), immunoelectron microscopy revealed that both viral nonstructural proteins 
(nsps) presumed to be part of the replication/transcription complex (RTC) and de novo 
made viral RNA are associated with these membranes [31, 32, 35, 201]. Based on these 
results, DMVs have been postulated to carry the enzyme complex that is responsible for 
nidovirus replication and sg mRNA synthesis.
One of the best studied nidovirus models is the arterivirus prototype EAV, which has 
been used extensively to study both replicase functions and the mechanism of nidovirus 
RNA synthesis. Of the 12.7 kb EAV genome (RNA1) 75% is occupied by the large replicase 
gene that consists of the open reading frames (ORFs) 1a and 1b. The EAV replication 
cycle starts with the translation of RNA1 to synthesize two large replicase polyproteins: 
the 1727-aa ORF1a-encoded pp1a and the 3175-aa pp1ab, which is synthesized after a 
-1 ribosomal frameshift that occurs immediately upstream of the ORF1a termination co-
don and results in the extension of pp1a with the ORF1b-encoded part of the replicase 
(reviewed in [213]). Subsequently, pp1a and pp1ab undergo extensive autoproteolytic 
processing by three ORF1a-encoded proteases, which leads to the generation of 13 end 
products (nsps), named nsp1 to nsp12 (a recently described cleavage within nsp7 yields 
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nsp7α and nsp7ß [214]). Most of these replicase subunits appear to become associated 
with intracellular membranes in the perinuclear region of the infected cell [33, 201, 202], 
where they are thought to assemble into RTCs. The ORF1b-encoded subunits contain 
the core enzymatic activities that are involved in viral RNA synthesis, like the RNA-
dependent RNA polymerase (RdRp) and RNA helicase [215, 216], while ORF1a encodes, 
in addition to the three protease domains, several putative trans-membrane subunits. 
The latter appear to play a more ‘structural’ role by inducing DMV formation [217] and 
presumably anchoring the RTC to intracellular membranes [32]. 
In EAV-infected cells, the RTC mediates the synthesis of genomic RNA (RNA1) and a 
nested set of six sg mRNAs (RNA2 - RNA7). These transcripts are 3’ co-terminal and also 
contain a common 211-nt 5’-leader sequence that is identical to the 5’ end of RNA1. 
Each sg mRNA is thought to be produced from its own subgenome-length minus strand 
template. The latter are produced via a mechanism of discontinuous minus strand RNA 
synthesis during which sequences encoding sg RNA “leader” and “body” are joined (for 
recent reviews, see [40, 196]). The production of a set of sg transcripts is a characteris-
tic feature of nidoviruses and serves to regulate the expression of the viral structural 
protein genes from the 3’-proximal part of the genome. Therefore, their synthesis is 
referred to as ‘transcription’, to distinguish it from the process of replication. Viral RNA 
synthesis involves partially and fully double-stranded intermediates, known as replica-
tive intermediates (RI) and replicative forms (RF), which are thought to be associated 
with plus- and minus-strand RNA synthesis, respectively [218, 219].
The isolation of replication complexes and the development of in vitro RNA synthesis 
assays (IVRAs) have proven to be valuable tools for studying the mechanistic details 
of the replication of several viruses. However, robust in vitro systems supporting the 
synthesis of the full spectrum of viral RNAs produced in nidovirus-infected cells have 
not been described and therefore we set out to develop such a system for EAV. The 
purification of active, membrane-associated RTCs should enhance our insight into their 
structure and function, including the molecular details of nidovirus replication and tran-
scription. We now describe the development, optimization, and characterization of such 
an in vitro system for EAV, in which both genome-sized and sg RNAs, mainly of positive 
polarity, were synthesized. The characterization of partially purified and enzymatically 
active RTCs revealed that several EAV nsps, including the nsp9-RdRp, cosedimented with 
endogenous and newly synthesized viral RNA in fractions that contained double mem-
brane structures. Subgenomic mRNAs appeared to be released from the RTC-containing 
fraction, while a large proportion of newly synthesized genomic RNA remained associ-
ated with it. Remarkably, the isolated RTC was not active unless it was supplemented 
with a preparation containing a cytosolic host protein factor. This host factor was found 
to be present in a wide variety of eukaryotes, and its preliminary characterization indi-
cated that it has a molecular mass in the range between 59 and 70 kDa. 







Cells, virus and antisera
BHK-21 cells were cultured and infected with EAV (Bucyrus strain) at a multiplicity of 
infection of 5, essentially as described [220], except that cells were grown in GMEM 
(Gibco) supplemented with 5% or 2% fetal calf serum before and after infection, respec-
tively. HeLa cells and Vero E6 cells were grown in DMEM supplemented with 10% fetal 
calf serum. C6/36 cells were grown as described [221]. One-day old deyolked zebrafish 
embryos were obtained from Christoph Bagowski (Department of Integrative Zoology, 
Institute of Biology, Leiden University). Saccharomyces cerevisiae strain FY1679 was 
grown in YPD. A new nsp9 rabbit antiserum was raised against bacterially expressed 
recombinant nsp9 [215]. The other antisera used in this study have been described 
previously [201, 222, 223]. 
Isolation of enzymatically active RTCs from EAV-infected cells
Approximately 1 x 108 EAV-infected BHK-21 cells were harvested by trypsinization at 6 h 
post infection (p.i.), when infection was carried out at the commonly used temperature 
of 39.5°C, or 10 h p.i. when infection was done at 37°C. Cells were resuspended in 2 
ml hypotonic buffer (20 mM HEPES, 10 mM KCl, 1.5 mM MgOAc, 1 mM DTT, 133 U/ml 
RNaseOUT (Invitrogen) and 2 µg/ml actinomycin D (ActD), pH 7.4). During harvesting 
and lysis 2 µg/ml ActD was present in all solutions used. The number of harvested cells 
was determined using a counting chamber and the percentage of infected cells was 
checked by immunofluorescence microscopy as described [33]. After incubation on ice 
in hypotonic buffer for 15 min, cells were disrupted in an ice-cold ball-bearing homog-
enizer (Isobiotek) with 16 µm clearance. HEPES, sucrose and DTT were added to yield a 
lysate containing 35 mM HEPES, pH 7.4, 250 mM sucrose, 8 mM KCl, 2.5 mM DTT, 1 mM 
MgOAc, 2 µg/ml ActD and 130 U/ml RNaseOUT. Nuclei, large debris and any remaining 
intact cells were then removed by two subsequent centrifugation steps at 1,000 x g and 
4ºC for 5 min and the post-nuclear supernatant (PNS) was either assayed immediately 
for RdRp activity or stored at -80°C, at which activity could be retained for at least 1 year. 
Protein concentrations were determined using the Bio-Rad protein assay reagent. 
In vitro RNA synthesis assay (IVRA)
Following optimization of reaction conditions (as described under “Results”), standard 
28-µl IVRA mixtures contained 25 µl of EAV-infected cell lysate (either PNS, S10, P10 or 
combinations), 30 mM HEPES pH 7.4, 220 mM sucrose, 7 mM KCl, 2.5 mM DTT, 2.5 mM 
MgOAc, 2 µg/ml ActD, 25 U RNaseOUT, 20 mM creatine phosphate (Sigma), 10 U/ml cre-
atine phosphokinase (Sigma), 1 mM ATP, 0.25 mM GTP, 0.25 mM UTP, 0.6 µM CTP and 0.12 
µM, 10 µCi [α-32P]CTP (GE Healthcare). Unless otherwise indicated, standard reactions 
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were performed for 100 min at 30°C. Reactions were terminated by the addition of 60 µl 
5% lithium dodecyl sulfate, 0.1 M Tris-HCl, 0.5 M LiCl, 10 mM EDTA, 5 mM DTT, 0.1 mg/
ml Proteinase K, pH 8.0. After an incubation of 15 min at 42°C, unincorporated label was 
removed using RNase-free Micro Bio-spin 30 columns (Bio-Rad) and RNA was isolated, 
dissolved in 20 µl of 1 mM sodium citrate, pH 6.5, and analyzed as described below.
Isolation, gel electrophoresis and detection of RNA
RNA was isolated by acid phenol extraction and isopropanol precipitation with Glyco-
Blue (Ambion) as coprecipitant, essentially as described [224]. Denaturing formaldehyde 
agarose gel electrophoresis was performed as described [225]. Semi-denaturing 7 M 
urea-3% polyacrylamide gel electrophoresis was performed essentially as described 
[226]. Before loading, samples were either incubated at 42°C for 15 min or heat-dena-
tured for 3 min at 96°C, followed by rapid cooling on ice. For detection of IVRA products, 
PhosphorImager screens were directly exposed to dried gels, after which screens were 
scanned with a Personal Molecular Imager FX (Bio-Rad) and incorporation of label was 
quantified using Quantity One v4.5.1 software. Incorporation of [α-32P]CTP was quanti-
fied by correlating the measurements to those from membrane strips containing known 
quantities of [α-32P]CTP. For the detection of unlabeled EAV RNA, direct hybridization of 
agarose gels was performed [225] using a 32P-labeled oligonucleotide probe (5’-TTG-
GTTCCTGGGTGGCTAATAACTACTT-3’) that is complementary to the 3’-end of all EAV 
mRNAs. For quantitative analysis, known quantities of in vitro transcripts were run on 
the same gel. 
Hybridization of IVRA products
In vitro transcribed RNAs (1 µg) corresponding to the ORF7 region (nt 12313-12660) of 
the EAV genome (RNA7+) or its complementary sequence (RNA7-) were immobilized to 
Hybond N+ membrane (GE Healthcare). Equal amounts of total cellular RNA isolated from 
mouse L cells and full-length Sindbis virus RNA transcripts were included as negative 
controls. The membrane with the immobilized probes was hybridized (0.8 ml volume; 16 
h at 60°C) with half of the 32P-labeled RNA recovered from a 28-µl IVRA. Membranes were 
washed twice for 20 min at 60°C with 4 ml of 15 mM NaCl, 1 mM NaH2PO4, 0.1 mM EDTA, 
0.05% SDS, pH 7.0. To confirm the specificity of the immobilized probes, membranes 
were also hybridized with either 32P-labeled RNA7+ or 32P-labeled RNA7- transcript. 
Hybridization was quantified by PhosphorImager analysis as described above. 
LiCl fractionation and RNase treatment of IVRA products
IVRA reactions were terminated with lithium dodecyl sulfate and proteinase K as de-
scribed above. After removal of unincorporated label, the LiCl concentration was raised 
to 2 M and samples were incubated at -20°C for 16 hours (40). RI and single-stranded 






(ss) RNA were pelleted by centrifugation for 1 hour at 16,000 x g and 4°C. Pellets were 
washed with 70% ethanol, dried and dissolved in 1 mM sodium citrate. The 2 M LiCl 
supernatant was desalted using Micro Bio-spin 30 columns (Bio-Rad). Samples were 
treated with a mix of RNase A (2.5 U/ml) and RNase T1 (100 U/ml) under low salt condi-
tions (15 mM NaCl, 2 mM sodium citrate pH 7.2) or high salt conditions (750 mM NaCl, 
75 mM sodium citrate pH 7.2) for 15 min at 37°C . Double-stranded RNA was specifically 
degraded by incubation with RNase III (Ambion; 50 U/ml) for 15 min at 37°C in 650 mM 
NaCl, 60 mM sodium citrate, 10 mM MgOAc, 1 mM DTT, 10 mM Tris-HCl, pH 7.2. After 
RNase treatment, RNA was isolated as described above, except that the phenol extrac-
tion step was omitted. 
Subcellular fractionation by differential centrifugation, ultrafiltration, and size 
exclusion chromatography
PNS fractions of BHK-21, HeLa, Vero E6, and C6/36 cells were prepared by mechanical 
disruption as described above for EAV-infected BHK-21 cells. A yeast PNS and a zebrafish 
PNS were prepared in a similar way except that yeast cells from a 50-ml culture were dis-
rupted by vortexing in the presence of 500 µm diameter glass beads in 0.5 ml hypotonic 
buffer, and zebrafish cells from 200 one-day old zebrafish embryos were disrupted in 
200 µl hypotonic buffer by passing them through a 27-gauge needle. The total protein 
concentration in all lysates was between 1 and 5 mg/ml. PNS fractions were centrifuged 
for 10 min at 4°C at 5,000 x g, 10,000 x g and 16,000 x g yielding supernatants S5, S10, 
S16 and pellets P5, P10, and P16 respectively. Pellets were resuspended in dilution buf-
fer (35 mM HEPES, 250 mM sucrose, 8 mM KCl, 2.5 mM DTT, 1 mM MgOAc pH 7.4) by 
carefully pipetting (20x) in 1/5 to 1/10 of the volume of the PNS from which the pellet 
was prepared. For IVRAs, 5 µl of a pellet fraction was mixed with either 20 µl dilution buf-
fer or 20 µl of a ‘supernatant fraction’, after which reactions were performed as described 
above. The S16 fraction was centrifuged for 1 h at 200,000 x g to yield a S200 supernatant 
fraction. Low molecular weight compounds (<6 kDa) were removed from S16 by size 
exclusion chromatography using Micro Bio-spin 6 columns (Bio-Rad), yielding fraction 
F>6. Ultrafiltration of S16 through filters with cut-off sizes of 10 kDa (Millipore Biomax 
10K NMWL), 100 kDa (Millipore Biomax 100K NMWL) and 1000 kDa (Vivascience Vivaspin 
1,000,000 MWCO) yielded filtrates F<10, F<100 and F<1000, respectively.
Gel filtration chromatography
A HeLa S200 fraction (240 µg protein in 200 µl) was fractionated by gel filtration chro-
matography using an ÄKTA FPLC (GE Healthcare) and a Superdex 200 HR10/30 column 
(GE Healthcare) at 4°C. The column was equilibrated with 20 mM HEPES, pH 7.4, 150 mM 
KCl, 2 mM DTT, 1 mM MgOAc. Elution was done in the same buffer, at a flow rate of 0.5 
ml/min, and 0.5-ml fractions were collected after the first 7 ml (which represented the 
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void volume of the column). For each fraction, the buffer was exchanged to dilution 
buffer using Micro Bio-spin 6 desalting columns (Bio-Rad). The Superdex column was 
calibrated with the HMW calibration kit (GE Healthcare) to obtain size estimates for the 
protein fractions obtained.
Protease and nuclease treatment
Fraction S16 was treated for 15 min at 30°C with 2 mg/ml, 0.4 mg/ml, 0.08 mg/ml and 0 
mg/ml of proteinase K, after which the protease was inactivated by adding 2 mM PMSF 
and samples were cleaned up with Micro Bio-spin 6 columns (Bio-Rad). Inactivation of 
proteinase K by this procedure was confirmed by testing the stability of 35S-labeled con-
trol proteins during a 100-min incubation. S16 was treated with 75 U/ml of microccocal 
nuclease (Fermentas) in the presence of 2 mM CaCl2 for 30 min at 30°C, after which the 
nuclease was inactivated by the addition of 5 mM EGTA. The extent of RNA degradation 
was monitored using a 3H-uridine-labeled in vitro transcript.
SDS-PAGE and Western blot analysis
After SDS-PAGE, proteins were transferred to Hybond-P PVDF membrane (GE Health-
care) by semi-dry blotting. Membranes were blocked with 1% casein in PBS containing 
0.1% Tween-20 (PBST) and were incubated with mono-specific anti-EAV replicase rabbit 
antisera: anti-nsp1 (1:2000), anti-nsp2 (1:2000), anti-nsp3 (1:2000), anti-nsp4 (1:2000), 
anti-nsp7-8 (1:2000), anti-nsp9 (1:5000) or anti-nsp10 (1:2000) antisera, all diluted in 
PBST containing 0.5% casein and 0.1% BSA. Peroxidase-conjugated swine anti rabbit 
IgG antibody (DAKO) and the ECL-plus kit (GE Healthcare) were used for detection. The 
SilverQuest kit (Invitrogen) was used for silver staining of SDS-PAGE gels. 
Electron microscopy
Formvar-coated grids were placed on top of 25-µl drops of P10 fractions and incubated at 
room temperature for 1 minute. After blocking with 1% BSA in PBS, grids were incubated 
with a rabbit anti-nsp3 or preimmune serum (1:200) in PBS containing 1% BSA for 30 min 
and bound rabbit IgG was detected with 15 nm protein A-gold. After fixation with 1.5% 
glutaraldehyde and negative staining with 3% uranyl acetate, grids were viewed with a 
Philips CM-10 transmission electron microscope at 100 kV. For ultrastructural analysis of 
native DMVs, EAV-infected BHK-21 cells grown on coverslips (Thermanox) were cryofixed 
by high-speed plunge freezing in liquid ethane, freeze substitution, and embedding in 
LX-112 epoxy resin [30]. Ultrathin sections were contrasted with uranyl acetate and lead 
hydroxide and viewed with a Philips CM-10 transmission electron microscope at 100 kV. 







EAV RTC activity in cytoplasmic extracts. 
To study the EAV RTC, we sought to isolate the virus-specific RNA-synthesizing activity 
from infected BHK-21 cells by mechanical disruption and cell fractionation. Metabolic 
labeling of EAV RNA synthesis with [3H]uridine revealed that it was maximal by 6 h p.i. 
(data not shown) and therefore RTCs were routinely isolated at this time point. In gen-
eral, approximately 108 infected cells were used to prepare a cytoplasmic extract (PNS) 
with a total protein concentration of 2 to 5 mg/ml. 
The PNS described above was used in IVRAs (see Materials & Methods), in which the 
incorporation of [α-32P]CTP into viral RNA was analyzed in a reaction mixture containing 
nucleoside triphosphates (NTPs), Mg2+, an energy regenerating system (creatine phos-
phate and creatine phosphokinase), and an inhibitor of cellular transcription (ActD). We 
used labeled CTP in our assays to minimize background incorporation that could result 
from the presence of cellular terminal transferases, which preferentially use ATP and UTP 
[227]. 
In a time course experiment (Fig. 1A), we observed the accumulation of several in 
vitro-synthesized, 32P-labeled RNA species with sizes corresponding to those of the EAV 
genome (RNA1) and all six sg mRNAs (RNAs 2 to 7). Upon incubations longer than 100 
min, the amount of labeled RNA decreased, probably due to the combination of the 
(continuous) activity of endogenous RNases and a decreasing synthesis rate. The half-
life of viral RNA in PNS at 30°C was estimated to be approximately 20 or 40 min, depend-
ing on whether we analyzed the integrity of 3’-terminal sequences (hybridization) or 
the degradation of [3H]uridine labeled RNA molecules to fragments smaller than 20 nt 
(data not shown). Concurrently, it was found that after a 100-min incubation only 2-10% 
remained of the endogenous EAV RNA or of an in vitro-made transcript when it was 
added to the assay (data not shown). The addition of fresh reaction components (NTPs 
and energy regenerating system) at 80 or 100 min into the assay did not boost product 
formation (data not shown), suggesting that the decrease in incorporation was not due 
to depletion of reaction components or cellular phosphatases [228], but rather to the 
absence of (re)initiation of RNA synthesis (in our system) or to loss of RTC activity. We 
favor the latter explanation, since a >75% reduction in activity was observed when the 
PNS was preincubated, prior to the IVRA, for 1 h at 4° C or 20°C (with or without reaction 
components), suggesting that the RTC activity is not very stable at these temperatures 
(data not shown).
IVRAs performed using varying Mg2+ concentrations revealed that RTC activity is 
strongly dependent on Mg2+ with a relatively narrow optimum (Fig. 1B). Further opti-
mization in the 2-4 mM range (data not shown) indicated 2.5 mM Mg2+ to be optimal, 
yielding maximal amounts of EAV-specific RNA products and minimal amounts of host 
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cell-derived background incorporation. Mg2+ could not be replaced by Mn2+, which 
strongly inhibited the RNA-synthesizing activity (Fig. 1B), even in the presence of Mg2+ 
(data not shown). Addition of Mn2+ led to the accumulation of many small, labeled 
products, suggestive of abortive RNA synthesis, possibly due to compromised RdRp 
processivity.
IVRAs performed at 25°C, 30°C, and 37°C were compared, with maximum yields ob-
tained at 30°C (data not shown). The optimal pH for the RNA-synthesizing activity was 
7.5 (Fig. 1C), since at lower pH hardly any incorporation was observed while at higher pH 
a decrease in EAV-specific incorporation was accompanied by a strong increase in the 
synthesis of background products (Fig. 1C). Both the energy regenerating system and 
exogenous NTPs were essential for activity (Fig. 1D). 
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Fig. 1. Reaction products from in vitro RNA synthesis assays on cytoplasmic extracts from EAV- and 
mock-infected cells. Incorporation of [α-32P]CTP in IVRA products was analysed on denaturing formalde-
hyde-agarose gels followed by PhosphorImager analysis. Marker lanes (hyb) depict the positions of EAV 
RNA1-7 and contain RNA isolated from infected cells, hybridised with a probe complementary to the 3’-
end of all EAV RNAs. The positions of genomic RNA (1) and sg RNA (2-7) are indicated next to the gels. 
Optimization of reaction conditions. (A) Time course analysis of the RNA synthesis assay. After initiation of 
an assay, samples were taken at the times indicated above each lane and RNA was isolated and analyzed 
as described under “Experimental Procedures”. (B) IVRAs carried out with varying Mg2+ concentrations or in 
the presence of Mn2+, as indicated above the lanes. (C) Reactions performed at the pH indicated above each 
lane. (D) Effect of the absence of the energy regenerating system (-energy) or nucleoside triphosphates 
(-NTP) or the presence of 0.1% Triton X-100 (+TX-100). (E) IVRA performed under fully optimised conditions 
with cytoplasmic extracts from mock-infected (mock) or EAV-infected cells (infected).* indicates bands that 
are not EAV-specific and are also detected in assays performed on lysates of mock-infected cells.






Effect of low molecular weight compounds on EAV RTC activity in vitro. 
Addition of KCl, which stimulated the in vitro activity of another RdRp [229], did not 
increase EAV RTC activity. As reported for other viruses [227, 229], Ca2+ strongly inhibited 
in vitro RTC activity, but addition of EGTA had no (stimulating) effect in the case of EAV 
(data not shown). Ionic and non-ionic detergents like SDS, DOC, NP-40, CHAPS (data not 
shown) and Triton-X-100 (Fig. 1D) all completely abolished the accumulation of radiola-
beled viral RNA when added to IVRAs at 0.5x or 5x their critical micelle concentration, 
suggesting a crucial role for membranes. Addition of 0.4 mM cap analogue (m7GpppG) 
had no effect (data not shown), whereas raising the DTT concentration to 10 mM or 
adding 2 mM spermidine resulted in a 60% and 40% reduction, respectively. Therefore, 
none of the aforementioned compounds, which have been used to stimulate the in vitro 
activity of replication complexes of other RNA viruses, were included in the assay that 
was used for further studies. 
The translation inhibitor cycloheximide had no significant effect on the in vitro RTC 
activity (data not shown). In conjunction with the observed lack of 35S-methionine incor-
poration during IVRAs (data not shown), this suggests that (continued) protein synthesis 
is not required for RdRp activity of the EAV RTC in vitro. 
Kinetics of EAV RTC activity in vitro. 
The Km for NTPs reported for in vitro assays with the replication complexes of other RNA 
viruses is in the range of 3-15 µM [229, 230]. Consequently, we presumed that the low 
CTP concentration (0.12 µM) would strongly limit RdRp activity when only radiolabeled 
CTP would be present in EAV IVRAs. To study the kinetics of RNA synthesis by the EAV 
RTC in vitro, reactions were performed with varying amounts of unlabeled CTP (up to 











































































Fig. 2. Kinetics of in vitro CTP incorporation into viral RNA by the EAV RTC. The incorporation of [α-32P]
CTP into total viral RNA at various CTP concentrations was quantified as described under “Experimental 
Procedures” and is expressed as fmol [α-32P]CTP incorporated per mg of protein per hour reaction time 
(squares). The total CTP incorporation (triangles) was calculated based on the specific activity of the iso-
tope.
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of [α-32P]CTP into viral RNA was quantified and the total CTP incorporation was calcu-
lated based on the known specific activity (Fig. 2A). At high specific activity, when the 
[α-32P]CTP was not supplemented with cold CTP, ~22.4 fmol of [α-32P]CTP per mg protein 
per hour was incorporated into viral RNA (Fig. 2A). At low specific activity, when radio-
labeled CTP was supplemented with 200 µM of unlabeled CTP, the CTP incorporation 
rate increased over 400-fold to 9,566 fmol/h/mg protein, while the incorporation rate 
of [α-32P]CTP decreased only 4-fold to 5.8 fmol/h/mg protein. For Sindbis virus and West 
Nile virus similar results have been reported: product detection was better using high 
specific activity radiolabel, while total CTP incorporation was higher when low specific 
activities of radiolabel were used [227, 228]. Using a double reciprocal plot of 1/S versus 
1/V, the Km of the RTC for CTP was estimated to be 48 µM and a Vmax of 11,000 fmol CTP/h/
mg protein was calculated. Using 0.12 µM [α-32P]CTP as a tracer, maximum incorporation 
of radiolabel was detected when the labeled CTP was supplemented with 0.6 µM of 
cold CTP (Fig. 2A). Despite the reaction rate of only 160 fmol CTP/h/mg protein, these 
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Fig. 3. Analysis of IVRA reaction products. (A) Determination of the polarity of in vitro synthesized EAV 
RNA. Control RNA from L-cells (control a) and Sindbis virus (control b) and RNA probes with either the sense 
sequence of the 3’-end of the EAV genome (RNA7+) or its complementary sequence (RNA7-) were immobi-
lized on membranes. These membranes were hybridized with 32P-labeled RNA7+ or RNA7- to determine the 
specificity of the method and with IVRA reaction products to determine the polarity of in vitro synthesized 
EAV RNA (IVRA products). Hybridization of a membrane with a 1:10 dilution of IVRA products was done to 
assess the sensitivity of the method. (B) Incorporation of [α-32P]CTP into the RI, RF and ss RNA forms of in 
vitro synthesized EAV genomic RNA. After a standard IVRA, isolated total RNA (lanes 1-6) underwent various 
treatments and was analyzed in a semi-denaturing 7 M urea-3% polyacrylamide gel. Completely double-
stranded, LiCl-soluble RF RNA (lanes 13-18) was separated from LiCl-insoluble ss and partially ss RI RNAs 
(lanes 7-12) by fractionation in 2 M LiCl. Samples were treated with RNaseA/T1 either using high salt condi-
tions (AH), under which ss RNA is specifically degraded, or under low salt conditions (AL), causing degrada-
tion of all RNA. Double-stranded RNA was specifically degraded by RNase III treatment, as indicated above 
the lanes (III). Some samples were heat-denatured prior to running the gel. The position of ss RNA1 in this 
gel system was determined using 32P-labeled in vitro transcribed RNA1 (IVT RNA1). Only RNA1 is visible in 
this figure, as the sg RNAs migrated off the gel under the electrophoresis conditions applied. The positions 
of RI, RF and ss RNA are indicated next to the gel.






EAV RTC activity in vitro under optimized conditions. 
Fig. 1E depicts the results of a fully optimized IVRA performed using PNS from mock- and 
EAV-infected cells. Besides EAV-specific products, several minor labeled RNA species 
with sizes not corresponding to those of the known EAV RNAs were observed. Probably 
these are cellular RNAs since they were also, often more prominently, detected in assays 
performed with PNS from mock-infected cells (Fig. 1E). Since host cell nuclei had been 
removed and ActD was present, it is unlikely that these aberrant products resulted from 
(residual) host cell transcription. Hence, cellular activities, such as terminal transferases, 
were likely responsible for the labeling of host RNAs [227]. A severe reduction in the 
synthesis of EAV-specific radiolabeled RNA products was observed when using CTP as 
the only NTP in the reaction (Fig. 1D), indicating that a bona fide RdRp activity rather 
than a template- and NTP-independent terminal transferase activity was monitored in 
our assay. The intensity of the background bands could be minimized by carefully opti-
mizing the reaction conditions (especially with respect to pH and Mg2+ concentration), 
resulting in the majority of label being incorporated into EAV-specific products.
Characterization of EAV-specific RNAs synthesized in vitro by the RTC. 
To determine the polarity of the EAV RNAs that are produced by the EAV RTC in vitro, 
32P-labeled IVRA products were hybridized to membranes containing immobilized sense 
(RNA7+) or antisense (RNA7-) probes representing a part (ORF7) of the 3’-proximal region 
of the EAV genome (Fig. 3A). The specificity of this method was confirmed by hybridizing 
these membranes with 32P-labeled, in vitro produced RNA7+ and RNA7- control tran-
scripts (Fig. 3A). The 32P-labeled IVRA products strongly hybridized to the RNA7- probe 
(Fig. 3A), indicating that the EAV RNAs synthesized were mainly of positive polarity. The 
quantity of radiolabeled material that hybridized to immobilized RNA7+ or control RNA 
was at least 60-fold less than that captured by the RNA7- probe. The fact that negative 
sense products were hardly detected was not due to low sensitivity of the assay, as the 
positive sense RNA was still readily detectable when 10x less IVRA products were used 
in the hybridization assay (Fig. 3A).
To study the incorporation of [α-32P]CTP into RI, RF and ss RNAs, reaction products 
were analyzed by LiCl fractionation and by treatment with RNases that specifically de-
grade either ds or ss RNA. Subsequently, products were analyzed in a semi-denaturing 7 
M urea-3% polyacrylamide gel (Fig. 3B), allowing the separation of the RI, RF and ss RNA 
forms [226]. In view of the anticipated complexity of the data for the various sg RNAs 
(which would yield a complex pattern of up to 18 additional bands), the present analysis 
is limited to genomic RNA and the analysis of the RI, RF and ss forms of the sg RNAs will 
be described elsewhere.
Approximately 68% of the radiolabel was detected in a product that migrated at the 
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Fig. 4. Characterization of a host factor required for EAV RTC activity. IVRAs were performed and prod-
ucts were analyzed as described in the legend to Fig. 1. (A) RTC activity in cellular fractions obtained by 
differential centrifugation of the PNS. IVRAs were performed on the lysate before centrifugation (PNS) and 
the supernatant after centrifugation for 10 minutes at 5,000 x g (S5), 10,000 x g (S10) and 16,000 x g (S16). 
(B) IVRAs containing either S16 or P10 alone or P10 supplemented with either S16 from infected cells or 
mock-infected cells as indicated above the lanes. (C) Ability of fractions to stimulate activity of sedimented 
RTCs. IVRAs were performed with 5 µl P10 supplemented with 20 µl of dilution buffer (lane 1) or various 
fractions (lanes 2-13). S16 & S200, 16,000 x g and 200,000 x g supernatant fractions prepared from the 
PNS of EAV-infected cells. F>6 was prepared from S16 by removal of molecules with a molecular mass <6 
kDa by size exclusion chromatography. F<10, F<100 and F<1000 were prepared from S16 by ultrafiltration 
over filters with 10, 100 and 1000 kDa cut-offs, respectively. S16 was treated (+) or mock-treated (-) with 
micrococcal nuclease (MNase) or 0, 2.0, 0.4 or 0.08 mg/ml proteinase K as indicated above lanes 10-13. (D) 
IVRAs performed with RTCs isolated from infected BHK-21 cells (5 µl of P10) and supplemented with 20 µl 
of dilution buffer (-) or 20 µl of S200 fractions from HeLa cells (Homo sapiens; Hs), Vero E6 cells (Cercopithecus 
aethiops; Ca), BHK-21 cells (Mesocricetus auratus; Ma), 1-day old zebrafish embryos (Danio rerio; Dr), C6/36 
cells (Aedes albopictus; Aa) or yeast cells (Saccharomyces cerevisiae; Sc), all diluted to result in the addition 
of 30 µg of total protein per IVRA reaction. (E) Purification of the host factor from a HeLa cell S200 fraction 
by gel filtration. IVRAs were performed with isolated RTCs (P10) supplemented with various fractions from 
the gel filtration colum, as indicated at the bottom of the gel. The molecular mass range of each fraction 
was extrapolated from a calibration curve and is indicated under the fraction numbers. (F) Analysis of 0.5 
µl of PNS, S200, and column fraction 13 by SDS-PAGE and silver staining (lane 1-3). Lane 4 contains 5 µl of 
column fraction 13.






in the faster migrating RF form of RNA1 (Fig. 3B, lane 1). When the IVRA products were 
heat-denatured prior to electrophoresis, a product migrating at the position of ss RNA 
was visible (Fig. 3B, lane 2). After degradation of ss RNA by RNase A/T1 treatment under 
high salt conditions, only a band at the position of the nuclease resistant RF form was 
observed (Fig. 3B, lane 4). The increased intensity of the RF band in lane 4 (compared 
to lane 1) was likely due to the redistribution of label from the RI form, which was con-
verted into RF through degradation of nascent strands. Likewise, the denaturation of 
RNase A/T1-treated RNA converted the RF into ssRNA (lane 5). All RNAs were completely 
degraded upon RNase A/T1 treatment under low salt conditions (lane 3). After treatment 
with the ds RNA-specific RNase III, labeled products were observed almost exclusively at 
the position of ss RNA1 (lane 6). 
The LiCl-insoluble fraction contained the (partially ss) RI and ss RNA1 and no RF RNA, 
the latter being LiCl-soluble (Fig. 3B, lane 7 and 13). After RNase A/T1 treatment of the 
LiCl pellet fraction, the ss RNA was no longer detectable and the RI was converted into 
the RF (Fig. 3B, lane 10). Upon denaturation of this sample, the band migrating at the RF 
position disappeared and a smear appeared at the position between the ssRNA and RF 
bands in the gel, which probably represented abrogated and partially degraded labeled 
molecules that had originally been part of the ds regions of the RI (lane 11). 
The RF form was soluble in 2 M LiCl (Fig. 3B, lane 13), which indicates that it was 
completely double-stranded. This was further substantiated by the observation that it 
was fully degraded by RNase III and completely resistant to RNase A/T1-treatment (lanes 
16 and 18). After denaturation of LiCl-soluble RNA that was either untreated or RNase A/
T1-treated, a discrete band migrating at the expected position of ssRNA was observed. 
This indicates that, unlike the RI (lane 11), the RF was completely double-stranded and 
consisted of two full-length molecules of opposite polarity (lanes 14 and 17). 
Taken together, these data indicate that the EAV RTC catalyzed the incorporation 
of nucleotides into the RI and RF forms of RNA1 in vitro and that ss genomic RNA was 
released from (one or both of ) these forms.
EAV RTC activity depends on a cytosolic host factor. 
To determine whether isolation of active EAV RTCs can be achieved by differential 
centrifugation, we first determined the g-force required to remove RdRp activity from 
the PNS. Supernatants prepared by centrifugation at 5,000 x g, 10,000 x g, or 16,000 x 
g retained 38%, 8%, and 3% of the activity, respectively (Fig. 4A). For subsequent ex-
periments pelleting at 10,000 x g was used, as we were able to routinely remove about 
95% of activity from the PNS, while the pellet could still be readily resuspended (this 
was more difficult for a 15,000 x g pellet, increasing the risk of mechanical damage to 
the RTC by sheering forces). The activity producing the background product migrating 
directly above RNA2 in all lanes of the gel in Fig. 4A remained in the cytosolic fractions, 
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suggesting that it is soluble, and could thus be separated from the RTC by this method. 
Surprisingly, the resuspended P10 pellet only exhibited very weak RTC activity (Fig 4B, 
lane 2). However, this activity could be stimulated considerably with an aliquot of a 
supernatant fraction (S16; lane 3). Importantly, S16 prepared from mock-infected cells 
was equally capable of restoring the RTC activity of P10, demonstrating that the factor 
involved must be of host origin (lane 4). 
To determine the nature of the host factor required for RTC activity, the S16 fraction 
was fractionated by centrifugation, ultrafiltration, and size exclusion chromatography, 
and was also treated with either a nuclease or a protease (Fig. 4C). The host factor did not 
















Fig 5. Distribution of nsps after fractionation of the PNS from EAV-infected cells into a 10,000 x g su-
pernatant (S10) and RTC-containing pellet (P10). Equivalent amounts of S10 and P10 derived from the 
same number of cells were analyzed by Western blotting with anti-nsp10, anti-nsp9, anti-nsp7-8, anti-nsp4, 
anti-nsp3, anti-nsp2, and anti-nsp1 antibodies. Numbers in brackets indicate the percentage of the protein 
that is present in the P10 fraction. 






associated with cellular organelles. A fraction from which molecules smaller than 6 kDa 
had been removed by size exclusion chromatography retained the ability to activate the 
isolated RTC (Fig. 4C, lane 4), indicating that the factor(s) is not a low molecular weight 
compound, like an NTP or metal ion. The host factor was removed by ultrafiltration using 
a filter with a 10 kDa cut-off value, but passed through filters with 100 kDa or 1000 kDa 
cut-offs (Fig. 4C, lanes 5-7). Nuclease treatment had no effect, while protease treatment 
destroyed the ability of an S16 fraction to activate pelleted RTCs (Fig. 4C, lanes 8-13). 
Taken together these data indicate that the host factor that is required for the activity 
of isolated RTCs is a soluble cytosolic protein with a native molecular mass in the range 
of 10-100 kDa.
To determine whether the host factor is also present in other cell types than BHK-21 
cells, S200 fractions from various (uninfected) mammalian, fish, insect and yeast cells 
were tested for their ability to activate RTCs isolated from EAV-infected BHK-21 cells (Fig. 
4D). With the exception of yeast, S200 fractions from all organisms tested were able to 
reconstitute RTC activity of the P10 fraction, indicating that the host factor is likely to be 
conserved in animal cells. 
The host factor was further purified from a HeLa cell S200 fraction by gel filtration 
chromatography, since we anticipated that the available data on the human genome 
and proteome would facilitate future identification of the factor by e.g. mass spectrom-
etry. Each gel filtration fraction was analyzed for the presence of the host factor by 
adding it to an IVRA with pelleted RTCs (P10 fraction) isolated from EAV-infected BHK-21 
cells (Fig. 4E). Fraction 13, which contains proteins with a mass of 53-70 kDa, exhibited 
the maximum stimulatory effect on RTC activity (Fig. 4E). In an independent experiment, 
in which slightly different column fractions were collected, the host factor was retrieved 
in the fraction containing 59-78 kDa proteins (data not shown). Taken together these 
studies suggest that the (native) mass of the host factor is between 59 and 70 kDa. 
Compared to PNS or an S200 fraction, the protein concentration of column fraction 
13 was greatly reduced and its composition was clearly less complex (Fig. 4F, lane 1-3), 
without affecting its ability to stimulate the RTC, indicating that we have achieved a 
significant purification of the host factor. However, fraction 13 still contained over 30 
proteins, as could be observed when a 10-fold larger sample was analyzed (Fig. 4F, 
lane 4), and therefore additional purification steps will be required for the unequivocal 
identification of the host factor. A potential complicating factor for this follow-up might 
be that the host factor is (part of ) one of the homo- or hetero-multimeric complexes 
that are apparently present in fraction 13, which would explain the presence of several 
polypeptides with a mass smaller than 53 kDa in this fraction (Fig. 4F, lane 4).
Quantitative analysis revealed that the sedimentation procedure used to prepare P10 
fractions led also to a substantial non-recoverable loss of RTC activity with a significant 
variation between individual experiments. Typically, 10-50% of the activity that was 
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originally present in the PNS could be recovered in P10 fractions when assayed in the 
presence of the trans-activating host factor. The considerable loss of activity was appar-
ently not due to the resuspension procedure of the RTC pellets, since resuspending less 
vigorously or not at all further reduced the recovery of activity (data not shown). The P10 
fractions typically contained 3-7% of the protein that was present in the PNS. Therefore, 
despite the low yield, a 2- to 13-fold increase in specific RTC activity was achieved when 
comparing P10- to PNS-based samples.
Distribution of EAV nsps between S10 and P10 fractions. 
To start defining the composition of the RTC and the potential roles of the various EAV 
nsps in viral RNA synthesis, the distribution of these proteins between the P10 and S10 
fractions was investigated by western blotting (Fig. 5). As anticipated, nsp2 and nsp3 
were almost exclusively present in the P10 fraction. These subunits contain hydrophobic 
domains [33, 202], have been implicated in virus-induced membrane modifications, and 
likely are a structural component of the DMVs [217]. The nsp9-RdRp and nsp10-helicase 
subunits were also predominantly found in P10. Significant amounts of larger nsp9 
precursors were recovered from the cytosolic S10 fraction, likely representing replicase 
polyproteins and cleavage intermediates, whose processing is relatively slow [223]. 
Mature nsp4-main protease largely remained in S10, separated from the nsp9-RdRp and 
nsp10-helicase, suggesting its presence is not (or no longer) required for RTC activity. On 
the other hand the long-lived nsp3-4 processing intermediate [231] was present in the 
P10 fraction, probably through membrane association of its hydrophobic nsp3 part [33]. 
Also a large proportion of the nsp3-8, nsp5-8 and nsp5-7 intermediates cosedimented 
with the RTC, probably as a result of the membrane-association of the hydrophobic nsp5 
part of these proteins. Polypeptides lacking this hydrophobic domain, like the nsp6-8, 
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Fig 6. Electron micrographs of the RTC-containing P10 fraction and EAV-infected cells. (A) 
Immunoelectron microscopy with anti-nsp3 rabbit serum on the chemically fixed P10 fraction. (B) Control 
labeling of the P10 fraction with preimmune serum from the same animal. (C) Electron micrograph of a thin 
section of cryofixed EAV- infected BHK-21cells. Scale bar: 100 nm.






nsp7-8 and nsp6-7 products of the minor proteolytic processing pathway [232], were 
mainly recovered from the cytosolic fraction (Fig. 5). In the case of nsp1, a multifunctional 
autoprotease whose zinc finger domain has been directly implicated in EAV transcrip-
tion [233-235], approximately 75% of the protein was found in the cytosolic S10 fraction, 
but ~25% of the protein was recovered from the RTC-containing P10 fraction, which is 
in line with its essential role in sg RNA synthesis. A comparable nsp1 distribution was 
observed in vivo by immunofluorescence microscopy of infected cells (D.D. Nedialkova, 
E.J. Snijder, et al., unpublished observations).
DMVs are present in the RTC-containing P10 fraction. 
The RTC-containing P10 fraction was analyzed by electron microscopy (negative 
staining) in combination with an immunogold labeling for nsp3 (Fig. 6A). The fraction 
contained abundant vesicles with a diameter of 60-80 nm that clearly appeared to have 
a double membrane and labeled strongly when using an anti-nsp3 rabbit serum. Im-
munogold labeling was not observed when the preimmune serum of the same rabbit 
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Fig 7. Distribution of endogenous and newly in vitro synthesized EAV RNA. (A) Distribution of endog-
enous EAV RNA. Viral RNA recovered from the 10,000 x g supernatant (S10) and pellet (P10) obtained after 
centrifugation of the PNS of EAV-infected cells was analyzed by denaturing formaldehyde-agarose elec-
trophoresis and hybridization with a 32P-labeled probe complementary to the 3’-end of all EAV RNAs. (B) 
Distribution of in vitro synthesized EAV RNA. After an IVRA, the PNS was fractionated into a 10,000 x g su-
pernatant (S10) and pellet (P10). 32P-labeled in vitro synthesized RNA was visualized by denaturing formal-
dehyde-agarose electrophoresis and direct PhosphorImager analysis. The percentage of each RNA species 
that is present in the P10 fraction is indicated to the right of each gel. Numbers for RNA 3, 4, 5 are absent in 
panel B because the signal obtained with the P10 fraction was too low to be reliably quantified.
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was used (Fig. 6B). These structures were slightly smaller than the DMVs observed in 
infected cells (Fig. 6C; [201]), which might be due to differences in fixation methods. The 
overall morphology, presence of a double membrane, and abundant presence of nsp3 
were all consistent with the notion that the P10 fraction is enriched for the virus-induced 
DMVs that are observed in EAV-infected cells. Such structures were not observed in P10 
fractions prepared from mock-infected cells (data not shown).
Distribution of EAV RNA between S10 and P10 fractions. 
The distribution of endogenous EAV RNA between the P10 and S10 fractions was ana-
lyzed by quantitative hybridization of RNA isolated from these fractions using a probe 
complementary to the 3’-end of all EAV mRNAs. Endogenous genomic RNA was approxi-
mately evenly distributed between the cytosolic S10 fraction and the RTC-containing 
P10 (Fig. 7A). Conversely, sg mRNAs were mainly recovered from the cytosolic S10 frac-
tion (Fig. 7A). This differential distribution of genome versus sg mRNA was even more 
striking for newly synthesized RNA that was labeled in vitro using PNS, after which a 
fractionation into P10 and S10 was performed (Fig. 7B). The bulk of newly made genomic 
RNA remained associated with the RTC in P10, while only a small fraction, presumably 
single-stranded RNA released from the RTC, was present in S10. In contrast, newly made 
sg mRNAs were mainly recovered from the cytoplasmic S10 fraction suggesting their 
rapid release from the complex in which they had been synthesized. 
DISCUSSION
Characterization of EAV RTC activity in vitro. 
In this study, we describe the first procedure for the isolation of an active arterivirus 
RTC from infected cells and the initial biochemical characterization of its composition 
and RNA synthesizing activity. Using EAV, one of the best studied nidovirus models, we 
succeeded in obtaining an RTC preparation capable of the in vitro synthesis of both viral 
genomic RNA and all sg RNAs. The isolated RTC incorporated radiolabel into EAV-specific 
products in a reaction mixture containing [α-32P]CTP, Mg2+ and an energy regenerating 
system. The absence of such products in IVRAs performed with lysates from mock-
infected cells, and their dependence on the presence of all four NTPs, demonstrated that 
they resulted from genuine viral RdRp activity. To our knowledge, this is the first robust 
in vitro system for nidovirus replication and transcription. RdRp activity in cell lysates has 
been reported previously for the (very distantly) related coronaviruses MHV and TGEV 
[236-240], but these activities were in some cases barely detectable and appeared to 
be rather unstable. Furthermore, reaction products were not characterized [236, 238], 
there were discrepancies between the sizes of in vitro and in vivo synthesized viral RNA 






[237, 240], only genome-sized RNA was detected [239] or conflicting observations were 
reported [237-239, 241]. The EAV in vitro assay described here should facilitate studies 
into the role of membranes, host factors and viral proteins involved in replication and 
transcription and allow for the more detailed characterization of the nidovirus RTC at 
the molecular level.
Up to 100 min into the reaction, radiolabeled products accumulated, after which a 
decrease was observed, probably due to a decreasing RNA synthesis rate in combina-
tion with a steady rate of degradation by cellular nuclease activity. Consistent with our 
results, nucleases in BHK-21 cell extracts were previously reported to be responsible for 
the cessation of in vitro RdRp activity of other viruses [228, 242, 243]. The Km for CTP of 
the EAV RTC was estimated to be 48 µM, slightly higher than values (3-15 µM) reported 
for other viruses [229, 230] and the Vmax of CTP incorporation was calculated to be ap-
proximately 11,000 fmol/h/mg protein. This is approximately 5-fold higher than the in 
vitro RdRp activity reported for several flaviviruses (1000-2700 fmol/h/mg; [229, 244, 
245]), more than 20-fold higher than activities previously reported for brome mosaic 
virus (59) and the coronaviruses TGEV [240] and MHV [236], and 5- to 20-fold lower than 
values reported for several alpha- and picornaviruses [228, 246-248]. For EAV an up to 
13-fold increase in specific activity could be achieved when the RTC was partially puri-
fied by sedimentation at 10,000 x g. Incorporation of radiolabel into the RI, RF and ss 
forms of EAV RNA1 was observed, mainly into RNA of positive polarity, which is in line 
with the asymmetric synthesis of a large excess of plus strands over minus strands that 
is commonly observed in vivo. 
The in vitro activity of the EAV RTC was strongly dependent on Mg2+, as also reported 
for other positive-stranded RNA viruses [227, 229, 230, 236, 239, 244, 246-258]. For EAV, 
Mn2+ could not replace Mg2+, and had a strong inhibitory effect, even at low concentra-
tions and despite the presence of Mg2+. This suggested that it competes for Mg2+ binding, 
while interfering with enzymatic activity. EAV RTC activity was also inhibited by other 
divalent cations, like Zn2+ and Ca2+ (manuscript in preparation), as has also been found 
for West Nile virus and Japanese encephalitis virus RdRp activity [227, 229]. A strong 
inhibitory effect of Mn2+ on in vitro RdRp activity was reported for various other viruses 
[240, 246, 247, 250, 252, 259], although for several flaviviruses Mn2+ could substitute for 
Mg2+ to a limited extent [227, 229, 253-255, 257, 260]. Addition of Mn2+ to the EAV IVRA 
promoted the accumulation of small products, suggesting elongation/processivity was 
affected, as was observed for Japanese encephalitis virus, hepatitis C virus and brome 
mosaic virus [229, 255, 261]. The inhibition of the EAV RTC activity by Mn2+ contrasts with 
the Mn2+-dependence of the purified EAV nsp9-RdRp that was recently reported [215]. 
However, this nsp9-RdRp activity was only observed on artificial templates rather than 
natural templates.
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An energy regenerating system was essential for EAV RTC activity, which might for 
example be due to the ATP-dependence of the nsp10-helicase that presumably plays a 
key role in RNA synthesis and/or release of ss RNA. Supporting this idea, in a pestivirus in 
vitro RdRp assay, radiolabel was only detected in ds RNA and no longer in ss RNA in the 
absence of an energy regenerating system [245].
Thus far, it remains unclear whether the isolated RTC is capable of initiation of viral 
RNA synthesis in vitro or is only elongating nascent RNA molecules (plus strands in RIs) 
initiated in vivo. Continuous incorporation of label in short sg RNAs, like RNA7, up to 100 
min after the start of the assay might indicate initiation of RNA synthesis in vitro, since 
in the absence of initiation, accumulation of short RNAs would be expected to peak 
before that of longer molecules. On the other hand, the isolated RTC did not evidently 
utilize an exogenous replication-competent plus strand RNA (replicon EDI [262]) as 
template for RNA synthesis (data not shown). However, it should be noted that such a 
positive sense RNA may be a poor template in our assay for a variety of reasons related 
to the properties of the RTC, like the predominant synthesis of plus strands, exogenous 
macromolecules being unable to enter (preformed) membrane-associated RTCs, or RTC 
formation occurring in cis, e.g. in conjunction with translation of the RNA, which is not 
likely to occur in this in vitro assay (see below). In support of this latter notion, it was 
found that preformed poliovirus replication vesicles, resulting from the expression of 
viral proteins, did not participate in the formation of active replication complexes after 
poliovirus superinfection [263]. 
No measurable protein synthesis was observed in our PNS and the addition of the 
translation inhibitor cycloheximide had little effect on viral RNA synthesis in vitro, sug-
gesting that continued protein synthesis is not required for in vitro RTC activity, as was 
also reported for poliovirus, hepatitis C virus and Kunjin virus [264-266]. However, for 
the coronavirus MHV, translation inhibition blocked viral RNA synthesis (particularly 
minus strand synthesis) both in vivo [241] and in vitro [236, 239]. These conflicting ob-
servations, might reflect fundamental differences in the mechanism of replication of 
arteri- and coronaviruses or might be due to technical differences between the systems 
used. 
The activity of isolated RTCs depends on a cytosolic host factor. 
EAV RTC activity was associated with heavy membrane structures that could be sedi-
mented from PNS at 10,000 x g (P10). The addition of non-ionic detergents destroyed 
all RTC activity, consistent with an important role of membranes in RTC structure and/
or function, a common feature of many positive-stranded RNA viruses. Hardly any RTC 
activity was detected in the resuspended P10 fraction when it was assayed in a standard 
IVRA. The activity was however considerably stimulated when the reaction was supple-
mented with the S16 fraction from either infected or mock-infected BHK-21 cells, and 






further experiments suggested that a cytosolic host protein is required for RTC activity. 
This host factor was also present in the cytosol of the various mammalian, fish and insect 
cells that were tested, but not in yeast cells, suggesting it is highly conserved in animal 
cells (Fig. 4D). The host factor was partially purified from the cytosol of HeLa cells by gel 
filtration chromatography, revealing a native mass of between 59 and 70 kDa. The future, 
unambiguous identification of the host protein factor required for EAV RTC activity will 
depend on the successful development of a protocol allowing its further purification 
without loss of activity. Follow-up studies to explore this issue are currently in progress. 
Besides EAV, the fact that the activity of isolated membrane-associated viral replica-
tion complexes depends on a host factor has only been reported for poliovirus [264] and 
not for the isolated membrane-associated replication complexes of various other viruses 
[229, 255, 267-270]. Whether this is due to fundamental differences between replication 
complexes of different viruses or due to variations in isolation and assay procedures 
remains to be seen. For instance, host factors might be involved in the RNA synthesis of 
all viruses, but their copurification with the active complex might depend on the mode 
of their association with the replication complex.
Structural characterization of the isolated EAV RTC. 
Ultrastructural analysis of the RTC-containing heavy membrane pellet fraction by im-
munoelectron microscopy revealed the presence of nsp3-containing DMVs, resembling 
those observed in EAV-infected cells [201]. Analysis of the distribution of replicase 
subunits between the cytoplasmic S10 fraction and the RTC-containing P10 fraction, re-
vealed that proteins previously implicated in viral RNA synthesis (nsp9-RdRp and nsp10-
helicase; [215, 216]) and DMV formation (nsp2 and nsp3; [217]) exclusively cosedimented 
with the active RTC. In contrast, the main protease nsp4 was found predominantly in the 
cytosolic S10 fraction and not cosedimenting with RTC activity, suggesting its presence 
is not (or, rather, no longer) required for RTC activity. The P10 fraction also contained 
substantial amounts of the nsp3-8, nsp5-8, nsp5-7 processing intermediates and the 
multifunctional nsp1 [233-235], which is in line with its essential role in sg RNA synthesis. 
In general, these data are in agreement with previously reported immunofluorescence 
and electron microscopy data [33, 201, 202]. 
The bulk of newly synthesized EAV genomic RNA remained associated with the RTC, 
while sg mRNAs were mainly found in the cytoplasmic fraction, suggesting their rapid 
release from the complex by which they had been synthesized. It is unlikely that the 
relative enrichment in genomic RNA is merely due to the slow release of labelled ss 
RNA from the RI, as 68% of radiolabel was present in the ss form and only 30% in the RI 
form of RNA1. These results might reflect the existence of separate pools of RNAs with 
distinct roles in the viral life cycle. The molecules that were released from the RTC might 
be destined for translation, leading to the synthesis of structural proteins (mRNA2-7) 
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and additional replicase subunits (mRNA1). The RNA1 molecules that remained associ-
ated with the RTC might serve as new templates for replication and transcription and/or 
become incorporated into new virions, assuming packaging occurs in coordination with 
replication. In this context, the reported partial colocalization of the N protein with the 
RTC of EAV [270] and other nidoviruses [32] is an interesting observation. Intracellular 
virions that were already present upon cell lysis probably contributed to the amount 
of (mainly unlabeled) endogenous genomic RNA recovered from the cytosolic fraction.
In conclusion, DMV-like double membrane structures, newly in vitro synthesized viral 
RNA, and several key replicase subunits cosedimented with EAV RTC activity, which was 
also found to be dependent on a cytosolic host factor. Taken together, these data confirm 
and extend the link between these modified membranes and nidovirus replication and 
transcription. Our analysis indicates that membranes are essential for RTC function, e.g. 
to protect the RTC against the observed cellular nuclease activity. In addition, seques-
tering the RTC in specific membrane-bounded compartments might be important for 
separating and/or coordinating different processes in the viral life-cycle (e.g. replicase 
processing, replication, translation, and packaging), which might be reflected by the 
differential distribution of genomic and sg RNA and the various viral proteins. 
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Cyclophilin inhibitors block arterivirus replication 
by interfering with viral RNA synthesis
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Virus replication strongly depends on cellular factors, in particular on host proteins. 
Here we report that the replication of the arteriviruses equine arteritis virus (EAV) and 
porcine reproductive and respiratory syndrome virus (PRRSV) is strongly affected by 
low-micromolar concentrations of cyclosporin A (CsA), an inhibitor of members of the 
cyclophilin (Cyp) family. In infected cells, the expression of a green fluorescent protein 
(GFP) reporter gene inserted into the PRRSV genome was inhibited with an IC50 of 5.2 
µM, whereas the GFP expression of an EAV-GFP reporter virus was inhibited with an 
IC50 of 0.95 µM. Debio-064, a CsA analog that lacks its undesirable immunosuppressive 
properties, inhibited EAV replication with an IC50 that was three-fold lower than that of 
CsA, whereas PRRSV-GFP replication was inhibited with an IC50 similar to that of CsA. The 
addition of 4 µM CsA after infection prevented viral RNA and protein synthesis in EAV-
infected cells, and CsA treatment resulted in a 2.5 to 4-log reduction of PRRSV or EAV 
infectious progeny. A complete block of EAV RNA synthesis was also observed in an in 
vitro assay using isolated viral replication structures. The siRNA-mediated knockdown of 
Cyp family members revealed that EAV replication strongly depends on the expression 
of CypA, but not CypB. Furthermore, upon fractionation of intracellular membranes in 
density gradients, CypA was found to cosediment with membranous EAV replication 
structures, which could be prevented by CsA treatment. This suggests that CypA is an 
essential component of the viral RNA-synthesizing machinery. 







The replication of RNA viruses strongly depends on their successful interplay with the 
host cell at multiple levels. By now, a wide variety of host cell proteins have been im-
plicated in RNA virus replication and some of these might in fact constitute interesting 
targets for antiviral therapy [60]. Thus, the possibility to target host factors rather than 
viral proteins is receiving increasing attention as an alternative and promising antiviral 
approach (reviewed in [130, 131]). In contrast to antiviral therapy that aims to inhibit 
viral protein functions, the use of drugs targeting host factors should not lead to drug 
resistance, which is a common problem when combating RNA viruses due to their high 
mutation rate and potential for rapid adaptation.
The drug cyclosporin A (CsA) was previously found to inhibit the replication of a num-
ber of RNA viruses [271-275]. Recently, multiple laboratories, including our own, reported 
that also the replication of various (human) coronaviruses, including SARS-coronavirus 
(SARS-CoV), can be inhibited by CsA treatment [276-278]. This drug affects the function 
of several members of the cellular cyclophilin (Cyp) protein family, which consists of 
peptidyl-prolyl isomerases (PPIase) that act as chaperones to facilitate protein folding, 
and are involved in protein trafficking and immune cell activation [279, 280]. Although 
Cyps share many similarities in terms of structure and activity, important differences 
in specific functions and subcellular localization have been documented [280]. In line 
with the inhibition of virus replication by CsA, Cyp family members were identified as 
essential host factors in the replicative cycle of several virus groups (reviewed in [281]). 
The drug CsA has been widely used as an immunosuppressant, e.g. in organ transplant 
patients [282], as its binding to various Cyps impairs calcineurin activity and abrogates 
the T cell response. As Cyps appeared to be relevant targets for antiviral therapy, several 
Cyp inhibitors have been developed that lack the immunosuppressive properties of 
CsA, which would be an undesirable side-effect during antiviral therapy. The efficacy of 
several of such compounds, e.g. Debio-025 and NIM811, is currently being explored in 
clinical trials for the treatment of hepatitis C virus (HCV) infection [283-285].
Since the replication of coronaviruses like SARS-CoV is inhibited by CsA [276, 277], 
we investigated whether this drug also inhibits the distantly related arteriviruses, which 
together with the coronavirus and ronivirus families constitute the order Nidovirales 
[286]. The arterivirus porcine reproductive and respiratory syndrome virus (PRRSV) is 
one of the leading veterinary pathogens, causing an estimated annual loss of 664 mil-
lion dollars in the swine industry in the USA alone [27]. Equine arteritis virus (EAV), in 
addition to being a relevant horse pathogen, has been used for decades as a model to 
dissect the molecular details of arterivirus and nidovirus replication [287]. 
Arteriviruses are positive-stranded RNA viruses with a genome size of about 13-16 
kb [37]. Their complex genome expression strategy involves genome translation to 
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produce the polyprotein precursors for the viral nonstructural proteins (nsps) as well 
as the synthesis of a nested set of subgenomic (sg) mRNAs to express the structural 
proteins [40]. The viral nsps, presumably together with various host factors, are thought 
to assemble into membrane-associated replication and transcription complexes (RTCs) 
that drive viral RNA synthesis (for recent reviews, see [37, 47]). Arterivirus RNA synthesis 
was reported to be associated with a virus-induced network of endoplasmic reticulum 
(ER)-derived membrane structures, including large numbers of double-membrane 
vesicles [29]. Many arteriviral proteins were found to be associated with these mem-
brane structures, on which viral RNA synthesis was found to depend [33, 52]. However, 
thus far, the identity and role of proviral host factors involved in the replicative cycle of 
arteriviruses has remained largely unexplored. 
Using EAV and PRRSV, our studies on the inhibition of nidovirus replication by CsA 
have now been extended to arteriviruses and explored the mechanism of action of the 
compound in more detail. We show that low micromolar concentrations of CsA can fully 
block arterivirus RNA synthesis and that the non-immunosuppressive cyclophilin inhibi-
tor Debio-064 is an even more potent inhibitor. These compounds probably exert their 
effect through their inhibition of CypA, as RNAi-mediated knockdown of CypA strongly 
affected EAV RNA synthesis and CypA was found to cosediment with EAV replication 
structures.  
MATERIALS AND METHODS
Cell culture, infection, and virus titration
BHK-21 [288], Vero E6 [220], and MARC-145 cells [289] were cultured as described previ-
ously. 293/ACE2 cells [74] were cultured in Dulbecco’s modified Eagle’s medium (DMEM; 
Lonza) supplemented with 8% FCS, 100 U/ml of penicillin and 100 µg/ml of streptomy-
cin, 2 mM L-Glutamine, and 12 µg/ml Blasticidin (PAA). A cell culture-adapted derivative 
of the EAV Bucyrus isolate [290] and GFP-expressing recombinant EAV [291] were used 
to infect monolayers of BHK-21, Vero E6, and 293/ACE2 cells at an MOI of 5 as described 
previously [220, 288]. MARC-145 cells were infected with a GFP-expressing recombinant 
PRRSV (SD01-08-GFP) at an MOI of 0.1 as previously described [292]. EAV titers in cell 
culture supernatants were determined by plaque assay on BHK-21 cells [288], whereas 
PRRSV titers were determined by fluorescent focus assay (FFA) on MARC-145 cells, as 
described previously [293]. For IC50 determinations, cells were grown in black 96-well 
plates (Greiner), infected with EAV-GFP or PRRSV-GFP and treated with compounds in 
octuplet. GFP reporter expression was quantified by measuring fluorescence in a 96-well 
plate reader, using an excitation wavelength of 485 nm and emission wavelength of 535 
nm.







Rabbit polyclonal antibodies against CypA (Abcam), CypB (Abcam), and Calnexin (BD), 
a goat polyclonal antiserum against GAPDH (Santa Cruz), and a mouse monoclonal 
antibody (mAb) against β-actin (Sigma) were used. Rabbit antisera recognizing the EAV 
replicase subunits nsp3 [201] and nsp9 [52], and the EAV membrane (M) protein [220], 
and a mAb against the EAV nucleocapsid (N) protein [294] have been described previ-
ously. The cyclophilin inhibitors CsA (Sigma) and Debio-064 (Debiopharm, Switzerland) 
were dissolved in DMSO. CsA was stored as 50 mg/ml stock at -20°C and Debio-064 
was stored as a 10 mM stock at 4°C in aliquots for single use. The IC50 of inhibitors was 
calculated with Graphpad Prism 5 using the nonlinear regression model. 
Immunofluorescence microscopy
EAV-infected or mock-infected BHK-21 cells, grown on coverslips at 39.5°C, were fixed 
with 3% paraformaldehyde in PBS, permeabilized with 0.1% Triton X-100, and processed 
for immunofluorescence microscopy as described previously [33]. Specimens were ex-
amined with a Zeiss Axioskop 2 fluorescence microscope with an Axiocam HRc camera 
and Zeiss Axiovision 4.4 software. 
Western blot analysis
After SDS-PAGE, proteins were transferred to Hybond-LFP membranes (GE Healthcare) 
by semi-dry blotting. Membranes were blocked with 1% casein in PBS containing 0.1% 
Tween-20 (PBST), and were incubated with anti-nsp3 (1:2000), anti-nsp9 (1:2000), 
anti-M (1:2000), anti-N (1:10,000), anti-CypA (1:1000), anti-CypB (1:2000), or anti-β-actin 
(1:50,000) antisera, diluted in PBST with 0.5% casein. Biotin-conjugated swine-anti-rabbit 
IgG (1:2000) or goat-anti-mouse IgG (1:1000) antibodies (DAKO) and Cy3-conjugated 
mouse-anti-biotin (1:2500) were used for detection. Blots were scanned with a Typhoon 
9410 imager (GE Healthcare) and analyzed with ImageQuant TL software.
Isolation of EAV RTC-containing replication structures and in vitro RNA 
synthesis assays
EAV replication structures were isolated from BHK-21 or Vero E6 cells, and in vitro RNA 
synthesis assays were performed essentially as described previously [52]. In short, ap-
proximately 1 × 108 EAV-infected BHK-21 or Vero E6 cells were harvested at 6 or 7 h p.i., 
and cells were lysed to obtain a post nuclear supernatant (PNS) [52]. A standard in vitro 
RNA synthesis assay contained 20 µl of PNS (the equivalent of 6 x 104 cells) from EAV-
infected BHK-21 cells, 5 µl of an inhibitor solution or 5 µl of RTC dilution buffer (control). 
Following gel electrophoresis, 32P-labeled reaction products were analyzed by denatur-
ing agarose gel electrophoresis and by exposing a PhosphorImager screen directly 
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to the dried gel, after which screens were scanned with a Typhoon 9410 imager (GE 
Healthcare), and incorporation of label was quantified using ImageQuant TL software.
Density gradient fractionation
Subcellular fractionation of PNS was performed in continuous 0-30% OptiPrep density 
gradients in RTC dilution buffer. The gradients were prepared in 13.2 ml Ultra Clear cen-
trifugation tubes (Beckman Coulter) using a Gradient Master (Biocomp). One ml of PNS 
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Fig. 1. Cyclosporin A treatment blocks EAV-GFP and PRRSV-GFP replication. (A) BHK-21 cells were in-
fected with EAV-GFP at a MOI of 5 and at 1 h p.i. the inoculum was replaced by medium containing different 
concentrations of CsA, as indicated on the x-axis. Cells were fixed at 18 h p.i. and GFP reporter expression 
was quantified and normalized to the GFP signal of control cells (100%) treated with DMSO (solvent con-
centration equal to that of the cultures that received 4 µM CsA). (B) The effect of CsA on cell viability, com-
pared to untreated control cells (100%), was determined using the CellTiter 96® AQueous Non-Radioactive 
Cell Proliferation Assay (Promega). Graphs show the results (avg and SD) of a representative experiment in 
quadruplo. (C) MARC-145 cells were infected with PRRSV-GFP at a MOI of 0.1 and at 1 h p.i. the inoculum 
was replaced by medium with CsA. Cells were fixed at 24 h p.i. and GFP reporter expression was quantified 
and normalized to the signal in solvent-treated control cells (100%). (D) The effect of CsA on the viability of 
the MARC-145 cells, compared to untreated control cells (100%). Graphs show the results (avg and SD) of a 
representative experiment (n=8). All experiments were repeated at least twice. 






gation for 17 h at 48,000 x g in a SW41 rotor at 4°C, the gradient was fractionated into 0.5 
ml fractions. The density of each fraction was determined with a refractometer (GETI).
Metabolic labeling of viral RNA synthesis
Labeling of viral RNA with [3H]uridine was performed essentially as described previously 
[295]. Briefly, at 4.5 h p.i. 4 x 105 EAV-infected BHK-21 cells in 4-cm2 dishes were given 
medium containing 10 µg/ml actinomycin D (ActD; Sigma-Aldrich), and either 4 µM CsA 
or 0.01% DMSO as solvent control. After 1 h, viral RNA synthesis was labeled by adding 
100 µCi of [3H]uridine to the medium. The 3H-labeled RNAs were isolated, separated in 
denaturing agarose gels, and visualized by fluorography. To verify that equal amounts of 
total RNA were loaded, the gel was hybridized with a 32P-labeled oligonucleotide probe 
(5’- TTCACGCCCTCTTGAACTCTCTCTTC -3’) recognizing 28S ribosomal RNA, as described 
previously [52].
RNA interference
ON-TARGETplus smartpool siRNA duplexes (Dharmacon) against CypA (PPIA; cat. nr. 
L-004979-04) and CypB (PPIB; cat. nr. L-004606-00) were used to silence CypA and CypB 
expression in 293/ACE2 cells. A non-targeting siRNA (D-001810-10) was used as a con-
trol and a GAPDH-targeting siRNA (D-001830-10) was used to monitor transfection and 
knockdown efficiency. Stock solutions of 2 µM were prepared by dissolving siRNAs in 
1x siRNA buffer (Dharmacon). For transfection of cells in 96-well clusters, 1 x 104 293/
ACE2 cells per well were transfected with a 100-μl mixture containing 100 nM siRNA, 
0.2 µg DharmaFECT1 (Dharmacon), OptiMEM (Invitrogen), and antibiotic-free culture 
medium, according to the manufacturer’s instructions. For cells in 12-well clusters, 600 
µl transfection mixtures were used. Medium was replaced at 24 h post transfection (p.t.) 
by antibiotic-free culture medium, and at 48 h p.t. cells were infected with EAV-GFP or 
wt EAV. Duplicate cultures were used to either prepare lysates to analyze protein expres-
sion levels or to monitor cell viability using the CellTiter 96® AQueous Non-Radioactive Cell 
Proliferation Assay (Promega), according to the manufacturer’s instructions. 
RESULTS
EAV-GFP and PRRSV-GFP replication is inhibited by CsA. 
The effect of CsA on arterivirus replication was investigated in cell culture using two 
representatives of the arterivirus family, EAV and PRRSV (European genotype). For the 
initial experiments, we employed GFP-expressing recombinant viruses, since quantifi-
cation of GFP expression provides a rapid and reliable method to detect inhibition of 
virus replication. BHK-21 cells were grown in 96-well plates and infected at an MOI of 
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5 with GFP-expressing recombinant EAV [291]. Upon removal of the inoculum (1 h p.i.), 
medium containing 0.03 to 4 µM of CsA was given, and at 18 h p.i. cells were fixed and 
GFP expression was quantified. We observed a strong dose-dependent inhibition of 
EAV-GFP replication (Fig. 1A) in the absence of significant cytotoxic effects at the CsA 
concentrations used (Fig. 1B). The half maximal inhibitory concentration (IC50) of CsA for 
EAV-GFP replication in BHK-21 cells was determined to be 0.95 µM. 
A similar experiment was performed with PRRSV-GFP in MARC-145 cells (Fig. 1C). 
Although less sensitive to CsA treatment than EAV-GFP, the replication of PRRSV-GFP 
was completely blocked at 16 µM of CsA and an IC50 of 5.22 µM was determined. Cell 
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Fig. 2. The CsA analog Debio-064 blocks EAV-GFP and PRRSV-GFP replication. (A) EAV-GFP-infected 
BHK-21 cells (MOI of 5) were incubated with various concentrations of Debio-064 from 1 h p.i. onwards. 
Cells were fixed at 18 h p.i. and GFP reporter expression was quantified and normalized to the GFP signal 
of control cells (100%) that were treated with DMSO (solvent concentration equal to medium containing 
4 µM Debio-064). (B) The effect of Debio-064 on BHK-21 cell viability, compared to untreated control cells 
(100%). (C) PRRSV-GFP-infected MARC-145 cells (MOI of 0.1) were incubated with various concentrations of 
Debio-064 from 1 h p.i. onwards. Cells were fixed at 24 h p.i. and GFP reporter expression was quantified 
and normalized to the GFP signal of control cells (100%) that were treated with DMSO. (D) The effect of 
Debio-064 on MARC-145 cell viability, compared to control cells (100%). Results (avg and SD) of a represen-
tative quadruplicate experiment are shown and all experiments were repeated at least twice.






The cyclophilin inhibitor Debio-064 blocks EAV-GFP and PRRSV-GFP 
replication. 
Although CsA has been found to effectively block the replication of various RNA viruses 
in cell culture [281], its use in antiviral therapy would be complicated by the immune 
suppression [296] that is a major side effect. Therefore, several alternative Cyp inhibitors 
have been developed that lack the immune suppressive properties of CsA, like SCY-635, 
NIM811, and Debio-025, which all block HCV replication [284, 285, 297]. 
In this study we tested whether the non-immunosuppressive Cyp inhibitor Debio-064 
is able to block EAV-GFP and PRRSV-GFP replication (Fig. 2A). Debio-064 is a structur-
ally modified cyclosporin exhibiting an approximately 5-fold higher affinity for CypA in 
comparison to CsA. Debio-064 is 300-fold less active than CsA at inhibiting mouse T-cell 
proliferation induced by concanavalin A, suggesting that the compound does not inhibit 
calcineurin [298]. EAV-GFP-infected BHK-21 cells (Fig. 2B) or PRRSV-GFP-infected MARC-
145 cells (Fig. 2D) were treated with various non-cytotoxic concentrations of Debio-064 
and viral replication was quantified as described for CsA treatment. Compared to CsA, 
Debio-064 had a stronger inhibitory effect on EAV-GFP replication. At a concentration 
of 0.5 µM Debio-064, the EAV-GFP signal was hardly detectable (Fig. 2A), and an IC50 of 
0.29 µM was determined, which is about 3-fold lower than that of CsA. For PRRSV-GFP, 
an almost complete block in GFP expression was observed at 8 μM and an IC50 of 5.14 
μM was determined (Fig. 2C), which is comparable to the inhibitory effect of CsA on 
PRRSV-GFP replication. 
CsA and Debio-064 prevent arterivirus protein expression. 
In our initial experiments, we tested the effect of CsA on the replication of a GFP-
expressing recombinant EAV. To verify that also wild-type (wt) EAV replication could be 
inhibited by the drug, we analyzed wt EAV-infected BHK-21 cells that were treated with 
0.25 to 8 µM of CsA. At 6 h p.i., cells were lysed and lysates were subjected to Western blot 
analysis. The expression of viral nonstructural proteins (the nsp5-8 precursor and nsp9) 
and the structural M and N proteins was hardly detectable after 4-µM CsA treatment, 
while a clear reduction in protein expression could already be observed at 2 µM of CsA 
(Fig. 3A). As observed for EAV-GFP, Debio-064 had a stronger inhibitory effect than CsA 
on the replication of wt EAV. Viral protein expression was clearly reduced in the presence 
of 0.5 µM of the drug, and became almost undetectable at 1 µM of Debio-064 (Fig. 3B). 
The effect of CsA and Debio-064 was further characterized by immunofluorescence 
microscopy of infected cells. For wt EAV, dsRNA (data not shown) and viral proteins were 
undetectable after a dose of 4 µM CsA (Fig. 3C) or 1 µM Debio-064 (Fig. 3D). In the case of 
PRRSV-GFP-infected MARC-145 cells (data not shown) maximal inhibition was observed 
at a 16 µM CsA dose. However, as previously observed for coronavirus-infected Vero E6, 














































Fig. 3. CsA and Debio-064 treatment block viral protein expression in cells infected with wild-type 
EAV. BHK-21 cells were infected with EAV (MOI 5) and treated from 1 h p.i. on with CsA (A) or Debio-064 (B) 
at the concentration indicated above each lane. Cells were lysed at 6 h p.i. and viral protein expression was 
analyzed by SDS-PAGE and Western blotting with antibodies against nsp9 and nsp5-8, the M protein and 
the N protein. β-actin was used as loading control. For immunofluorescence microscopy, mock-infected or 
EAV-infected and CsA- (C) or Debio-064-treated (D) cells were fixed at 6 h p.i. and stained with an anti-nsp3 
antiserum. The drug concentrations used are indicated in each panel. Scale bar, 50 µm.






supporting PRRSV-GFP virus replication, even at high CsA doses of up to 64 µM (data 
not shown). We did not observe such a small, residual population of apparently drug-
insensitive cells in EAV-infected BHK-21 cultures treated with either CsA or Debio-064 
(Fig. 3C-D). 
CsA and Debio-064 block the production of arterivirus infectious progeny. 
To assess to which extent CsA and Debio-064 treatment affected infectious progeny 
titers, we performed plaque assays to measure EAV titers at 12 h p.i. using supernatants 
from infected (MOI 5) BHK-21 cells that had been treated with CsA or Debio-064 (Fig. 4A). 
CsA strongly reduced EAV progeny titers, with an almost 4-log reduction at 4 µM CsA. 
Treatment probably completely abolished virus production as the titers observed after 
treatment with 4 µM CsA were similar to those measured at 1 h p.i., which likely reflected 
the remainder of the high MOI inoculum used (data not shown). These data correlated 
well with the barely detectable expression of nsp5-8, nsp9, M, and N protein and the 
lack of dsRNA after treatment with 4 µM CsA (Fig. 3A and C). Treatment with Debio-064 
also resulted in a ~4-log reduction of infectious progeny at 2 µM, while a 2- to 3-log 
reduction was already achieved by treatment with 1 µM of the compound. 
Using a fluorescent focus assay, we also analyzed the production of PRRSV-GFP 
infectious progeny in 24 h p.i.-culture supernatants of CsA-treated MARC-145 cells. As 
observed for EAV, the production of PRRSV-GFP infectious progeny was affected by 
CsA treatment, although significantly higher concentrations were required. At 16 µM 
of CsA, a ~1.5-log reduction in the yield of infectious progeny was observed, while an 
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Fig. 4. Treatment of infected cells with cyclophilin inhibitors strongly reduces arterivirus yields. 
(A) EAV-infected BHK-21 cells (MOI of 5) were treated with various concentrations of CsA (grey bars) or 
Debio-064 (white bars) from 1 h p.i. onwards, and virus titers in the culture medium at 12 h p.i were deter-
mined by plaque assay. (B) MARC-145 cells infected with PRRSV-GFP (MOI 0.1) were treated from 1 h p.i. 
onwards with the CsA (grey bars) or Debio-064 (white bars) concentrations indicated below the x-axis and 
virus titers in the medium at 24 h p.i. were determined by fluorescent focus assay. 
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bars). Treatment with Debio-064 resulted in a ~1.5-log reduction at 16 µM and a ~2.5-log 
reduction of infectious progeny at 32 µM (Fig. 4B; white bars), which is comparable to 
the reduction in PRRSV progeny observed upon CsA treatment.
Cyclophilin inhibitors affect EAV RNA synthesis both in vivo and in vitro. 
The above experiments showed that CsA can effectively block both EAV and PRRSV 
replication in cell culture. To establish that this lack of viral protein synthesis was due 
to a block of viral RNA synthesis, we measured the effect of CsA treatment on EAV RNA 
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Fig. 5. The in vitro and in vivo RNA-synthesizing activity of EAV RTCs can be blocked by CsA or 
Debio-064 treatment. (A) Metabolic labeling of EAV-infected cells with [3H]uridine between 5.5 and 6.5 
h p.i. in the presence or absence of 4 µM CsA. Total RNA was isolated, analyzed in denaturing agarose gels, 
and detected by fluorography. The amount of [3H]uridine that was incorporated into viral genomic RNA 
was quantified and normalized to that in EAV-infected,untreated control cells (100%). 28S RNA detected 
by hybridization with a 32P-labeled probe (lower panel) was used as a control to correct for variations in 
loading during viral RNA quantification. (B and C) Semi-purified RTCs isolated from EAV-infected BHK-21 
cells at 6 h p.i. were used in an in vitro RNA synthesis assay in which [32P]CTP is incorporated into viral RNA. 
Reactions, performed in the presence of various concentrations of CsA (B) or Debio-064 (C) as indicated 
above the lanes, were terminated after 100 minutes. RNA was isolated and reaction products were analyzed 
in denaturing formaldehyde agarose gels. The positions of the genomic RNA (1) and sub-genomic RNAs 
(2-7) are indicated next to the gels. 






synthesis in infected Vero E6 cells in vivo, by metabolic labeling with [3H]uridine (in the 
presence of actinomycin D). When 4 µM of CsA was given at 4.5 h p.i., 3H incorpora-
tion into viral RNA during a pulse labeling from 5.5 to 6.5 h p.i. was reduced to 8% 
of the incorporation measured for non-treated control cells (Fig. 5A). To obtain more 
insight into the mechanism by which CsA inhibits arterivirus replication, we tested its 
effect in a previously developed in vitro assay to study the RNA-synthesizing activity of 
semi-purified EAV RTCs [52]. These assays were performed with PNS from EAV-infected 
BHK-21 cells and the reactions, during which 32P-labeled CTP is incorporated into viral 
RNA, were conducted in the presence of various concentrations of CsA. In the absence 
of the drug, in vitro synthesis of EAV genomic and sg RNAs was observed (Fig. 5B, lane 
1), as documented previously [52]. RNA synthesizing activity was completely abolished 
when the reaction was performed in the presence of 12 µM of CsA (lane 4), while a >50% 
reduction of viral RNA synthesis was observed in the presence of 8 µM CsA (lane 3). 
Comparable results were obtained with Debio-064, which also caused a >50% reduction 
of EAV RTC activity around 8 µM and a complete inhibition at 16 μM Debio-064 (Fig. 
5C; lane 3 and 5). These data strongly suggest that Cyp inhibitors can directly affect 
the RNA-synthesizing capacity of the membrane-associated EAV RTCs in PNS samples. 
We recognize that the concentrations needed to fully block EAV RTC activity in vitro are 
~3-fold higher than those required to block virus replication in cell culture. This might 
be due to differences in the experimental set-up, as the PNS used for the in vitro reaction 
constituted a concentrated preparation of RTCs (and host factors), and reaction condi-
tions might influence the interaction between Cyps and their inhibitor. 
EAV replication depends on cyclophilin A. 
CsA is known to inhibit the PPIase activity of several members of the cyclophilin family. 
In particular CypA and CypB have been implicated in the replication of several viruses 
(reviewed in [281]). We therefore analyzed the effect of siRNA-mediated knock-down of 
CypA and CypB expression levels on the replication of EAV-GFP. We made use of the same 
human 293/ACE2 cells that we previously used to study the role of Cyps in SARS-CoV 
replication [276]. This cell line was also susceptible to EAV infection, although only ~40% 
of the cells became GFP-positive after a high MOI infection with EAV-GFP, as judged by 
immunofluorescence microscopy of infected cells fixed at 8 h p.i. (data not shown). 
Knockdown of CypA and CypB expression was monitored by Western blot analysis 
and a ~80% reduction of expression was typically observed compared to the level in 
control cells transfected with a non-targeting control siRNA (Fig. 6A). Depletion of CypA 
or CypB did not have a significant effect on cell viability during the 48 h of the knock-
down experiment (Fig. 6B). Compared to control cells, knockdown of CypB expression 
did not influence GFP reporter expression when these cells were infected with EAV-GFP, 

























































































































Fig. 6. RNAi-mediated knock-down of CypA, but not CypB, strongly affects EAV replication. 293/ACE2 
cells were transfected with a non-targeting control siRNA or siRNAs targeting CypA or CypB. Knockdown 
of CypA (A, upper panel) and CypB (A, middle panel) levels was monitored by Western blotting with CypA- 
and CypB-specific antisera. β-actin was used as loading control. (B) Viability of cells 48 h post transfection 
with the various siRNAs normalized to the MTS signal of cells transfected with the non-targeting control 
siRNA (100%). (C) GFP reporter expression of cells transfected with the siRNAs indicated below the graph, 
and infected 48 h post-transfection with EAV-GFP at an MOI of 5. Cells were fixed at 24 h p.i. and GFP fluo-
rescence was quantified and normalized to that in infected cells transfected with non-targeting siRNA. (D) 
Virus titers at 32 h p.i. in the culture medium of cells transfected with the siRNAs indicated below the graph, 
and infected 48 h post transfection with wt EAV at an MOI of 0.01. 






of CypA resulted in a ~60% reduction of the GFP signal in EAV-GFP-infected cells, com-
pared to that of the control cells (Fig. 6C). Furthermore, wt EAV titers at 32 h p.i. in the 
culture medium of infected 293/ACE2 cells (MOI 0.01) that had been depleted for CypA 
showed a ~4-fold decrease in virus progeny compared to control cells (Fig 6D). These 
data strongly suggest that EAV replication and the production of virus progeny depend 
on the availability of the host factor CypA.
Cyclophilin A cosediments with EAV RTCs.
Since our RNAi experiments suggested that EAV RNA synthesis depends on the avail-
ability of CypA, we investigated whether CypA cosediments with EAV RTC-containing 
membranes. We therefore fractionated post-nuclear supernatants (PNS) from EAV-
infected and mock-infected Vero E6 cells in a 0-30% OptiPrep density gradient. Gradient 
fractions were analyzed by Western blot using antisera against CypA, CypB, several EAV 
nsps, and various organelle marker proteins (Fig. 7). Densities in the gradient ranged 
from 1.04 g/ml to 1.18 g/ml (Fig. 7A) and the low-density fractions of both EAV-infected 
and mock-infected PNS contained the cytosolic marker glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), while several organelle markers, like the ER protein calnexin 
and the mitochondrial marker CoxIV (data not shown) were found in higher-density 
fractions (Fig. 7B-C). This confirmed the separation of membrane-containing fractions 
from the cytosol. The membrane-associated EAV RTCs, detected with an antiserum 
directed against nsp9 (RdRp), sedimented at densities around 1.15 g/ml (Fig. 7C). The 
nsp9-containing fraction also contained significant amounts of the normally cytosolic 
CypA (Fig. 7C). Upon density gradient fractionation of PNS from uninfected cells CypA 
was only found in the low-density cytosolic fractions (Fig. 7B), but in PNS from EAV-
infected cells a fraction of CypA was found to cosediment with the RTC-containing 
membranes (compare fraction 3 in Fig. 7B and C). CypB, being an ER-associated protein, 
was observed in the high-density gradient fractions of both mock- and EAV-infected cell 
lysates (Fig. 7B). Therefore the protein was present in the fractions containing the EAV 
RTCs, in particular in the nsp9-containing fraction (Fig. 7C, fraction 3-4), but was clearly 
more dispersed in the gradient with mock-infected PNS. 
To analyze whether CsA can prevent the cosedimentation of CypA with EAV RTCs, we 
pretreated the PNS from EAV-infected cells with 12 µM of CsA - the concentration that 
completely inhibited EAV RTC activity in vitro - for 30 minutes on ice before separating 
the material in an OptiPrep density gradient. Subsequently, the high-density nsp9-
containing membrane fractions were analyzed for the presence of CypA by Western 
blotting (Fig. 7D). In the absence of CsA a clear cosedimentation of CypA and nsp9 was 
observed, while CypA was no longer detectable in the high-density nsp9-containing 
fraction of CsA-treated lysates. This suggests that CsA can prevent the cosedimentation 
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Fig. 7. Co-sedimentation of CypA with EAV RTCs in density gradients. The post-nuclear supernatant of 
EAV- and mock-infected Vero E6 cells was fractionated using a continuous 0-30% OptiPrep density gradient. 
(A) Densities of the fractions were determined with a refractometer. (B) Distribution of CypA, CypB, the cyto-
solic marker protein GAPDH, and ER marker protein calnexin in density gradient fractions of mock-infected 
cell lysates as analyzed by Western blotting. (C) Distribution of CypA, CypB, the cytosolic marker protein 
GAPDH, ER marker protein calnexin and EAV RdRp nsp9 in density gradient fractions of EAV-infected cells 
as analyzed by Western blotting. (D) Before loading on a 0-30% OptiPrep gradient, PNS was pretreated with 
12 µM CsA for 30 minutes on ice. Western blot analysis of the sedimentation of CypA, the ER marker protein 
Calnexin, and the cytosolic marker protein GAPDH in nsp9-containing membrane fractions of CsA-treated 
and untreated PNS, and a fraction with the same density prepared from mock-infected cells.







Our study shows that arterivirus replication can be inhibited by the cyclophilin inhibitor 
CsA and the non-immunosuppressive CsA-analog Debio-064, which inhibit EAV RNA 
synthesis, likely through their effect on the host protein CypA that appears to be re-
cruited to EAV RTCs. CsA inhibits the PPIase function of CsA-sensitive Cyp family mem-
bers, like CypA, by binding to their active site [279]. We here show that low-micromolar 
concentrations of CsA can block the replication of both EAV and PRRSV, two prominent 
representatives of the arterivirus family. PRRSV-GFP replication was inhibited with an 
IC50 of 5.22 µM and an almost complete block was observed upon treatment with 16 µM 
CsA (Fig. 1C). These values are comparable to those previously observed for the inhibi-
tion of coronavirus replication by CsA [276, 277]. Compared to PRRSV and coronaviruses, 
the inhibitory effect of CsA was even stronger for EAV, for which we calculated IC50 values 
of 0.95 µM (Fig. 1A). The IC50 values obtained for arteriviruses are in the range of those 
observed for other viruses, like HCV [274, 299], several flaviviruses [275], vaccinia virus 
[300], and HIV-1 [272]. A remarkable and yet not understood phenomenon is that a small 
fraction (1-5%) of PRRSV-infected MARC-145 cells and, previously, coronavirus-infected 
Vero E6, 17Cl1, or Huh7 cells [276] appeared to be refractive to CsA treatment, even at 
high concentrations. This effect was not observed for EAV-infected BHK-21 cells (Fig. 3C), 
which might be explained by the higher sensitivity of EAV to the compound. In any case, 
the fact that the distantly related coronaviruses [276, 277] and arteriviruses can both be 
inhibited by CsA suggests the nidovirus-wide conservation of a cyclophilin-dependent 
function in viral replication.
Previously, CsA was found to inhibit the replication of a variety of RNA viruses, in-
cluding important human pathogens like HCV, HIV-1, and Dengue virus (reviewed in 
[281]). For example, both CypA and CypB were found to specifically interact with the 
flaviviral nonstructural proteins NS5A and NS5B and these interactions are sensitive to 
CsA treatment [273, 301-303]. In the case of the interaction of CypA with HCV NS5A, the 
PPIase activity of the former was proposed to induce a conformational change in the 
latter [304] that promotes RNA binding to NS5A and enhances RNA replication [305]. 
Chatterji et al. reported that, in addition to the CypA-NS5A interaction, HCV replication 
also depends on the binding of CypA to the enzymatic pocket of NS5B, the viral RdRp, 
thus enhancing its affinity for RNA. On the other hand, PPIase-defective CypA failed 
to interact with HCV NS5B [306], suggesting that the isomerase activity of CypA is an 
essential factor in the interaction with NS5B that promotes HCV replication. Liu et al. 
showed that the binding of CypA to NS5B mediates the proper folding of enzymatically 
active NS5B and facilitates the incorporation of the latter into replication complexes. 
The interaction between CypA and NS5B can be inhibited by CsA [307]. In addition, Kaul 
et al. showed that the development of resistance against the Cyp inhibitor Debio-025 
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involved mutations (V2440A and V2440L) in HCV NS5B that are close to the NS5A/NS5B 
cleavage site. These are thought to delay processing of the NS5A/NS5B junction, thus 
extending the time during which the CypA binding site in NS5B is accessible [308]. As 
a result, lower amounts of CypA would suffice to mediate the proper folding of NS5B 
and its incorporation into replication complexes. Similar functions were attributed to 
CypB, since also the interaction between CypB and NS5B was found to be essential for 
RNA binding by NS5B and for HCV replication as a whole [309]. Furthermore, Japanese 
encephalitis virus replication depends on the binding of CypB to NS4A and on CypB 
isomerase activity [273]. For a number of RNA viruses, CypA was found to be incorporat-
ed into newly formed virions, although the functional relevance of this finding remains 
to be addressed in more detail [271, 310, 311]. CypA also interacts with the SARS-CoV 
N protein [312] suggesting that the protein could be incorporated into virions [312], 
although coronavirus N proteins have also been implicated in viral RNA synthesis [313, 
314] and are associated with intracellular replication structures [32]. 
We here show that expression of CypA is required for efficient EAV replication, as 
siRNA-mediated knockdown of CypA drastically reduced EAV-GFP replication (Fig. 6), 
while targeting CypB or Cyp40 (Fig. 6 and data not shown) had no effect. The importance 
of - the normally cytosolic - CypA was further substantiated by its co-sedimentation 
with RTC-containing membrane structures in the high-density gradient fractions of 
EAV-infected cell lysates. In such gradients, the sedimentation of the ER marker protein 
calnexin was essentially similar when comparing infected and mock-infected PNS (Fig. 
7B-C). Furthermore, CsA treatment was able to prevent the sedimentation of CypA to 
the part of the gradient that also contained the EAV RTCs, following their biochemical 
isolation from infected cells (Fig. 7D), and the in vitro RNA synthesizing activity of such 
replication structures was found to be inhibited by CsA and Debio-064 (Fig. 5B-C). The 
distribution of CypB appeared to be less dispersed in gradients containing infected cell 
lysates compared to mock-infected lysates, even though EAV-GFP replication was not 
affected by the siRNA-mediated knockdown of CypB levels (Fig. 6). This suggests that 
although the subcellular localization of CypB might be affected by the extensive EAV-
driven modification of intracellular membranes [29], this does not have a measurable 
effect on virus replication. By using fluorescence microscopy, colocalization of CypA 
and viral RTCs could not be observed, presumably because the fraction of CypA that 
localizes to replication structures is too small (data not shown). Interestingly, we could 
previously not measure an effect on SARS-CoV replication when CypA or CypB expres-
sion was (largely) silenced [276] in the same 293/ACE2 used here for our EAV studies. 
The ~20% residual Cyp expression that remained after siRNA-mediated knockdown may 
have been sufficient to support normal SARS-CoV replication, whereas it appears insuf-
ficient to support the efficient replication of the apparently more sensitive EAV, in line 
with the higher sensitivity of this arterivirus to CsA treatment. 






As reported for HCV [305-307], the association of CypA with the EAV replication struc-
tures suggests the existence of a functional – presumably PPIase activity-dependent 
- interaction that is essential for virus replication. This member of the cyclophilin protein 
family appears to directly promote the RNA-synthesizing activity of the EAV RTC (Fig. 5). 
Based on studies that analyzed binding sites for CypA using a set of 40 potential CypA-
inhibiting peptides [315], we identified several potential CypA binding sites in EAV nsp10, 
the viral helicase protein. A functionally important interaction with such a key enzyme in 
arterivirus RNA synthesis could certainly explain that efficient EAV replication depends 
on the availability of sufficient CypA. Clearly, at this moment, we cannot exclude (direct 
or indirect) interactions with any of the other viral proteins, including – in analogy to 
HCV [306] - the viral RdRp subunit (nsp9). In line with the ideas regarding the influence 
of CypA on the RNA-binding capacity of HCV NS5A and NS5B, EAV RTC-associated CypA 
may be involved in the proper folding or activation of viral enzymes and/or their binding 
to viral RNA, which might directly affect their function in RNA synthesis. 
CsA analogs like Debio-025, NIM811, and SCY635, which have an increased affinity 
for Cyps and lack the undesired immunosuppressive effect of CsA [284, 285, 297], can be 
considered promising antiviral compounds, as they could block HCV replication almost 
completely and resistance to these compounds does not easily develop, compared to 
inhibitors directly targeting viral enzymes [316]. In our study we compared the inhibition 
of EAV and PRRSV replication by CsA with that caused by the non-immunosuppressive 
CsA-analog Debio-064. For Debio-064 we obtained an IC50 value of 0.32 µM, 3-fold lower 
than that of CsA (Fig. 2), which is in line with Debio-064’s higher affinity for Cyps. We 
also observed an inhibitory effect of Debio-064 on PRRSV-GFP replication, although 
in contrast to EAV, its IC50 was similar to that of CsA. Therefore, more potent (non-
immunosuppressive) CsA analogs not only constitute a promising class of molecules for 
the treatment of viral infections, but these compounds are also valuable research tools 
for mechanistic studies into the role of cyclophilins in the replication of nidoviruses and 
other +RNA viruses.  
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Cyclosporin A inhibits the replication 
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Low micromolar, non-cytotoxic concentrations of cyclosporin A (CsA) strongly affected 
the replication of SARS-coronavirus (SARS-CoV), human coronavirus 229E, and mouse 
hepatitis virus in cell culture, as was evident from the strong inhibition of green fluo-
rescent protein reporter gene expression and up to 4 log reduced progeny titres. Upon 
high-multiplicity infection, CsA treatment rendered SARS-CoV RNA and protein synthesis 
almost undetectable, suggesting an early block in replication. siRNA-mediated knock-
down of the expression of the prominent CsA targets cyclophilin A and B did not affect 
SARS-CoV replication, suggesting that either these specific cyclophilin family members 
are dispensable or that the reduced expression levels suffice to support replication.







The 2003 outbreak of Severe Acute Respiratory Syndrome (SARS) sparked a renewed in-
terest in coronaviruses, a group of positive-strand RNA viruses that can cause respiratory 
or gastrointestinal disease in humans and livestock (reviewed in [317]). Several inhibitors 
of coronavirus enzymes (reviewed in [318]) and compounds that inhibit replication in 
cell culture have been described [143, 159, 319], but effective treatment of coronavirus 
infections is currently unavailable [187]. An inherent risk of the use of inhibitors directed 
against viral functions is the development of antiviral resistance due to the rapid adap-
tive evolution of RNA viruses. Coronavirus replication relies on a variety of host factors 
[320-322], which also constitute potentially interesting targets for antiviral therapy, as 
resistance is less likely to develop when host factors are targeted instead of viral proteins. 
While aiming to identify host factors involved in SARS-coronavirus (SARS-CoV) 
replication, we established that the drug cyclosporin A (CsA) inhibited coronavirus 
replication. CsA affects the function of many members of the cyclophilin family, which 
consists of peptidyl-prolyl isomerases that act as chaperones and facilitate protein fold-
ing (reviewed in [279]). CsA was previously reported to inhibit the replication of human 
immunodeficiency virus [272], vesicular stomatitis virus [271], hepatitis C virus (HCV) 
[274, 299, 323] and other flaviviruses [273, 275]. 
Initially, using GFP-expressing recombinant coronaviruses, we investigated the effect 
of CsA on the replication of representatives of different coronavirus genera, i.e. human 
coronavirus 229E (HCoV-229E), mouse hepatitis virus (MHV) and SARS-CoV. In order to 
rigorously evaluate the inhibitory potential of the drug, each of these viruses was tested 
in single-cycle, high-multiplicity of infection (MOI) experiments, in which the drug was 
added upon removal of the inoculum at 1 h post infection (p.i.). Experiments were 
performed in 96-well plate format and GFP expression was quantified using a Berthold 
Mithras plate reader. When using SARS-CoV-GFP [324] and Vero E6 cells (MOI 10), a 
CsA dose range of 0 to 64 µM was used and cells were fixed at 18 h p.i. CsA inhibited 
SARS-CoV-GFP replication in a dose-dependent manner, with GFP expression becoming 
undetectable upon treatment with 16 µM CsA (Fig. 1a, upper panel). Cell viability was 
not affected at any of the CsA concentrations tested (Fig. 1a, lower panel). To confirm 
that CsA also inhibits SARS-CoV replication in human cells, the experiment was repeated 
using 293/ACE2 cells, which stably express the SARS-CoV receptor ACE2 [74]. Indeed, 
in these cells, CsA inhibited SARS-CoV-GFP replication to the same extent as in Vero E6 
cells (Fig. 1b). 
To investigate whether CsA also inhibits the replication of other coronaviruses, Huh7 
cells infected with HCoV-229E-GFP [325] and 17CL1 cells infected with MHV-GFP [326] 
were given CsA at 1 h p.i. and GFP expression was quantified at 24 and 18 h p.i., respec-
















































































































































































































Fig. 1. CsA inhibits the replication of GFP-expressing recombinant coronaviruses. Vero E6 cells (a) or 
293/ACE2 cells (b) were infected with SARS-CoV-GFP at a MOI of 10 and at 1 h p.i. the inoculum was re-
placed by medium containing different CsA concentrations. Cells were fixed at 18 h p.i. and GFP reporter 
expression was measured and normalized to the signal in control cells (100%) that were treated with DMSO, 
the solvent used for CsA (upper panels, grey bars). Huh7 cells infected with HCoV-229E-GFP were treated 
with CsA from 1 h p.i. on and were fixed for GFP measurements at 24 h p.i. (c, upper panel). 17CL1 cells were 
infected with MHV-GFP, treated with CsA from 1 to 18 h p.i., and GFP fluorescence was quantified (d, upper 
panel). The effect of CsA treatment on the viability of the various cell lines used, compared to untreated 
control cells (a-d, lower panels) was determined using the Cell Titer 96 AQ MTS assay (Promega). Graphs 
show the results (average and SD) of a representative quadruplicate experiment. All experiments were re-
peated at least twice.






was strongly inhibited by 16 µM CsA. HCoV-229E-GFP appeared to be somewhat less 
sensitive, as complete inhibition of GFP expression required 32 µM CsA (Fig. 1c). The 
viability of 17CL1 and Huh7 cells was not affected by the CsA concentrations used (Fig. 
1c and d, lower panels). It should be noted that SARS-CoV replication appeared to be 
somewhat enhanced by low CsA doses (up to 4 μM). 
Western blot analysis of SARS-CoV-GFP-infected Vero E6 cells that were treated with 0 
to 32 µM CsA from 1 to 10 h p.i. showed that the expression of SARS-CoV non-structural 
protein (nsp) 8, nucleocapsid (N) protein and GFP was strongly reduced in cells treated 
with 16 µM CsA (Fig. 2a). This suggested that CsA treatment strongly inhibited an early 
step in the SARS-CoV replicative cycle. To verify the inhibitory effect of CsA with wild-
type (wt) SARS-CoV, we repeated the experiments using the Frankfurt-1 isolate (Fig. 2b) 
and found that the expression of nsp8 and N protein was barely detectable upon treat-
ment with 16 µM CsA. At lower CsA concentrations, little effect on viral protein synthesis 
was observed, indicating that the replication of recombinant and wt SARS-CoV is equally 
sensitive to CsA treatment. The steep dose-response curve, showing a strong reduction 
in SARS-CoV replication between 8 and 16 μM CsA, is in line with the observations made 
for several other +RNA viruses, like HCV [274, 299, 327]. 
The conclusions from Western blot studies were further substantiated by immuno-
fluorescence labelling of nsp4 and dsRNA in SARS-CoV-infected cells, as markers for 
viral protein and RNA synthesis, respectively (Fig. 2c). Hardly any nsp4 or dsRNA was 
detectable upon treatment with 16 µM CsA and the immunolabelling for these mark-
ers was visibly reduced when 8 or 4 µM CsA was given. Remarkably, about 1-5% of 
the infected cells remained SARS-CoV positive in immunofluorescence analysis, even 
at CsA concentrations up to 64 µM, suggesting they were somehow insensitive to CsA 
treatment and remained capable of supporting a certain level of SARS-CoV replication. 
Compared to untreated cells the signals for nsp4 and dsRNA were clearly reduced in 
these cells, although - probably due to the relatively high avidity of the antibodies used 
- the N protein remained readily detectable (data not shown), suggesting that SARS-CoV 
replication was indeed impaired although not fully blocked.
To assess whether CsA treatment also affected the production of infectious progeny, 
virus titres were determined for supernatants harvested at 16 h p.i. from CsA-treated 
Vero E6 cultures infected with wt SARS-CoV or SARS-CoV-GFP (Fig. 2d). CsA indeed 
dramatically reduced progeny titres, with a 16 µM CsA dose resulting in approximately 
4- and 3-log reductions for SARS-CoV-GFP and wt SARS-CoV, respectively. These data 
correlate well with the barely detectable expression of GFP, nsp4, nsp8 and N protein 
after treatment with 16 µM CsA (Fig. 1a and 2a-c). The 3-4 log progeny titre reduction 
also suggested that the low percentage of cells that remained SARS-CoV positive in im-
munofluorescence assays upon treatment with 16 µM CsA produced reduced levels of 
infectious progeny. CsA also affected HCoV-229E-GFP titres (Fig. 2e), although a 32-µM 
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Fig. 2. CsA treatment inhibits coronavirus protein and RNA synthesis, and the production of infec-
tious progeny. Vero E6 cells were infected with SARS-CoV-GFP (a) or wt SARS-CoV (b) and treated with 
CsA from 1 to 10 h p.i. Viral protein expression was analysed by Western blotting using polyclonal rabbit 
antisera against nsp8 [53], the N protein [295], and GFP as indicated next to the panels. β-actin, detected 
with a rabbit antiserum (Sigma), was used as loading control. (c) Immunofluorescence analysis of Vero E6 
cells infected with SARS-CoV (MOI 10) and treated from 1 to 10 h p.i. with the CsA concentration indicated 
below each panel. Cells were stained with an anti-SARS-CoV nsp4 rabbit antiserum (upper panel; [53]) or an 
anti-dsRNA monoclonal antibody (lower panel; [30]). Scale bar: 50 µm. (d) Vero E6 cells infected with SARS-
CoV-GFP (grey bars) or wt SARS-CoV (white bars) were treated with various concentrations of CsA from 1 
h p.i. on, and virus titres in the culture supernatant were determined at 16 h p.i. by plaque assay on Vero 
E6 cells. Huh7 cells infected with HCoV-229E-GFP (e) or 17CL1 cells infected with MHV-A59 (f ) were treated 
with CsA from 1 h p.i. on, and infectious progeny titres were determined at 30 h p.i. and 8 h p.i., respectively. 
The graphs show the mean of two independent duplicate experiments.






CsA concentration was required to achieve a 2-log reduction. Progeny titres of MHV, 
the fastest replicating of the three coronaviruses tested, were also 2-log reduced upon 
treatment with 16 µM CsA (Fig. 2f ). Also, as observed for SARS-CoV-infected cells, a sub-
population of the HCoV-229E-infected Huh7 and MHV-infected 17CL1 cells appeared to 
be resistant to CsA treatment.
CsA inhibits the peptidyl-prolyl isomerase activity of several members of the cy-
clophilin family [279]. Specifically cyclophilin A (CypA) [271, 307, 308, 328] and B (CypB) 
[273, 309] have been reported to enhance the replication of several viruses. Furthermore, 
CypA was identified as interaction partner of the SARS-CoV N protein [312]. CsA might 
exert its inhibitory effect on coronavirus replication by inhibiting cyclophilin function or 
- alternatively - by direct inhibition of a virus-specific function. A direct inhibitory effect 
on the activity of the SARS-CoV nsp12 RNA-dependent RNA polymerase, was excluded 
using an in vitro assay and recombinant nsp12 (data not shown; [329]). We next analysed 
the effect of siRNA-mediated knock-down of cellular CypA and CypB expression (for 
48 h) on the replication of SARS-CoV-GFP in 293/ACE2 cells. Western blot analysis of 



















































































Fig. 3. SARS-CoV-GFP replication in Cyclophilin A- or B-depleted cells. Using DharmaFECT1 
(Dharmacon), 293/ACE2 cells were transfected with siRNAs (Dharmacon ON-Target PLUS pools) targeting 
CypA and CypB mRNAs. Non-targeting siRNA, and siRNA targeting GAPDH expression were used as nega-
tive and positive control for transfection and depletion efficiency, respectively. Expression levels of CypA 
(a, upper panel) and CypB (a, middle panel) in cells transfected with the siRNA pools indicated below the 
lanes, were analysed by Western blotting using specific antisera (Abcam). β-actin, detected with a rabbit an-
tiserum (Sigma), was used as loading control. The viability of cells transfected with the various siRNAs was 
monitored using the Cell Titer 96 AQ MTS assay (b). Data were normalized to the average MTS assay value of 
cells transfected with non-targeting control siRNAs (100%). Forty eight hours after siRNA transfection, cells 
were infected with SARS-CoV-GFP and 24 h later cells were fixed and GFP fluorescence was quantified (c). 
The level of GFP expression was normalized to that in infected cells transfected with non-targeting siRNA.
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were significantly reduced, to approximately 25 % of the original level (Fig. 3a). Deple-
tion of CypA or CypB did not affect cell viability (Fig. 3b), but did also not significantly 
inhibit the replication of SARS-CoV-GFP in 293/ACE2 cells, compared to infected cells 
transfected with a non-targeting control siRNA (Fig. 3c). These data suggest that these 
specific cyclophilins, which have been implicated in the replication of other viruses, are 
not required for SARS-CoV replication. Alternatively, the remaining cyclophilin levels in 
siRNA-treated cells may suffice to support normal virus replication. 
In conclusion, CsA inhibits the replication of diverse coronaviruses at non-cytotoxic, 
low-micromolar concentrations. Treatment of infected cells with 16 µM CsA strongly 
reduced viral and reporter gene expression of SARS-CoV-GFP, the amount of dsRNA in 
infected cells and the virus titre in culture supernatants (by more than 3 logs). In cells in-
fected with HCoV-229E-GFP and MHV-GFP reporter gene expression and the production 
of infectious progeny were also significantly decreased upon CsA treatment. Compared 
to other RNA viruses [272-274, 299, 330], somewhat higher CsA concentrations were 
required to block coronavirus replication (16 versus 0.5-3 µM), suggesting coronaviruses 
to be less sensitive to CsA treatment. However, we cannot exclude that this may in part 
be due to differences in experimental set-up, including the cells and high MOI used and 
whether or not cells were pretreated with CsA [275, 307, 327]. 
The inhibitory effect of CsA and its analogues and the role of cyclophilins in virus rep-
lication have been studied in considerable detail for HCV and several other RNA viruses. 
In the case of HCV, cyclophilin inhibitors lacking the undesirable immunosuppressive 
properties of CsA – NIM811, Debio-025 and SCY-635 - are currently being tested in clini-
cal trials [283-285]. Several mechanism of action studies on the inhibitory effect of CsA 
identified mainly CypA and CypB to be involved in virus replication. CypA was found to 
interact with HCV NS2 [331], NS5A [302, 304, 332] and NS5B [306] and was shown to be 
required for HCV replication. Furthermore, CypA was found to functionally interact with 
West Nile Virus NS5 [275] and vesicular stomatitis virus N protein [271]. In addition, an 
interaction between CypB and Japanese encephalitis virus NS4A [273] was documented 
and CypB also appears to be a functional regulator of the HCV polymerase [309]. Also 
Cyp40 was found to play a role in HCV replication [303, 333].
Although the exact mechanism by which CsA inhibits coronavirus replication remains 
to be established, it is likely that the drug also interferes with functional interactions 
between viral proteins and one or multiple members of the large cyclophilin family. If 
this indeed proves to be true, it will be interesting to explore the potential of these host 
proteins for the development of a coronavirus-wide antiviral strategy. 
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A kinome-wide siRNA screen identifies proviral and 
antiviral host factors in SARS-coronavirus replication, 
including PKR and early secretory pathway proteins
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To identify host factors that influence SARS-coronavirus (SARS-CoV) replication, we 
performed an  siRNA library screen targeting the human kinome. Protein kinases are key 
regulators of many cellular functions and the systematic knockdown of their expression 
should provide a broad perspective on factors and pathways promoting or antagoniz-
ing coronavirus replication. In addition to 40 proviral proteins that promote SARS-CoV 
replication, our study identified 90 factors with an antiviral effect. Pathway analysis 
grouped subsets of these factors in specific cellular pathways, like the innate immune 
response and the metabolism of complex lipids, which thus appear to play an important 
role in SARS-CoV-infected cells. Two factors were selected for more extensive validation 
and follow-up experiments. In cells depleted for the beta 2 subunit of the coatomer 
protein complex (COPB2), the strongest proviral hit, we observed reduced SARS-CoV 
protein expression and a 2-log reduction in virus yield. The effect of knockdown of 
the COPB2-related factors COPB1 and Golgi-specific brefeldin A-resistance guanine 
nucleotide exchange factor 1 (GBF1) also suggested that COPI-coated vesicles and/or 
the early secretory pathway are important for SARS-CoV replication. Depletion of the an-
tiviral double-stranded RNA-activated protein kinase (PKR) enhanced virus replication, 
and validation experiments using PKR-directed siRNAs confirmed increased SARS-CoV 
protein expression and virus production upon PKR depletion. The inventory of pro- and 
antiviral host factors and pathways described in this study expands our understanding 
of the replication of SARS-CoV, and may contribute to the identification of novel targets 
for antiviral therapy.







Positive-stranded RNA (+RNA) viruses interact with the infected host cell at many levels 
during their replicative cycle, and thus far numerous host cell proteins with a role in 
virus replication have been identified [60-65]. These include on the one hand host fac-
tors that are used by the virus during the various stages of its life cycle, and on the other 
hand factors that are part of the host defense against virus infection. Such proteins may 
constitute interesting targets in the development of novel antiviral strategies, as drug 
resistance is less likely to develop when cellular rather than viral functions are targeted. 
Antiviral drug resistance is a serious problem, in particular when combating RNA viruses, 
due to their high mutation rate and potential for rapid adaptation. 
Systems biology approaches have been instrumental in advancing our knowledge 
of individual proteins and cellular pathways that influence +RNA virus infection. For 
example, systematic functional genomics screens using small interfering RNA (siRNA) 
libraries  have identified numerous host genes with a role in the replication of important 
human pathogens like West Nile virus [334], Dengue virus [335], human immunodefi-
ciency virus 1 [336], hepatitis C virus [337-342], and influenza virus [338, 343, 344]. For 
coronaviruses a number of relevant host proteins were previously described ([321], and 
reviewed in [65, 320]), but the use of larger-scale siRNA screens to systematically identify 
such factors was not documented thus far.
Coronaviruses, and other members of the order Nidovirales [286], have the largest 
RNA genomes known to date (27-31 kb [37]) and the complexity of their molecular 
biology clearly distinguishes them from other +RNA virus groups. Although infection 
with most human coronaviruses is associated with relatively mild respiratory disease 
[19, 345], the 2003 outbreak of severe acute respiratory syndrome (SARS) highlighted 
the potential of coronaviruses to cause lethal disease in humans. The zoonotic transfer 
of SARS-coronavirus (SARS-CoV), which likely originated from bats, initiated an outbreak 
that affected about 8,000 humans, with a mortality of about 10% [317]. Strikingly, a 
similar outbreak of coronavirus-induced severe respiratory disease has been developing 
in a number of Arab countries since April 2012, with 9 of the 15 confirmed cases thus 
far (March 2013) having a fatal outcome (http://www.who.int/csr/don/archive/disease/
coronavirus_infections/en/). The causative agent, human coronavirus EMC/2012, was re-
cently identified as a previously unknown member of betacoronavirus subgroup 2c [15, 
16]. Although the source of this emerging human pathogen remains to be identified, it 
is striking that – as in the case of SARS-CoV - its closest known relatives are coronaviruses 
circulating in bats [16]. These recent developments highlight once again the relevance 
of the systematic dissection of coronavirus-host interactions and the development of 
antiviral approaches to combat coronavirus infection.
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Many aspects of coronavirus molecular biology remain poorly understood. SARS-CoV 
RNA synthesis, like that of many +RNA viruses [56], takes place at modified cytoplasmic 
membranes [30, 53]. The viral replication and transcription complexes (RTCs) are associ-
ated with a reticulovesicular network (RVN) of modified endoplasmic reticulum [30], 
which is thought to form a suitable microenvironment for RNA synthesis and possibly 
protects against cellular antiviral activities. Multiple host factors and cellular processes 
are likely involved in RVN formation and also the RTCs themselves may include various 
host factors in addition to the SARS-CoV nonstructural proteins (nsps) that drive viral 
RNA synthesis. 
Previous studies identified a number of interactions between coronavirus factors and 
the antiviral immune response [65, 277, 320, 321]. Several evasion mechanisms were 
attributed to protein functions that can be either conserved across CoVs or specific for 
certain CoV lineages. Proteins such as nsp1 [346], the nsp3 papain-like proteinase [347], 
the nsp16 2’-O-methyltransferase [348], the nucleocapsid (N) protein [349], and the 
products of SARS-CoV ORFs 3b, 6, and 7a [105, 109, 350, 351] have all been reported to 
prevent interferon (IFN) induction and/or signalling. 
To gain more insight into the role of host factors in the replicative cycle of SARS-CoV, 
we set out to systematically identify kinase-regulated cellular processes that influence 
virus replication. Protein kinases are key regulators in signal transduction and control a 
wide variety of cellular processes. Thus, assessing their relevance for virus replication can 
provide a broad perspective on cellular factors and pathways that influence SARS-CoV 
replication, as previously illustrated by studies identifying cellular kinases as host factors 
in various stages of the replicative cycle of other +RNA viruses [340, 341, 352, 353].
In this study, we screened an siRNA library that targets the cellular kinome (779 genes) 
and identified 40 proviral and 90 antiviral factors, whose depletion significantly reduced 
or enhanced SARS-CoV replication, respectively. Pathway analysis grouped several sub-
sets of hits in specific cellular pathways, suggesting that these play an important role in 
the SARS-CoV-infected cell. Two prominent hits from the siRNA screen, the proviral beta 
2 subunit of the coatomer complex (COPB2) and the antiviral double-stranded RNA-
activated protein kinase (PKR), were selected for independent validation and follow-up 
analysis, which confirmed their importance for SARS-CoV replication. Our data offer a 
glimpse into the complex interplay between SARS-CoV and the host cell, and provide a 
basis for more focused studies to enhance our understanding of coronavirus replication 
and coronavirus-host interactions.







Cell culture, viruses, and virus titration
293/ACE2 [74] and Vero E6 cells were cultured as described previously [354]. SARS-CoV 
strain Frankfurt-1 [208] and GFP-expressing recombinant SARS-CoV (Urbani strain) [324] 
were used to infect cell monolayers as described previously [354]. Virus titrations were 
performed essentially as described before [355]. All work with live wild-type (wt) SARS-
CoV and SARS-CoV-GFP was performed inside biosafety cabinets in a biosafety level 3 
facility at Leiden University Medical Center. 
siRNA library and transfection reagents
The ON-TARGETplus SMARTpool Protein Kinases siRNA Library that targets the mRNAs 
of 779 genes, comprising the complete human kinome and some additional targets, 
was obtained from Dharmacon. Each individual siRNA SMARTpool consisted of four 
siRNAs targeting the same gene. A non-targeting (scrambled) siRNA (cat. nr. D-001810-
10; Dharmacon) served as a negative control and a GAPDH-targeting siRNA (cat. nr. 
D-001830-10; Dharmacon) was used to routinely monitor transfection and knockdown 
efficiency. Stock solutions (2 µM) of siRNA SMARTpools were prepared by dissolving 0.5 
nmol of siRNA SMARTpools in 250 µl of 1x siRNA buffer (60 mM KCl, 6 mM HEPES (pH 7.5), 
0.2 mM MgCl2; Dharmacon), according to the manufacturer’s instructions. Using a 96-
well pipettor (Rainin Liquidator 96), the contents of the siRNA library master plates were 
aliquoted into volumes appropriate for individual screening experiments. The resulting 
ten deep-well 96-well library plates (Greiner Bio-One) were stored at -80°C until further 
use.
siRNA library screening
In each siRNA screen, 293/ACE2 cells in 96-well plates containing ~104 cells per well were 
transfected with a 100-µl mixture containing 100 nM siRNA, 0.2 µg DharmaFECT1 (Dhar-
macon), OptiMEM (Invitrogen), and antibiotic-free cell culture medium, supplemented 
with 8% FCS and 2.5mM L-Glutamine, according to the manufacturer’s instructions. 
Transfection mixes were prepared in the ten deep-well 96-well plates that together con-
tained the complete library of 779 siRNA SMARTpools (see above). Using the contents of 
these library plates, we transfected black and transparent 96-well plates with 293/ACE2 
cells, each in triplicate. For a schematic representation of the experimental set-up and 
plate lay-out, see Figs. 2A and 3A. Transfection of individual siRNA duplexes targeting 
PKR (cat. nr. LU-003527-00; Dharmacon), or siRNA SMARTpools targeting COPB1 (cat. nr. 
L-017940-01) and GBF1 (cat. nr. L-019783-00) was performed as described previously 
[354]. Twenty-four hours post transfection (p.t.), the medium was replaced, and cells 
were incubated for another 24 h at 37°C. At 48 h p.t., cells were infected with SARS-CoV-
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GFP at an MOI of 10, and 24 h later they were fixed with 3% paraformaldehyde (PFA) in 
PBS. GFP expression was quantified by measuring fluorescence in a 96-well plate reader 
(Berthold Mithras LB 940), using excitation and emission wavelengths of 485 and 535 
nm, respectively. The fluorescence in wells containing mock-infected cells was used to 
correct for background signal. 
GAPDH and cell viability assays
At 48 h p.t., GAPDH enzyme activity in lysates of siRNA-transfected cells was measured 
using the KDalert™ GAPDH Assay Kit (Ambion) according to the manufacturer’s instruc-
tions. Possible cytotoxic effects of siRNA transfection were analyzed (in triplicate) at 48 
h p.t., using the CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (Promega). 
After 90 min, the reaction was terminated by the addition of 25 µl of 10% SDS and absor-












































































Fig. 1. siRNA-transfected 293/ACE2 cells are susceptible to SARS-CoV infection. 293/ACE2 cells were 
transfected with siRNAs targeting GAPDH mRNA and a scrambled control siRNA. At 48 h p.t., the cells were 
infected with SARS-CoV-GFP (MOI 10) and 24 h later cells were fixed and GFP fluorescence was measured 
(black bars). Cell viability (dark grey bars) was analyzed at 48 h after siRNA transfection and knockdown of 
GADPH expression was monitored by measuring enzymatic activity (light grey bars). All values were nor-
malized to those obtained with non-transfected control cells (100%).







Raw data from GFP fluorescence and cell viability measurements were analyzed per 
individual screen with the Bioductor/R package CellHTS2 [356] with minor modifications 
(see results section and Fig. 2B for details). The average GFP expression (n=3) and cell 
viability were calculated and normalized to the signals of scrambled siRNA-transfected 
(control) cells. A two-sided one-sample Student’s t test was used on the log2-transformed 
normalized values to determine the significance (p < 0.05) of the changes in GFP expres-
sion caused by siRNA transfection. The siRNA transfection was considered non-cytotoxic 
when the normalized cell viability assay readings (A490) were above 0.85 (p < 0.05). 
Significance was determined using a one-sided one-sample Student’s t test on the log2-
transformed normalized values using µ ≤ 0.85 as the null hypothesis.
Gene silencing using lentivirus-expressed shRNAs
Vectors for expression of short hairpin RNAs (shRNAs) targeting human COPB2 (cat. nr. 
TRCN-065114; accession nr. NM_004766) or human PKR (cat. nr. TRCN-001382; acces-
sion nr. NM_002759) were picked from the MISSION TRC-1 library of shRNA-expressing 
lentiviruses (Sigma) and lentivirus stocks were prepared according to the manufacturer’s 
instructions. A lentivirus expressing a non-targeting (scrambled) shRNA (cat. nr. SHC-
002) was used as negative control. Lentivirus particle titers were determined using a 
p24 ELISA (Zeptometrix) according to the manufacturer’s instructions. Wells (4 cm2) 
containing 8 x 104 293/ACE2 cells were transduced with shRNA-expressing lentiviruses 
at an MOI of 3 in culture medium containing 8 µg/ml polybrene, and after 24 h fresh 
medium was given. At 72 h p.t., cells were infected with wt SARS-CoV or SARS-CoV-GFP 
(MOI 0.01), or depletion of COPB2 or PKR was validated by Western blot analysis of cell 
lysates using target-specific antibodies.
Protein analysis and antibodies
Total cell lysates were prepared in 4x Laemmli sample buffer (100 mM Tris-HCl, pH 6.8, 
40% glycerol, 8% sodium dodecyl sulfate (SDS), 40 mM DTT, 0.04 mg/ml bromophenol 
blue), after which samples were heated at 95°C for 15 min. Following SDS-PAGE, proteins 
were transferred to Hybond-LFP membranes (GE Healthcare) by semi-dry blotting, and 
membranes were blocked with 1% casein in PBS containing 0.1% Tween-20 (PBST). The 
following antisera against cellular proteins were used: rabbit anti-PKR (cat. nr. 610764; 
BD Biosciences), goat anti-COPB2 (sc-13332; Santa-Cruz), and mouse monoclonal anti-
bodies against β-actin (A5316; Sigma) and the transferrin receptor (TfR; cat. nr. 13-6890; 
Invitrogen). Rabbit antisera against SARS-CoV nsp8 and N protein [30, 52] were used to 
analyze viral protein expression. After overnight incubation with the primary antibody, 
membranes were probed with biotinylated secondary antibodies (biotinylated rabbit 
anti-goat, swine anti-rabbit, or goat anti-mouse) for 1 h at RT, after which a tertiary 
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mouse anti-biotin-Cy3 antibody was used to visualize protein bands using a Typhoon 
9410 scanner (GE Healthcare).
Canonical pathway analysis
The Ingenuity Pathway Analysis (IPA™) package was used to place hits in canonical 
cellular pathways. The significance of the association between the data set and the 
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Fig 2. siRNA library screening procedure and data analysis. (A) Schematic overview of the experimental 
design of the siRNA library screen. See text for details. (B) Flow chart outlining the data analysis procedure 
that was performed with the Bioconductor/R package CellHTS2. See text for details.






data set that map to a specific pathway divided by the total number of molecules in that 
canonical pathway (the higher the percentage of hits identified in a specific pathway, 
the higher the likelyhood it plays a role in the viral replicative cycle); (ii) Fisher’s exact 
test was used to determine the probability that the association between the genes in 
the dataset and the canonical pathway is explained by chance alone.
RESULTS 
Developing siRNA library screening for host factors involved in nidovirus 
replication. 
A commercial human kinome-directed siRNA library (779 targets) was used to assess the 
effect of systematic knockdown of individual host kinases on the replicative cycle of the 
coronavirus SARS-CoV (this study) and the distantly related arterivirus EAV (K. F. Wannee, 
A. H. de Wilde et al., unpublished data). We performed our siRNA screens in 293/ACE2 
cells [74], which express the SARS-CoV receptor angiotensin-converting enzyme 2 and, 
in contrast to other cell lines tested, were found to be permissive to infection with both 
SARS-CoV and EAV. This property facilitates direct comparative studies between these 
two distantly related nidoviruses [354]. Furthermore, 293/ACE2 cells could be efficiently 
transfected with siRNAs, as illustrated by a consistent ~75% reduction of GAPDH activity 
at 48 h p.t. with an siRNA SMARTpool targeting the GAPDH mRNA (Fig. 1; light grey bars). 
No change in cell viability was detected by 48 h p.t. following transfection with either 
a scrambled siRNA or the GAPDH-specific siRNA (Fig. 1; dark grey bars). When these 
siRNA-transfected 293/ACE2 cells were subsequently infected with SARS-CoV-GFP (MOI 
10), no significant differences in GFP expression were observed at 24 h p.i. compared 
to control cells that had not been transfected with siRNAs. This demonstrated that the 
siRNA transfection procedure per se did not adversely affect SARS-CoV-GFP replication 
(Fig. 1; black bars).
siRNA screening for host kinases involved in SARS-CoV replication.  
A human kinome-directed siRNA screen was performed to identify host cell kinases that 
affect SARS-CoV-GFP replication,  according to the experimental set-up outlined in Fig. 
2A. For each independent siRNA screening experiment, we used a set of ten 96-well 
library plates, each containing approximately 80 specific siRNA SMARTpools and several 
controls (see plate layout in Fig. 3A). Transfection mixes (final concentration of 100 nM 
siRNA) were prepared in these library plates and their contents was used to transfect 
- per library plate - 293/ACE2 cells in three black and three transparent 96-well plates. 
Forty-eight hours after siRNA transfection, the black plates were infected with the 
SARS-CoV-GFP reporter virus (MOI 10), and at 24 h p.i. GFP expression was analyzed by 
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fluorimetric quantitation. At the moment of infection, the transparent plates were used 
to monitor (potential) cytotoxic effects of siRNA transfection using a colorimetric cell 
viability assay. The complete siRNA screen, i.e. the viability controls and the quantitation 
of SARS-CoV-driven GFP expression (in triplicate for each siRNA), was repeated three 
times, after which data sets were processed as outlined in Fig. 2B. The data, obtained 
from a 96-well plate reader (step 1) were processed with the Bioconductor/R package 
CellHTS2 as described [356] (step 2). Experimental controls were assigned (step 3.1 and 
Fig. 3A), and the NPI method (normalized percent of inhibition; step 3.2) was used to 
normalize GFP fluorescence values to those of scrambled siRNA-transfected cells, and to 
correct for  plate-to-plate variation. Subsequently, the GFP data were transformed to a 
multiplicative scale (the value obtained using scrambled siRNA-transfected cells was set 
to 1; step 3.3). Next, the results for each replicate library screen were summarized and 
used for further data analysis (step 4), including the assignment of GeneIDs to each well 
(step 5). Finally, the data of the three independent library screens were combined and 
summarized (step 6).
The processed data output of a representative library screen, showing the distribu-
tion of the hits for each plate, is depicted in Fig. 3A. Column 1 of each plate contained 
the infected control cells described above, whereas column 12 contained mock-infected 
cells. Host cell kinases were considered to have a proviral effect when their siRNA-
mediated knockdown reduced the GFP signal (negative score values) and kinases were 
considered antiviral when the GFP signal increased upon their knockdown (positive 
score values). Graphical representations of the hit distribution per plate were visually 
inspected in order to minimize the chance of false positive or false negative hits due to 
major (technical) artifacts (Fig. 3A). 
Using scrambled siRNA-transfected control cells as a reference, the knockdown 
of most cellular kinases was found to be non-cytotoxic within the time frame of this 
experiment (Fig. 3B and Data set S1). The cut-off value below which siRNA treatment 
was considered to be toxic was set at 85% cell viability relative to scrambled siRNA-
transfected control cells (p < 0.05) (Fig. 3B). Using this criterion, 222 out of 779 (28.5%) 
transfections with the specific siRNA pools appeared to be toxic to the cells. A minor 
fraction (50 targets; 6.4%) appeared to be highly detrimental (normalized viability value 
below 75%). To prevent false-positive proviral hits due to a general negative effect on 
cell viability or cell division, we excluded all targets whose knockdown was associated 
with viability measurements below 85%. Such data filtering was not applied for antiviral 
hits (i.e. knockdown enhancing GFP expression) since siRNA-induced cytotoxicity is 
expected to inhibit virus replication and should therefore not give rise to false-positive 
antiviral hits.
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Fig. 3. Quality plots of the siRNA screen for host factors involved in SARS-CoV replication. (A) Plate-
wise quality-plots of the score values for one replicate of a representative siRNA library screen. In total, 
three screens, each consisting of three replicates, were performed. Score values of -1, 0, and 1 represent 0%, 
100%, and 200% SARS-CoV-driven GFP expression compared to infected control wells, respectively. Cells 
transfected with control siRNAs were present in the first column (“controls”) of each plate, while the cells in 
column 12 were mock-infected to allow correction for background GFP signal. The remaining wells of each 
plate (columns 2-11) contained cells transfected with the siRNA SMARTpools. The GFP expression level in 
each well compared to that of control siRNA-transfected cells (score value) is represented by the color-
coded squares according to the legend below panel A. (B) Relative cell viability of cells transfected with the 
779 siRNA pools in the kinome-wide siRNA library. Viability assays were done at 48 h p.t. and the data were 
normalized to the measurements for control cells transfected with scrambled siRNA (100%). Data were 
binned into 4 viability categories and the number in each bar is the absolute number of targets within that 
category, which represents the percentage of the 779 siRNA targets in the screen that is indicated above 
each bar. The viability data are the average of three independent library screens, each including triplicate 
measurements for each siRNA pool in the library.  
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Identification of proviral and antiviral hits and pathways influencing SARS-CoV-
GFP infection. 
After exclusion of toxic siRNA SMARTpools that decreased GFP expression (see above), 
the remaining 684 targets were ranked on the basis of the GFP signal measured in 
SARS-CoV-GFP-infected cells (log2-fold GFP expression compared to control cells; Fig. 4). 
Targets were qualified as antiviral or proviral hits if GFP expression differed significantly 
from that in control cells transfected with the scrambled siRNA pool (p < 0.05). Knock-
down of the majority of the targets (552 proteins) did not significantly alter GFP reporter 
gene expression (p > 0.05). However, as common in this kind of screening experiments, 
we cannot formally exclude that our results may have been influenced by insufficient 
knockdown of certain target genes by the library’s siRNA pools. 
Using the criteria outlined above, a total of 90 cellular proteins (19.4% of all targets) 
were identified as antiviral factors, since their depletion significantly increased GFP 
expression. For 36 of these antiviral hits, knockdown resulted in an increase of at least 
1.5-fold (Fig. 5A). Forty proviral factors were identified and the knockdown of  nine of 
those reduced GFP expression by more than 2-fold (Fig. 5B; for the complete data set, 
see Dataset S2). 
Although, according to the criteria formulated above (p < 0.05), ANGPT4 (214%; p 
= 0.0555) and PKR (210%; p = 0.0884) formally did not qualify as antiviral hits, we have 
included these proteins in view of the exceptionally strong stimulation of GFP expres-
sion triggered by their knockdown (Fig. 5A). Furthermore, since its knockdown resulted 
in an almost 3-fold decrease of GFP signal (35%; p = 0.0004), DGKE was included as a 
proviral hit, despite the fact that the viability assay did not rigorously exclude cytotoxic 
effects for this siRNA pool (viability 88%, p = 0.0540).
The pro- and antiviral hits identified in the siRNA screen were mapped to cellular 
pathways using the IPA software package. Fig. 6 shows the canonical pathways and more 
general functional categories (highlighted in color) in which the proviral (red) and anti-
viral (green) hits were strongly represented (p < 0.05). The pathways included apoptosis, 
cellular immune response, growth factor signaling, cellular homeostasis, metabolism of 
complex lipids, and intracellular and second messenger signaling.
Validation of COPB2 as a proviral factor in SARS-CoV replication. 
COPB2 (or β’-COP) was identified as the strongest proviral hit in our screen, as its knock-
down resulted in an 82% decrease of GFP expression (p = 0.0143; Fig. 5B). The coatomer 
protein complex, of which COPB2 is a subunit, contains a total of seven protein subunits 
(α-, β-, β’-, γ-, δ-, ε-, and ζ-COP), and drives the formation of COPI-coated vesicles, which 
function in retrograde transport in the early secretory pathway [357]. To validate its role 
as a proviral host factor in SARS-CoV replication, COPB2 was depleted by transducing 
293/ACE2 cells with lentiviruses expressing COPB2 mRNA-specific shRNAs. This reduced 






COPB2 levels by ~70%, compared to control cells transduced with a lentivirus expressing 
a scrambled shRNA (Fig. 7A), and this reduction in COPB2 levels did not affect cell vi-
ability (Fig. 7B). Subsequent infection of COPB2-depleted cells with SARS-CoV-GFP (MOI 
0.01) resulted in a decrease of N protein and GFP expression at 32 h p.i. (Fig. 7C; left 
panel). To verify that knockdown experiments with recombinant SARS-CoV-GFP prop-


















































Fig. 4. Results of the siRNA screens for host factors influencing SARS-CoV replication. The plot shows 
the distribution of the log2-transformed values of reporter gene expression by SARS-CoV-GFP in siRNA-
transfected cells, normalized to the GFP signal of infected control cells that were transfected with scram-
bled siRNA. Targets were ranked based on the magnitude of the effect of their knockdown on SARS-CoV 
replication. Targets were considered to have an important antiviral effect when their knockdown increased 
reporter gene expression to at least 150% (red area above x-axis). Proviral hits, whose knockdown induced 
an at least 2-fold reduction in GFP expression, are depicted in the green area below the x-axis. Proviral 
targets whose knockdown reduced cell viability to below 85% were excluded (see main text), leaving a 
total of 684 targets included in the final analysis. The positions of the targets used for follow-up validation 
experiments (COPB2 and PKR) are indicated. The plot represents the average of three library screens (each 
done in triplicate).
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virus yield in COPB2-depleted cells at 24 h after infection with wt SARS-CoV (MOI 0.01). 
As for SARS-CoV-GFP, a clear reduction in N protein expression was observed compared 
to cells transduced with a lentivirus expressing a scrambled shRNA (Fig. 7C; right panel). 
Titration of culture supernatants from SARS-CoV-GFP-infected cells (32 h p.i.) and wt 
SARS-CoV-infected cells (24 h p.i.) revealed a 2- to 3-log reduction for both viruses (Fig. 
7D).
Proteins of the early secretory pathway are important for SARS-CoV replication. 
To further substantiate the importance of COPI-coated vesicles for SARS-CoV replication, 
the expression of another component of the coatomer protein complex, subunit beta 
1 (COPB1) was depleted by transfection of 293/ACE2 cells with a COPB1 mRNA-specific 
siRNA SMARTpool. After 48 h, transfected cells were infected with SARS-CoV-GFP (MOI 
10) and 24 h later GFP expression was quantified. Depletion of COPB1 resulted in a 
reduction of SARS-CoV-driven GFP expression with 83% (Fig. 7E). The formation of COPI-
coated vesicles is mediated through activation of ADP-ribosylation factor 1 (Arf1) by 
Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1 (GBF1) [358]. 
Therefore, we also analyzed the importance of GBF1. GFP reporter gene expression 
by SARS-CoV-GFP was reduced by 89% in 293/ACE2 cells that had been depleted for 
GBF1 by siRNA transfection and were subsequently infected at 48 h p.t. (Fig. 7E). Taken 
together, these data suggest that COPB2 and COPI-coated vesicles play an essential role 
in SARS-CoV replication. 
Validation of PKR as antiviral hit affecting SARS-CoV replication. 
PKR was one of the strongest of the 90 antiviral hits that were identified in the siRNA 
library screen. In two independent follow-up experiments with PKR-specific siRNA 
SMARTpools, a more than 2-fold increase in GFP expression by SARS-CoV-GFP was ob-
served (data not shown), suggesting that PKR is a bona fide antiviral hit. PKR is a serine/
threonine protein kinase that is activated by double-stranded (ds)RNA, a hallmark of 
RNA virus infection, and the activated form of PKR blocks translation initiation through 
eIF-2α phosphorylation (reviewed in [68]).
To further validate the antiviral role of PKR in SARS-CoV replication, a deconvoluted 
set of four individual PKR-directed siRNAs was used. Transfection of 293/ACE2 cells with 
three of these siRNAs (numbers 2, 3, and 4) significantly increased SARS-CoV-driven GFP 
expression (Fig. 8A; black bars). Cell viability was slightly reduced after transfection with 
these PKR-directed siRNAs, in particular using siRNA 2 which caused a 14% reduction in 
cell viability (Fig 8A; grey bars). Nevertheless, despite the fact that this siRNA adversely 
affected cell viability, an increase rather than a decrease of SARS-CoV-driven GFP expres-
sion was observed.

























ANGPT4 1.8 3.1 1.8 2.1
PKR 3.0 1.4 2.3 2.1
CLK1 2.1 2.1 1.8 2.0
MAP2K6 2.0 2.0 1.8 1.9
CSNK1G1 1.7 2.1 1.8 1.9
EPHA3 1.7 1.6 2.1 1.8
CDK6 1.7 2.1 1.7 1.8
AURKB 1.9 1.8 1.8 1.8
GCK 1.8 2.0 1.6 1.8
DGKD 1.8 1.6 2.0 1.8
STK24 2.0 1.5 1.9 1.8
CKS1B 2.1 1.6 1.6 1.7
CLK4 1.6 2.1 1.6 1.7
HK1 1.6 2.1 1.5 1.7
ACVR1 1.7 1.7 1.6 1.7
AKAP6 1.8 1.7 1.5 1.7
FLJ12476 1.7 1.6 1.6 1.6
LATS1 1.8 1.6 1.5 1.6
CDKL2 1.4 1.8 1.7 1.6
MAPK9 1.9 1.6 1.5 1.6
PTPRG 1.9 1.4 1.6 1.6
BMPR2 1.7 1.4 1.8 1.6
DCK 1.6 1.5 1.7 1.6
MAP2K3 1.6 1.9 1.4 1.6
MYO3B 1.7 1.5 1.5 1.6
EIF2AK3 1.6 1.6 1.5 1.6
CLK3 1.7 1.6 1.4 1.6
FYB 1.8 1.5 1.4 1.6
ALS2CR7 1.5 1.8 1.4 1.5
STK25 1.7 1.4 1.6 1.5
HAK 1.5 1.7 1.5 1.5
ITK 1.6 1.5 1.5 1.5
MAPK1 1.6 1.5 1.5 1.5
DGUOK 1.5 1.6 1.5 1.5
MVD 1.7 1.4 1.5 1.5
EKI1 1.7 1.4 1.4 1.5
EPHA5 1.4 1.4 1.8 1.5
DAPK3 1.4 1.7 1.5 1.5
COPB2 0.2 0.3 0.1 0.2
CDK5R2 0.2 0.4 0.2 0.2
PFTK1 0.4 0.3 0.3 0.3
ABI1 0.4 0.3 0.3 0.3
DGKE 0.3 0.4 0.4 0.4
NME2 0.5 0.4 0.4 0.4
AZU1 0.5 0.4 0.5 0.4
IHPK1 0.5 0.3 0.5 0.5
PSKH1 0.5 0.5 0.4 0.5
PRKCI 0.6 0.4 0.5 0.5
GeneID 1 2 3 average




0.0555 NM_015985 Angiopoietin 4
0.0884 NM_002759 Double-stranded RNA-activated protein kinase
0.0077 NM_004071 CDC-like kinase 1
0.0014 NM_002758 Mitogen-activated protein kinase kinase 6
0.0067 NM_022048 Casein kinase 1, gamma 1
0.0176 NM_005233 EPH receptor A3
0.0140 NM_001259 Cyclin-dependent kinase 6
0.0016 NM_004217 Aurora kinase B
0.0119 NM_000162 Glucokinase (hexokinase 4, maturity onset diabetes of the young 2)
0.0135 NM_003648 Diacylglycerol kinase, delta 130kDa
0.0241 NM_003576 Serine/threonine kinase 24 (STE20 homolog, yeast)
0.0298 NM_001826 CDC28 protein kinase regulatory subunit 1B
0.0282 NM_020666 CDC-like kinase 4
0.0318 NM_000188 Hexokinase 1
0.0018 NM_001105 Activin A receptor, type I
0.0068 NM_004274 A kinase (PRKA) anchor protein 6
0.0004 NM_022784 IQ motif containing H
0.0074 NM_004690 LATS, large tumor suppressor, homolog 1 (Drosophila)
0.0265 NM_003948 Cyclin-dependent kinase-like 2 (CDC2-related kinase)
0.0207 NM_002752 Mitogen-activated protein kinase 9
0.0259 NM_002841 Protein tyrosine phosphatase, receptor type, G
0.0261 NM_001204 Bone morphogenetic protein receptor, type II (serine/threonine kinase)
0.0051 NM_000788 Deoxycytidine kinase
0.0369 NM_002756 Mitogen-activated protein kinase kinase 3
0.0087 NM_138995 Myosin IIIB
0.0014 NM_004836 Eukaryotic translation initiation factor 2-alpha kinase 3
0.0138 NM_001292 CDC-like kinase 3
0.0217 NM_001465 FYN binding protein (FYB-120/130)
0.0327 NM_139158 Cyclin-dependent kinase 15
0.0224 NM_006374 Serine/threonine kinase 25 (STE20 homolog, yeast)
0.0130 NM_052947 Alpha-kinase 2
0.0004 NM_005546 IL2-inducible T-cell kinase
0.0042 NM_002745 Mitogen-activated protein kinase 1
0.0007 NM_001929 Deoxyguanosine kinase
0.0211 NM_002461 Mevalonate (diphospho) decarboxylase
0.0172 NM_018638 Ethanolamine kinase 1
0.0385 NM_004439 EPH receptor A5





Note: siRNAs are slightly toxic to cells (88% viability, but p = 0.0540)
0.0143 NM_004766 Coatomer protein complex, subunit beta 2 (beta prime)
0.0251 NM_003936 Cyclin-dependent kinase 5, regulatory subunit 2 (p39)
0.0087 NM_012395 PFTAIRE protein kinase 1
0.0055 NM_005470 Abl-interactor 1
0.0004 NM_003647 Diacylglycerol kinase, epsilon 64kDa
0.0027 NM_002512 Non-metastatic cells 2
0.0075 NM_001700 Azurocidin 1 (cationic antimicrobial protein 37)
0.0405 NM_153273 Inositol hexaphosphate kinase 1
0.0094 NM_006742 Protein serine kinase H1
0.0157 NM_002740 Protein kinase C, iota
Gene nameAccessionp-value
†  







Fig. 5. Heat-maps of the identified pro- and antiviral hits. (A) List of the antiviral hits causing an at least 
1.5-fold increase in GFP expression (p < 0.05). (B) Proviral hits yielding a more than 2-fold decrease in GFP 
expression (p < 0.05). For each target, the p-value, accession number, and gene name are shown. Each data 
point represents the result of a single library screen and is the average of the 3 replicates that were done 
in each screen.  
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Transfection with PKR-specific siRNAs reduced PKR levels in 293/ACE2 cells up to 87% 
compared to control cells, depending on the siRNA used (Fig. 8B). To verify that PKR 
knockdown increased wt SARS-CoV replication, siRNA-transfected 293/ACE2 cells were 
infected with wt SARS-CoV (MOI 0.01) and viral protein expression was analyzed at 24 
h p.i. by Western blot analysis. In line with the effect of PKR siRNA 2 on 293/ACE2 cell 
viability (Fig. 8A), cells transfected with this siRNA contained reduced levels of β-actin, 

























* Selected hits for validation
Peptidase
FLJ13052
Fig. 6. Cellular pathways influencing SARS-CoV-GFP replication. Graphical representation of the canon-
ical pathways (white ellipses) identified in the siRNA library screen for cellular factors affecting SARS-CoV 
replication. The proviral (red) and antiviral hits (green) are represented by nodes with lines linking them 
to one or more canonical pathways. The color intensity of the nodes indicates the strength of the pro- or 
antiviral effect (log2-ratio of GFP expression normalized to infected control cells), e.g. factors with a stronger 
antiviral effect have a more intense red color. The identified canonical pathways were clustered into more 
general categories that are indicated by text boxes in the colored background shading. 






four individual PKR-directed siRNAs (siRNA 2 and 3) clearly increased the expression of 
SARS-CoV N protein (Fig. 8C, upper panel), and also led to an ~1-log increase in infec-































































































































Fig. 7. Proteins of the early secretory pathway are important for SARS-CoV replication. (A) 293/
ACE2 cells were transduced with lentiviruses expressing a COPB2 mRNA-specific or a scrambled shRNA. 
Knockdown of COPB2 expression at 48 h p.t. was monitored by Western blotting with a COPB2-specific 
antiserum and cyclophilin B (CypB) was used as loading control. (B) Cell viability in COPB2-depleted 293/
ACE2 cells was analyzed at 48 h after transduction (% of value for cells transduced with lentiviruses express-
ing a scrambled shRNA). (C) COPB2-depleted and control cells were infected with either SARS-CoV-GFP or 
wt SARS-CoV and protein expression was analyzed by Western blotting with N-specific and GFP-specific 
antisera, using the TfR as a loading control. SARS-CoV N protein expression was quantified and its level nor-
malized to the value for scrambled siRNA-transfected cells (100%) is indicated under each lane. (D) SARS-
CoV-GFP (black bars) and wt SARS-CoV (grey bars) progeny titers in the culture supernatant of infected, 
COPB2-depleted and control cells. (E) Normalized GFP expression by SARS-CoV-GFP in 293/ACE2 cells trans-
fected with siRNA SMARTpools targeting COPB1 or GBF1 and a scrambled control siRNA. Cells were infected 
48 h p.t. at an MOI of 10 and 24 h later GFP fluorescence was quantified and normalized to that in infected 
cells transfected with a scrambled siRNA.
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and infectious progeny titer correlate well with the magnitude of PKR knockdown, 
which makes an off-target effect in the initial siRNA library screen unlikely and suggests 
a true antiviral role for PKR in SARS-CoV infected cells.
DISCUSSION
In the past decade functional genomics studies have - in an systematic way - identi-
fied host factors that can influence the replication of diverse +RNA viruses [334, 335, 
338-340, 352, 359]. We here describe a human kinome-wide siRNA screen for factors 
influencing the entry and replication of SARS-CoV, to our knowledge the first systematic 
functional genomics study of this kind for any coronavirus. As kinases are key regula-
tors of many cellular processes, the pro- and antiviral factors identified by this strategy 
should pinpoint cellular pathways that are important for SARS-CoV replication. 
For SARS-CoV, screening of the kinome-directed library of 779 siRNA SMARTpools re-
sulted in the identification of 90 antiviral and 40 proviral proteins. Canonical cellular pro-
cesses and pathways in which these factors were strongly represented included inositol 
phosphate metabolism, signaling by Rho family GTPases, and SAPK/JNK signaling (Fig. 
6). Many hits could also be mapped to the interleukin (IL)-2, -6, -8, and IL-17 signaling 
pathways, which have previously been implicated in controlling coronavirus infection 
and coronavirus-induced inflammation (reviewed in [65]). For example, the SARS-CoV 
spike (S) protein was shown to induce the expression of the pro-inflammatory cytokine 
IL-8 [360], and IL-6 and IL-8 levels were elevated in the serum of SARS-CoV-infected 
patients [360, 361]. Furthermore, mouse hepatitis virus (MHV) and infectious bronchitis 
virus (IBV) infections were reported to upregulate the synthesis of these same cytokines 
[362, 363]. Although our siRNA library screen did not target interleukins directly, the 
identification of (kinase-regulated) interleukin signaling pathways is in line with these 
earlier studies, and emphasizes their importance in SARS-CoV infection. 
Coronavirus replication is associated with a cytoplasmic RVN of modified ER, includ-
ing double-membrane vesicles and convoluted membranes [30]. Despite the in-depth 
characterization of their ultrastructure, the biogenesis of these membrane structures 
and the cellular factors involved have remained largely uncharacterized. For example, the 
membrane source of these virus-induced structures is still controversial, with advanced 
EM analyses showing the RVN to be derived from and continuous with the ER [30, 208, 
295] and other studies implicating the autophagy pathway [54] or EDEMosomes [55] as 
the primary membrane source. Our earlier work already suggested that the integrity of 
the early secretory pathway is important for efficient SARS-CoV replication, as brefeldin 
A (BFA) treatment of SARS-CoV-infected cells significantly reduced replication as well as 
the accumulation of virus-induced membrane structures [295]. In line with these find-






ings, COPI-coated vesicles were also implicated in the biogenesis of MHV replication 
structures [364, 365]. In addition, SARS-CoV nsp3 was shown to interact with three COPI 
subunits [366]. In none of these previous SARS-CoV and MHV studies a complete block 
of virus replication could be achieved, neither by reducing COPI vesicle formation by 
depletion of one of the coatomer subunits, nor by treatment with BFA. These results 
might partially be explained by incomplete knockdown or the presence of residual COPI 
vesicles (complete knockdown is probably not possible due to its detrimental effect on 
intracellular trafficking and cell viability). Although our study clearly demonstrates the 
importance of COPI-vesicles in SARS-CoV replication, the role of COPI vesicles in the 
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expression
Fig. 8. Validation of PKR as an antagonist of SARS-CoV replication. 293/ACE2 cells were transfected with 
four individual siRNAs targeting PKR or a scrambled control siRNA. (A) At 48 h p.t. cells were infected with 
SARS-CoV-GFP (MOI 10), fixed 24 later, and GFP fluorescence (black bars) was quantified and normalized 
to the value measured in infected, scrambled siRNA-transfected cells (100%). The effect of siRNA transfec-
tion on cell viability was analyzed in parallel (grey bars) and values were normalized to those of scrambled 
siRNA-transfected control cells (100%). Average ± SD is given (***; p-value < 0.001). (B) Knockdown of PKR 
expression at 48 h p.t. was monitored by Western blotting with a PKR-specific antiserum and TfR was used 
as loading control. The percentage of remaining PKR expression compared to scrambled siRNA-transfected 
cells is hown below each lane. (C) Cells transfected with PKR specific siRNAs and control cells were infected 
with SARS-CoV (MOI 0.01) and 24 h later these cells were lysed to assess SARS-CoV N levels by Western blot-
ting (shown below the panels as percentage of control), using β-actin as loading control. (D) Virus titers in 
the 24-h p.i. culture supernatants of wt SARS-CoV-infected cells (MOI 0.01) transfected with PKR-specific or 
scrambled siRNA. 
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analysis. The importance of COPI-coated vesicles is further supported by their essential 
role in the replication of many other RNA viruses, such as poliovirus [367, 368], other 
enterovirus family members [353, 369-371], vesicular stomatitis virus [372], Drosophila C 
virus [373], and influenza A virus [344, 374].     
Interestingly, our screen yielded a relatively high proportion of antiviral hits, with 
PKR knockdown having one of the strongest effects (~2-fold increase of GFP expres-
sion in SARS-CoV-GFP-infected cells). During hit validation, three out of four individual 
PKR-directed siRNAs caused a clear  increase in SARS-CoV protein expression and virus 
yield (Fig. 8C-D). PKR is one of four mammalian kinases that can phosphorylate eIF-2α in 
response to stress signals (the others being the PKR-like endoplasmic reticulum kinase 
(PERK), GCN2, and HRI). Many virus families have evolved gene products and strategies 
to counteract or evade the antiviral action of PKR, illustrating the importance of this 
kinase in the antiviral defense. Previously, it was found that PKR inhibits the replication 
of the coronavirus IBV, as overexpression of a kinase-defective PKR mutant enhanced 
IBV replication by almost 2-fold . Furthermore IBV appeared to (weakly) antagonize the 
antiviral activity of PKR through two independent mechanisms, including the partial 
blockage of PKR activation [69]. For the distantly related arterivirus porcine reproductive 
and respiratory syndrome virus (PRRSV), it was shown that IFN-β- [375] and IFN-γ-treated 
[376] MARC-145 cells were no longer permissive to infection, while treatment with the 
PKR inhibitor 2-aminopurine restored PRRSV replication. This suggests an important 
antiviral role for PKR in controlling PRRSV infection. Krähling et al. show that PKR was 
activated in SARS-CoV-infected 293/ACE2 cells, but conclude that knockdown of PKR 
did not significantly affect virus replication, despite the fact that a ~1-log increase in 
SARS-CoV titer was observed in their experiments [377]. This is in contrast to our PKR 
knockdown experiments that point to an antiviral role for PKR (Fig. 8). Our data clearly 
shows that depletion of PKR significantly increased SARS-CoV-driven GFP expression 
(Fig. 8A), and also enhanced N protein expression (Fig. 8C) and virus progeny release 
(Fig. 8D). This discrepancy cannot be due to host cell differences, as the same 293/ACE2 
cells were used in both studies [377], and might be due to differences in the experimen-
tal set-up, choice of controls, or normalization and interpretation of data. 
In line with the findings for PKR, reducing the expression of PERK (or EIF2AK3), one of 
the other kinases known to phosphorylate eIF-2α, resulted in an increase of SARS-CoV-
GFP reporter gene expression by 57% (p < 0.01; Fig. 5A). The unfolded protein response 
- i.e. the detection of misfolded proteins within the ER lumen - activates PERK, which 
in turn phosphorylates eIF2α, and ultimately triggers apoptosis. The relatively strong 
antiviral effect of PERK observed in this study is in line with previous studies suggesting 
that the phosphorylation of eIF-2α in SARS-CoV-infected cells is mediated by the activa-
tion of PERK [377]. Our findings support the hypothesis that upon SARS-CoV infection 
the unfolded protein response is activated as an antiviral strategy. Multiple cellular re-






sponses that induce apoptosis, including the activation of PKR and PERK, might actually 
be involved in controlling SARS-CoV infection, which could also explain several other 
hits involved in apoptosis, like those from the SAPK/JNK pathway. 
In conclusion, our kinome-wide siRNA screen has identified several cellular proteins 
and processes that influence SARS-CoV replication. These include novel factors that may 
play a role in coronavirus infections in general. Our data thus provide a starting point 
for further validation and in-depth mechanistic studies, preferably involving multiple 
factors from the identified pathways, which should enhance our understanding of the 
complex interplay between coronaviruses and their host.  
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Coronavirus (CoV) infections are commonly associated with respiratory and enteric 
disease in humans and animals. The 2003 outbreak of severe acute respiratory syndrome 
(SARS) highlighted the potentially lethal consequences of CoV-induced disease in hu-
mans. In 2012, a novel CoV (Middle East Respiratory Syndrome coronavirus; MERS-CoV) 
emerged, causing 49 human cases thus far, of which 23 had a fatal outcome. In this 
study, we characterized MERS-CoV replication and cytotoxicity in human and monkey 
cell lines. Electron microscopy of infected Vero cells revealed extensive membrane 
rearrangements, including the formation of double membrane vesicles and convoluted 
membranes, which were previously implicated in the RNA synthesis of SARS-CoV and 
other CoVs. Following infection, we observed rapidly increasing viral RNA synthesis and 
release of high titres of infectious progeny, followed by pronounced cytopathology. 
These characteristics were used to develop an assay for antiviral compound screening 
in 96-well format, which was used to identify cyclosporin A as an inhibitor of MERS-CoV 
replication in cell culture. Furthermore, MERS-CoV was found to be 50-100 times more 
sensitive to interferon-alpha (IFN-α) treatment than SARS-CoV, an observation that may 
have important implications for the treatment of MERS-CoV-infected patients. MERS-
CoV infection did not prevent the IFN-induced nuclear translocation of phosphorylated 
STAT1, in contrast to infection with SARS-CoV where this block inhibits the expression 
of antiviral genes. These findings highlight relevant differences between these distantly 
related zoonotic CoVs in terms of their interaction with and evasion of the cellular innate 
immune response. 







In June 2012, a previously unknown coronavirus was isolated from a 60 year-old Saudi-
Arabian patient who died from acute respiratory distress syndrome and multiple organ 
failure [15]. Subsequently, the novel virus was isolated from several additional residents 
and visitors of the Arabian Peninsula suffering from similar respiratory symptoms. In 
retrospect, also a cluster of respiratory infections in Jordan (April 2012) was linked to 
the same agent, although no convincing evidence for human-to-human transmission 
was obtained. This was clearly different for a cluster of three U.K. cases in early 2013, 
consisting of a patient who had travelled to Saudi Arabia and two family members 
without recent travel history outside the U.K. In the past year, various names have been 
used to refer to this newly identified CoV, including novel (beta)coronavirus (nCoV) and 
human coronavirus EMC (HCoV-EMC), but following a recent recommendation by the 
coronavirus study group of ICTV and other experts [14] we will use Middle East Respi-
ratory Syndrome coronavirus (MERS-CoV) throughout this paper. Up to May 2013, 49 
confirmed MERS cases, including 23 fatalities, have been recorded (http://www.who.int/
csr/don/archive/disease/coronavirus_infections/en/).
Coronavirus (CoV) infections are associated with respiratory and enteric disease in 
humans and animals. Since the 1960s, two human CoVs (HCoVs OC43 and 229E) were 
known to cause mild respiratory disease [20, 21], but it was the 2003 outbreak of severe 
acute respiratory syndrome (SARS; fatality rate ~10%) that revealed the potentially 
lethal consequences of CoV-induced disease in humans [6, 7]. Two years later, bats were 
identified as the most likely animal reservoir for this zoonotic CoV [11, 12]. Subsequently, 
a wide variety of bat-associated CoVs  was discovered [378, 379] and also two additional 
human CoVs (NL63 and HKU1; [22, 23, 380]) were identified. Although the general ca-
pacity of bat CoVs to switch hosts appears to be rather restricted [18], the possibility 
of SARS-CoV re-emergence or zoonotic transfer of other animal CoVs has remained a 
public health concern over the past 10 years. 
Coronaviruses are classified in four genera (alpha-, beta-, gamma- and deltacoro-
naviruses; [286]) and our previous analysis of the MERS-CoV genome [16] identified 
the newly emerging agent as a member of lineage C of the genus Betacoronavirus. 
Strikingly, as in the case of SARS-CoV, the closest known relatives of MERS-CoV are bat 
coronaviruses, like HKU-4 and HKU-5[16, 378]. The evolutionary distance to SARS-CoV 
(lineage B) is considerable, a notion further supported by recent comparative studies 
revealing important differences in receptor usage [18, 381]. 
Mammalian viruses have to cope with the host cell’s innate responses, including 
those triggered by activation of the type I interferon (IFN) pathway (reviewed in [382]). 
Coronaviruses, including SARS-CoV, appear to have evolved a variety of mechanisms 
to block or evade such antiviral responses (reviewed in [65, 317]). For example, it was 
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postulated that the sensing of double-stranded (ds) RNA replication intermediates 
by the innate immune system is inhibited by the elaborate virus-induced membrane 
structures with which CoV RNA synthesis is associated [30, 383]. Other evasion mecha-
nisms were attributed to protein functions that can be either conserved across CoVs or 
specific for certain CoV lineages. Proteins such as the nsp3 proteinase [347], the nsp16 
2’-O-methyltransferase [348], and the products of SARS-CoV ORFs 3b, 6 and 7a [105, 109, 
350, 351] have all been described to prevent IFN induction/signalling. In particular, the 
SARS-CoV ORF6 protein is known to inhibit IFN-induced JAK-STAT signalling by block-
ing the nuclear translocation of phosphorylated STAT1 (p-STAT1), which contributes to 
the pathogenic potential of the virus in a mouse model [384]. In spite of these immune 
evasion strategies, treatment with type I IFNs can inhibit CoV replication in vitro [188-
192] and, for example, protected type I pneumocytes against SARS-CoV infection in 
macaques [190].
Clearly, well-characterized systems for MERS-CoV replication in cell culture will be 
invaluable for future studies into basic virus properties and interactions with the host, 
including innate immune responses. Therefore, we set out to characterize the replication 
of MERS-CoV in different cell lines. Using this information, an assay to screen for antiviral 
compounds was developed, which identified cyclosporin A (CsA) as an inhibitor of 
MERS-CoV replication. Our first screening experiments also established that, compared 
to SARS-CoV, MERS-CoV replication is more sensitive to type I interferon treatment.
MATERIALS AND METHODS
Cells culture and virus infection
Vero cells (ATCC: CCL-81) were cultured in Eagle’s minimal essential medium (EMEM; 
Lonza) with 8% fetal calf serum (FCS; PAA) and antibiotics. Huh7 cells were grown in Dul-
becco’s Modified Eagle Medium (DMEM; Lonza) containing 8% FCS, 2 mM L-Glutamine 
(PAA), non-essential amino acids (PAA), and antibiotics. Vero E6 and Calu3/2B4 cells 
were cultured as previously described [208, 385]. Infection of Vero, Vero E6, Huh7, and 
Calu3/2B4 cells with MERS-CoV (strain EMC/2012; [15, 16]) at high multiplicity of infec-
tion (MOI 5) was done in PBS containing 50 μg/ml DEAE-dextran and 2% FCS. Inocula-
tions with a low dose (MOI ≤ 0.05) of MERS-CoV or SARS-CoV (strain HKU-39849; [386]) 
were done directly in EMEM containing 2% FCS. Virus titrations by plaque assay were 
performed as described before [355]. All work with live MERS-CoV and SARS-CoV was 
performed inside biosafety cabinets in biosafety level 3 facilities at Leiden University 
Medical Center or Erasmus Medical Center.







Rabbit antisera recognizing the SARS-CoV replicase subunits nsp3, nsp4, nsp5 and nsp8 
have been described previously [53, 208]. Rabbit antisera recognizing the SARS-CoV 
nucleocapsid (N) protein and MHV nsp4 were raised  as described [222]. Antigens were 
a full-length recombinant SARS-CoV N protein (purified from E. coli) and a synthetic 
peptide representing the 23 C-terminal residues of MHV nsp4, respectively. p-STAT1 
was detected with Alexa Fluor 488-labelled mouse-anti-STAT1 (pY701) (BD Biosciences) 
and FITC-labelled anti-mouse-IgG was used to enhance the green fluorescence. Virus 
infection was detected using the above-mentioned anti-nsp3 sera and Alexa Fluor 
594-labeled anti-rabbit IgG.
Cyclosporin A (CsA; Sigma) was dissolved in DMSO and a 10-mM stock was stored in 
aliquots for single use at -20°C. Peg-interferon alfa-2b (PEG-IFN; Pegintron, Merck, USA) 
was prepared according to the manufacturer’s instruction as a 100 µg/ml stock stored 
at 4°C.
Immunofluorescence microscopy
Cells were grown on coverslips and fixed with 3% paraformaldehyde in PBS or with 4% 
formaldehyde and 70% ethanol (p-STAT1 experiments), permeabilized with 0.1% Triton 
X-100, and processed for immunofluorescence microscopy as described previously [33]. 
Specimens were examined with a Zeiss Axioskop 2 fluorescence microscope with an 
Axiocam HRc camera and Zeiss Axiovision 4.4 software or with a confocal microscope 
(Zeiss, LSM 700) (p-STAT1 experiments).  
Electron microscopy
Vero cells were grown on sapphire discs and fixed at 8 h p.i. for 30 min at room tempera-
ture with 3% paraformaldehyde and 0.25% glutaraldehyde in 0.1 M PHEM buffer pH 6.9 
[60 mM piperazide-1,4-bis (2-ethanesulfonic acid), 25 mM HEPES, 2mM MgCl2, 10mM 
EGTA] containing 50% diluted Eagle’s minimal essential medium and 1% FCS. Cells 
were stored in fixative at 4°C for 72 h and then high-pressure frozen using a Leica EM 
PACT2. Freeze-substitution was performed in an automated system (Leica AFS2) using 
as freeze-substitution medium acetone containing 1% OsO4, 0.5% uranyl acetate and 
10% H2O. First, the samples were maintained at -90°C for 6 h in this medium and then 
slowly warmed to -20°C within 14 h, kept at -20°C for 1 h, warmed to 0°C at a 5°C/h rate 
and left at 0°C for 1 h before letting the samples reach room temperature. After washing 
with acetone, the samples were gradually infiltrated with epoxy resin LX-112 and po-
lymerized at 60°C. The samples were cut into thin sections (100 nm) and counterstained 
with uranyl acetate and lead citrate. Imaging was performed in an FEI Tecnai12 TWIN 
electron microscope operating at 120 kV and equipped with an Eagle 4k cooled slow-
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scan charge-coupled device (CCD) camera (FEI company). The images were acquired 
using binning mode 2.
Intracellular viral RNA analysis
Isolation of intracellular viral RNA was described previously [102]. After drying of the gel, 
viral mRNAs were detected by hybridization with a 32P-labeled oligonucleotide probe 
(5’-GCAAATCATCTAATTAGCCTAATC-3’) complementary to the 3’-end of all MERS-CoV 
mRNAs. Equal loading was verified in  a second hybridization using a 32P-labeled oli-
gonucleotide probe (5’-GTAACCCGTTGAACCCCATT-3’) recognizing 18S ribosomal RNA 
[52]. ImageQuant TL (GE Healthcare) software was used for quantification.
Real-time reverse transcription-polymerase chain reaction (RT-PCR)
RNA from 200 μl culture medium of CoV-infected cells was isolated with the MagnaPure 
LC total nucleic acid isolation kit (Roche) and eluted in 100 μl. RT-PCR conditions for 
quantifying MERS-CoV and SARS-CoV RNA and amplification parameters were described 
previously [8, 381]. Dilutions of viral RNA isolated from MERS-CoV or SARS-CoV virus 
stocks with a known virus titre were used to produce a standard curve. 
Development of a screening assay for antiviral compounds
Huh7 or Vero cells were seeded in 96-well plates at a density of 104 or 2x104 cells per well, 
respectively. After overnight growth, cells were infected with an MOI of 0.005 or 0.05. 
One to three days after incubation, differences in cell viability caused by virus-induced 
CPE or by compound-specific side effects were analysed using the CellTiter 96® AQueous 
Non-Radioactive Cell Proliferation Assay (Promega), according to the manufacturer’s 
instructions. Absorbance (A490) was measured using a Berthold Mithras LB 940 96-well 
plate reader. Infected cells were given CsA or DMSO (solvent control) prior to infection 
(MOI 0.005). Cytotoxic effects caused by CsA treatment alone were monitored in parallel 
plates containing mock-infected cells. 
IFN sensitivity and p-STAT1 translocation experiments
One day prior to infection, Vero cells were plated at a density of 104 cells per well in a 
96-well plate format. At -4, 0 and 4 h p.i., cells were incubated with 0 to 1000 ng/ml PEG-
IFN in 250 µl. At t=0 h, all wells were washed with PBS and infected with MERS-CoV or 
SARS-CoV (100 TCID50 per 100 µl medium). Those cultures receiving treatment from t=-4 
or t=0 were infected in the presence of the indicated concentration PEG-IFN. After 1 h, 
150 µl medium was added to the cultures of t=-4 or t=0 cultures, and 100 µl medium was 
added to the untreated cultures, which at 4 h p.i. received 50 µl medium supplemented 
with PEG-IFN to reach a final concentration of 0 to 1000 ng/ml PEG-IFN. At 48 h p.i., RNA 
was isolated from 50 µl cell culture supernatant and quantified using virus-specific real 










































lane: 1 2 3 4 5 6 7 8 9 10
Time of harvest (h p.i.)
RNA abundance (%)*
1 4.1 ± 1.1
2 4.5 ± 0.9
3 12.5 ± 1.4
4 12.1 ± 0.1
5 6.7 ± 0.6
6 1.4 ± 0.5
b
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Fig. 1. Kinetics of MERS-CoV replication in Vero and Huh7 cells. Vero and Huh7 cells were infected with 
MERS-CoV (MOI 5). (a) Hybridization analysis of viral mRNAs isolated from MERS-CoV-infected cells using 
an oligonucleotide recognizing the viral genome and all sg mRNAs. Additional minor bands of ~3 and ~4 
kb were observed (*) and may represent additional viral mRNA species that remain to be studied in more 
detail. However, the corresponding positions in the ORF4a/b and ORF5 coding regions do not contain a 
canonical core TRS sequence (AACGAA; [16] that might provide a direct explanation for their synthesis. (b) 
Analysis of the relative molarities of viral genome and each of the sg mRNAs (% of total viral mRNA). mRNA 
sizes were calculated on the basis of the TRS positions in the viral genome sequence [16]. Phosphorimager 
quantification was performed on the gel lanes with the RNA samples isolated from Vero cells at 10, 13 and 
24 h p.i. (Fig. 1a; lanes 3, 4, and 5; avg ± SD). (c) Release of infectious MERS-CoV progeny into the medium 
of infected Vero or Huh7 cells at the indicated time points, as determined by plaque assay (avg ± SD; n=4). 
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time RT-PCR assays (see above). Furthermore at 48 h p.i., CPE was scored microscopically 
as either (0) none, (1) mild, (2) moderate, (3) severe or (4) complete.
For p-STAT1 nuclear translocation experiments, Vero cells were infected with MERS-
CoV or SARS-CoV (MOI 1). At 8 h p.i., cells were treated with 1000 ng/ml PEG-IFN for 30 
min and fixed with 4% formaldehyde and 70% ethanol and subsequently stained for 
presence of viral antigen and p-STAT1 translocation.
RESULTS
Kinetics of MERS-CoV replication in Vero and Huh7 cells 
Only a few laboratory studies on MERS-CoV replication have been reported thus far. 
Cells from a variety of mammalian hosts were found to be susceptible and infection 
can induce pronounced cytopathology and cell death [15, 18]. Following entry, the CoV 
replicative cycle starts with the translation of the positive-stranded RNA genome into 
replicase polyproteins that are cleaved into 16 nsps [16, 37]. These direct both genome 
replication and the synthesis of the subgenomic (sg) mRNAs required to express the 
structural and accessory proteins. To investigate MERS-CoV replication in more detail, 
we used Vero and Huh7 cells to analyse viral RNA synthesis and progeny release in 
single-cycle infection experiments.
Hybridisation analysis of the accumulation of viral RNA revealed the presence of 
genome RNA and seven sg transcripts, with sizes closely matching those previously 
predicted from the positions of conserved transcription regulatory sequences (TRS) 
in the viral genome [16] (Fig. 1a). The relative abundance of the various sg mRNAs is 
similar to what has been observed for other CoVs, with the smallest species (encoding 
the N protein) being by far the most abundant transcript (Fig. 1b). In both cell lines, viral 
mRNAs could be readily detected at 7 h p.i. and reached maximum levels around 13 h 
p.i. (Fig. 1a). Viral RNA levels remained more or less constant until 24 h p.i. in Vero cells, 
whereas the amount isolated from Huh7 cells declined due to the more rapid develop-
ment of cytopathology in this cell line between 13 and 24 h p.i. (see below). After the 
peak of viral RNA accumulation had been reached, the titre of virus released from MERS-
CoV-infected Vero cells steadily increased from ~5 x 105 to ~5 x 107 PFU per ml (Fig. 1c). 
Interestingly, the bulk of the viral progeny was released significantly earlier from Huh7 
cells, although the final titre at 24 h p.i. was comparable to that obtained from Vero cells.
Antisera raised against non-structural proteins of other betacoronaviruses 
cross-react with MERS-CoV proteins
Despite the relatively large evolutionary distance to better-characterized CoVs, we 
tested a panel of antisera from our laboratory for cross-reactivity with MERS-CoV-






infected cells. In contrast to a polyclonal serum recognizing the SARS-CoV nucleocapsid 
(N) protein (data not shown), antisera against various SARS-CoV nsps (nsp3, nsp5, nsp8; 
[208]) raised using purified recombinant proteins as antigen, were found to strongly 
cross-react (Fig. 2a). In addition, rabbit antisera raised against synthetic peptides (23-
mers) representing a small but conserved C-terminal part of SARS-CoV and MHV nsp4 
strongly cross-reacted with MERS-CoV. Only small but apparently immunogenic parts 
of these peptides (e.g., LYQPP) are absolutely conserved between MHV and MERS-CoV 
nsp4 (Fig. 2b). Conservation in other betacoronaviruses (data not shown) suggests that 




















Fig. 2. Selected rabbit antisera raised against SARS-CoV and MHV nsps cross-react with MERS-CoV 
proteins. (a) MERS-CoV-infected Vero cells (MOI 5) were fixed at 8 h p.i. For immunofluorescence micros-
copy, cells were double-labelled with a mouse monoclonal antibody recognizing dsRNA (bottom row) and 
rabbit antisera raised against SARS-CoV nsp3, nsp4, nsp5 or nsp8, or MHV nsp4 (top row). Bar, 20 μm. (b) 
Sequence comparison of the C-terminal domain of nsp4 of SARS-CoV (isolate Frankfurt 1), MERS-CoV (strain 
EMC/2012) and MHV (strain A59). The SARS-CoV and MHV sequences corresponds to the synthetic pep-
tides used to raise rabbit anti-nsp4 sera. Residues conserved in all three viruses are highlighted in yellow, 
whereas residues conserved in two out of three are highlighted in grey. Amino acid numbers refer to the 
full-length pp1a sequence. (c) Monolayers of Vero, Vero E6, Huh7 and Calu3/2B4 cells were infected with 



















Fig. 3. Membrane structures induced by MERS-CoV infection. Electron micrographs of thin sections 
(100 nm) of (a-d) MERS-CoV-infected Vero cells at 8 h p.i. (a) Low magnification images of a cell containing a 
small cluster of double-membrane vesicles, enlarged in (b). Some DMVs are indicated by black arrowheads 
and the inset displays a close-up of the boxed DMV in (b). (c) Extensive membrane alterations in the peri-
nuclear region. The boxed area in (c) is displayed at higher magnification in (d), where CMs (white arrows, 
inset) embedded in clusters of DMVs (black arrowheads) can be observed. For comparison, (e) shows the 
unaltered cytoplasm of a mock-infected cell and (f ) contains SARS-CoV-induced DMV (black arrowheads) 
as observed after HPF and freeze substitution.  N, nucleus; m, mitochondria. Scale bars, 2 µm (a,c,e), 500 
nm (b,d,f ).







Subsequently, we employed a monoclonal antibody recognizing dsRNA to localize 
intermediates in viral RNA synthesis [30, 387]. In various cell types, the immunolabelling 
signals for both replicase and dsRNA localized to the perinuclear region (Fig. 2c), where 
the replication structures induced by other CoVs are known to accumulate [30, 31, 34-
36, 208].  
We next used electron microscopy (EM) to investigate the ultra-structural and 
potentially cytopathic changes that MERS-CoV induces in infected cells, and focused 
on the membranous replication structures that support MERS-CoV RNA synthesis. The 
preservation of such structures, typically double-membrane vesicles (DMVs) and con-
voluted membranes (CMs), was previously found to be significantly improved by using 
protocols that include cryo-fixation and freeze-substitution [30, 208]. We now applied 
these advanced preservation techniques, including newly developed protocols for high-
pressure freezing (HPF), to MERS-CoV-infected Vero cells. Images of similarly prepared 
SARS-CoV-infected Vero E6 cells are included for comparison (Fig. 3f ).
Compared to mock-infected control cells (Fig. 3e), different degrees of distinct altera-
tions were observed at 8 h p.i. Some cells contained relatively small DMV clusters (Fig. 3a,b; 
black arrowheads, inset), whereas in others large numbers of DMVs occupied extensive 
areas of the perinuclear region (Fig. 3c,d), differences that likely reflect different stages in 
infection progression. The diameter of MERS-CoV-induced DMVs ranged from 150 to 320 
nm, comparable to what was previously measured for SARS-CoV-induced structures [30]. 
An interesting morphological difference with our previous studies of SARS-CoV-infected 
cells was the presence of a dense inner DMV core, which can be attributed to technical 
differences in sample preparation. In terms of ultrastructural preservation, HPF is widely 
considered superior to the previously used plunge-freezing protocols. Also in the case 
of SARS-CoV (Fig. 3f ) and the distantly related equine arteritis virus [29], a similar dense 
DMV core became apparent when HPF was employed. Although DMV cores are known 
to contain dsRNA, the implications of these ultrastructural observations remain unclear. 
Interestingly, CMs were always surrounded by DMV clusters and were only observed in 
cells that appeared to be more advanced in infection (Fig. 3c,d; white arrows, inset). This 
observation strengthens the notion that DMV formation precedes the development of 
CMs, as previously postulated for SARS-CoV [30]. 
MERS-CoV-induced cytophatology and cell death. 
In cell culture, many CoVs induce severe cytopathic effect (CPE) and cell death. Infection 
with a number of CoVs can also induce extensive syncytium formation, due to fusion 
activity of the viral spike protein at neutral pH (reviewed in [388]). MERS-CoV-induced 
cytopathology was monitored by light microscopy following low-MOI inoculation of 
monkey and human cells (Fig. 4). In line with previous observations [15], Vero cells de-
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veloped clear CPE at 2 days post infection (d p.i.) and detached at 3 d p.i. (Fig. 4a). Similar 
observations were made for Calu3/2B4 cells (Fig. 4b). In contrast, MERS-CoV-infected 
Vero E6 cells displayed only mild CPE starting at 3 d p.i and cell death was not complete 
after six days (Fig. 4c). The development of CPE in Huh7 cells was strikingly faster com-
pared to the three other cell lines and, following extensive syncytium formation, cells 
detached already around 17 h (Fig. 4d). Given the low MOI used and the viral replication 
kinetics (Fig. 1), the syncytium formation in these only partially infected Huh7 cultures 
Mock MERS-CoV
Vero cells (2 d p.i.)
Vero E6 cells (3 d p.i.)
Vero E6 cells (6 d p.i.)
Huh7 cells (17 h p.i.)





Fig. 4. MERS-CoV infection induces severe cytopathology in monkey and human cell lines. Monolayers 
of Vero (a), Calu3/2B4 (b), Vero E6 (c) and Huh7 (d) cells infected with MERS-CoV (MOI 0.05) and analysed by 
light microscope at the indicated time points. Bar, 100 μm. 






appeared to be a major factor in CPE development. DPP4 expression on Vero and Huh7 
cells [381] and expression levels of DPP4 on Calu3/2B4 and Vero E6 cells correlated with 
susceptibility to MERS-CoV (data not shown).
Development of an assay to screen for compounds inhibiting MERS-CoV 
replication. 
The virus-induced CPE in Vero and Huh7 cells was used to develop a first assay to screen 
for compounds that inhibit MERS-CoV replication in cell culture. Vero cells were seeded 
in 96-well plates and infected at an MOI of 0.005 or 0.05 (Fig. 5a). After two and three 
days, CPE formation was monitored microscopically and cytotoxicity was measured us-
ing a commercial cell viability assay. Moderate CPE was observed on day 2, and by day 
3 cell viability had dropped below 10% with both virus doses used (Fig. 5a), indicating 
near-complete cell death. In MERS-CoV-infected Huh7 cells (Fig. 5b), already after day 1, 
cell viability had dropped to 79% or 24% (after MOI 0.005 or 0.05 infection, respectively), 
which was in line with our observations on rapid syncytium formation and CPE in this 
particular cell line (Fig. 4d). One day later, CPE was complete for both virus doses used 
and cells had detached (Fig. 5b). Based on this comparison, further experiments were 
done using an MOI of 0.005 and Huh7 and Vero cells were incubated for two or three 
days, respectively, before measuring cell viability. 
Previously, it was shown that replication of various CoVs, including SARS-CoV, can 
be inhibited by the immunosuppressive drug CsA [276, 277].  Therefore, while testing 
whether the CPE-based assay described above could be used as an antiviral screening 
method, we used CsA treatment to obtain a first proof of principle. Infected Vero cells 
were given 3 or 9 μM of CsA and were analysed at 3 d p.i. At the concentrations used, CsA 
did not adversely affect the viability of mock-infected cells (Fig. 5c). Treatment with 9 μM 
completely inhibited CPE and left cell viability unchanged compared to mock-infected 
control cells. The inhibitory effect of CsA was confirmed in Huh7 cells (Fig. 5d), which 
displayed reduced and lack of CPE upon treatment with 7.5 μM and 15 μM CsA, respec-
tively. These results were corroborated by immunofluorescence microscopy analysis of 
CsA-treated and high MOI-infected Vero and Huh7 cells and by determining virus titres 
released into the medium. Both assays confirmed an almost complete block of MERS-
CoV-infection (data not shown). However, as previously reported for other CoVs [276], 
a small fraction of MERS-CoV-infected cells appeared to be refractive to CsA treatment 
and supported a low level of MERS-CoV replication, even at high CsA concentrations 
(data not shown). 
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Enhanced sensitivity of MERS-CoV to pegylated IFN-α treatment in comparison 
to SARS-CoV. 
Type I IFNs inhibit CoV replication and can protect against infection in animal models 
[189, 190]. We therefore compared the effect of pegylated interferon-α (PEG-IFN) treat-
ment on MERS-CoV and SARS-CoV replication in vitro. Vero cells were given PEG-IFN 4 
h before low-MOI infection, together with the inoculum or 4 h after infection. At 2 d p.i. 
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Fig. 5. Development of an assay to screen for compounds inhibiting MERS-CoV replication. (a,c) Vero 
and (b,d) Huh7 cells in a 96-well plate format were infected at an MOI of 0.005 or 0.05. Mock-infected cells 
were used as reference for unchanged cell viability (their relative viability was set at 100%). (a) Infected 
Vero cells were incubated for 2 or 3 days and (b) Huh7 cells were incubated for 1 or 2 days. (c) Vero cells 
were infected with MERS-CoV (MOI 0.005) in the presence of 3 µM or 9 µM CsA, or 0.09% DMSO as solvent 
control. (d) Huh7 cells were infected with MERS-CoV (MOI 0.005) in the presence of 3.75 to 15 µM CsA, or 
0.15% DMSO. (c,d) Graphs show the results of a representative experiment (avg ± SD; n=4). All experiments 
were repeated at least twice.






Treatment with PEG-IFN profoundly inhibited both MERS-CoV- and SARS-CoV-induced 
CPE and RNA levels in a dose-dependent manner (Fig. 6). At 2 d p.i., SARS-CoV-induced 
CPE was reduced for all time points of PEG-IFN addition when using a dose of at least 
30 ng/ml PEG-IFN (Fig. 6a), whereas MERS-CoV-induced CPE already decreased using a 
dose of 1 ng/ml (Fig. 6b).  For SARS-CoV, only pre-treatment with 1000 ng/ml PEG-IFN 
completely prevented CPE. For MERS-CoV, complete inhibition of CPE was observed at 
much lower concentrations, specifically 3, 10 or 30 ng/ml when the drug was added to 
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Fig. 6. Sensitivity of MERS-CoV and SARS-CoV to PEG-IFN. Vero cells were incubated with 0 to 1000 ng/
ml PEG-IFN at t=-4, t=0, at t=4 h p.i. Cells were infected with 100 TCID50 virus per well. (a,b) At 2 d p.i. cells 
were examined for CPE. Effect of PEG-IFN treatment on CPE induced by (a) SARS-CoV or (b) MERS-CoV. CPE 
was scored as either (0) none, (1) mild, (2) moderate, (3) severe or (4) complete. (c,d) Viral genomes in the 
culture medium of virus-infected cells were determined by RT-PCR. Influence of PEG-IFN treatment on the 
viral RNA load (genome equivalents (gen. eq.) per ml) in the supernatants of cells infected with (c) SARS-
CoV or (d) MERS-CoV.
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observed in SARS-CoV-infected cultures treated with 30 ng/ml PEG-IFN, only a 30-fold 
reduction of viral RNA was detected in their medium at 2 d p.i. (Fig. 6c). For comparison, 
treatment of MERS-CoV-infected cells with the same PEG-IFN dose completely blocked 
CPE and reduced viral RNA levels in the medium 600- to 2,000-fold, depending on the 
timing of PEG-IFN addition (Fig. 6d). 
Our data revealed that in the same cell line MERS-CoV infection is 50-100 times more 
sensitive to PEG-IFN treatment than SARS-CoV infection. This difference may be ex-
plained by important lineage-specific genetic differences between these two zoonotic 
betacoronaviruses in terms of accessory protein genes encoded in the 3’ part of the 
genome [16, 389]. In particular, MERS-CoV does not encode a homolog of the SARS-
CoV ORF6 protein, which was reported to block the IFN-induced nuclear translocation 
of phosphorylated transcription factor STAT1. As nuclear translocation of p-STAT1 is 
essential for transcriptional activation of downstream antiviral genes, the ORF6 protein 
makes SARS-CoV less sensitive to treatment with type I IFN [105, 384]. IFN-induced trans-
location of p-STAT1 was readily observed in IFN-treated mock-infected Vero cells (Fig. 
7a-d), but not in IFN-treated SARS-CoV-infected cells (Fig. 7e,f ). In contrast, in MERS-CoV-
infected and IFN-treated cultures the translocation of p-STAT1 was detected (Fig. 7g,h). 
Together with the data on IFN sensitivity (Fig. 5), these observations highlight important 
differences between SARS-CoV and MERS-CoV in terms of their interaction with the IFN 
signalling pathways.
DISCUSSION
Following the 2003 SARS epidemic, global CoV hunting efforts identified a wealth of 
previously unknown family members, in particular in bat species from several conti-
nents [286]. Moreover, at least three of the four current ‘established’ human CoVs (NL63, 
229E, and OC43) were postulated to have originated from zoonotic reservoirs [24, 390, 
391]. Recently, about a decade after the SARS outbreak, MERS-CoV was identified as 
the next zoonotic CoV [15] and appears to be highly pathogenic to humans: of the 49 
cases confirmed thus far, 23 had a fatal outcome (http://www.who.int/csr/don/archive/
disease/coronavirus_infections/en/). Whether zoonotic CoVs cause transient epidemics 
or establish a long-lasting relationship with the human host, an in-depth understanding 
of virus-host interactions will be required to develop effective countermeasures. In this 
study, we defined several basic but important parameters of MERS-CoV replication in 
cell culture (Figs. 1-4). Among the tools for MERS-CoV research developed are immuno-
assays based on cross-reacting antisera raised against other betacoronaviruses (Fig. 2) 
and a CPE-based assay that can be used to screen for antiviral effects (Figs. 5-6).

















Fig. 7. IFN–α induced nuclear translocation of p-STAT1 in MERS-CoV-infected Vero cells. Confocal im-
munofluorescence microscopy of uninfected Vero cells (a-d) and Vero cells infected (MOI 1) with SARS-CoV 
(e,f ) or MERS-CoV (g,h). At 8 h p.i. cells were (a, b) left untreated or (c-h) treated with 1000 ng/ml PEG-IFN for 
30 minutes, fixed and double-labelled with antisera against SARS-CoV nsp3 (red; a-h), or p-STAT1 (green; 
b,d,f,h), and nuclear DNA was stained with DAPI (blue; a,c,e,g). 
126 Chapter 6
Following the development of a high-throughput screening method for antiviral 
effects, proof of principle was obtained using CsA, a recently discovered inhibitor of 
CoV replication [276, 277]. This drug affects the function of several members of the cel-
lular cyclophilin (Cyp) family and appears to block functional interactions between viral 
proteins and one or multiple cyclophilin family members [281]. Low-micromolar CsA 
concentrations blocked MERS-CoV-induced CPE in Vero and Huh7 cells (9 μM and 15 
μM, respectively) as previously observed for other CoVs [276, 277]. As in those previous 
studies [276], a small fraction of the cells somehow remained susceptible to MERS-CoV 
infection, even at high CsA concentrations. Thus, virus replication could not be com-
pletely eliminated, which may ultimately lead to the development of CsA resistance in 
cell culture. In conclusion, these experiments established that monitoring MERS-CoV-
induced CPE can be a valuable and rapid tool in screening for the potential antiviral 
activity of e.g. small-molecule compounds or FDA-approved drugs like PEG-IFN.
Type I IFN induction, a hallmark of the early innate immune response, is counteracted 
by different CoV-encoded proteins. Despite these evasion strategies, IFN can be detected 
in sera of CoV-infected mice and humans [188, 189, 392], and CoV-infected plasmacytoid 
DCs have been identified as a source of high IFN-α levels [393, 394]. The SARS-CoV ORF6 
protein, however, (partially) disrupts the downstream IFN-induced signalling in infected 
cells by inhibiting the nuclear translocation of p-STAT1, a critical component of both the 
IFN-α and IFN-γ signalling pathways [105]. Although contributions from additional im-
mune evasion mechanisms are likely, the lack of a SARS-CoV ORF6 homolog [16] may be 
a major factor in the higher sensitivity of MERS-CoV to PEG-IFN treatment, as observed in 
this study and other recent work [395]. This was further substantiated by the finding that 
nuclear translocation of p-STAT1 is not blocked in MERS-CoV-infected cells (Fig. 7), which 
indicates that MERS-CoV has not evolved an alternative strategy to achieve the same 
goal. MHV has been shown to be relatively insensitive to IFN pre-treatment, however 
also this virus does not block activation and translocation of p-STAT1 but instead inhibits 
the induction of a subset of ISGs by IFN-α/β [396]. Future studies may elucidate whether 
MERS-CoV has evolved alternative strategies to cope with the host’s IFN response. In 
addition, it will be important to test whether MERS-CoV is attenuated in vivo as a result 
of the relative high IFN sensitivity.
PEG-IFN is a registered drug used for the treatment of chronic hepatitis B and C 
infections in humans [397]. Several CoVs, including SARS-CoV, were shown to be sensi-
tive to both type I IFN treatment in vitro and PEG-IFN treatment in vivo [190-192], and 
in this study we established a relatively high sensitivity for MERS-CoV. For example, in 
cynomolgus macaques plasma levels of 1-5 ng/ml  were reached [190], a dose which in 
this study significantly reduced MERS-CoV replication in vitro. The sensitivity of MERS-
CoV to exogenous IFN suggests that administration of recombinant IFN merits further 






evaluation as a therapeutic intervention strategy if new infections with the novel virus 
would occur.
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THE NEED FOR ANTIVIRAL THERAPIES AGAINST PATHOGENIC CORONAVIRUS 
INFECTIONS
The 2003 SARS-CoV outbreak, which had an immense global impact and almost led to a 
pandemic, and the ongoing MERS-CoV outbreak illustrate it is important to be prepared 
for emerging pathogenic coronaviruses. The re-emergence of SARS-CoV or the zoonotic 
transfer of other animal coronaviruses like MERS-CoV to humans remains a serious pub-
lic health concern. The preparedness for these outbreaks should obviously include the 
availability of antiviral intervention strategies. The number of confirmed MERS cases that 
have been reported is relatively low (94 cases and 46 deaths till August 2013), but the 
mortality rate in this group of patients is alarmingly high (~50%). Moreover, in view of 
the distribution of these cases in time and over distant geographical locations, it is now 
widely assumed that the actual number of human infections could be much higher. A 
major factor that may contribute to an underestimation of that number obviously is the 
possibility of mild or asymptomatic infections, but also inadequate surveillance, lack of 
proper diagnostic procedures  and/or the political and social climate in the Middle East 
may play a role. Therefore, the true number of cases and the risk of the virus spreading 
to other regions might be underestimated. Nevertheless, in-depth analysis of the small 
MERS clusters described so far suggests that the currently circulating MERS-CoV  strains 
do not have pandemic potential [398]. 
The SARS outbreak triggered the rapid development of vaccine candidates (reviewed 
in [399]) and one of these even entered a phase I clinical trial [400] within a relatively 
short period of time, but still 1.5 years after the start of the outbreak. Since the 2002/2003 
global SARS outbreak was controlled within about 4 months and only a few additional 
cases have been reported since then, no further clinical trials were conducted. Consider-
ing the time required to test and register a vaccine, it is important to develop alternative 
intervention strategies (e.g. pan-coronavirus inhibitors) as a first line of defence, to 
combat any new pathogenic coronavirus that might emerge in the future.  
A better understanding of coronavirus replication and the complex interplay be-
tween the abovementioned viruses and their host should provide starting points for 
the development of such antiviral strategies. They may also offer possibilities to limit 
or circumvent the problem of antiviral drug resistance, a common problem when using 
compounds that directly target RNA viruses, due to their high mutation rate and rapid 
adaptation. Therefore, there is a growing interest in druggable host targets to block vi-
rus replication [401], as drug resistance is less likely to develop when cellular rather than 
viral functions are targeted (reviewed in [130, 131]). Chapters 2, 3 and 5 of this thesis 
shed some light on the interplay between nidoviruses and the host cell. The different ap-
proaches used in these studies, each with their own benefits and limitations, identified 







functional replication and transcription complexes (RTCs) from arterivirus-infected cells 
contributed to the identification of antiviral compounds and proviral host factors. An 
siRNA screen identified kinases and various other host factors that affect SARS-CoV 
replication. Finally, the cyclophilins (Cyps), a promising class of host targets for antiviral 
therapy, were shown to play a role in the replication of both arteri- and coronaviruses 
(Chapters 3, 4 and 6). Below, a selection of these host factors, their functions in the host 
cell and their role in nidovirus replication will be discussed in more detail.
Characterisation of replication complexes isolated from infected cells
The isolation of viral replication complexes (RCs) from infected cells and the development 
of in vitro assays (IVRAs) to analyse their RNA synthesising activity have provided mecha-
nistic insights into the replication of several +RNA viruses, including human pathogens 
like poliovirus [259, 264, 268, 402], West Nile virus [227, 244], Japanese encephalitis virus 
[403], and HCV [254, 404]. The development of such assays for model viruses like Sindbis 
virus [228], brome mosaic virus [261] and Flock house virus [405] has contributed to our 
understanding of +RNA virus replication in general. Besides providing information on 
viral RNA synthesis mechanisms and the role of membrane structures in replication, also 
the involvement of host proteins in RNA synthesis [264, 406] was established and the 
mode of action of certain inhibitors was resolved, for example in the case of Gliotoxin, 
which was shown to be an inhibitor of the poliovirus polymerase 3Dpol [407]. 
For nidoviruses, several previous attempts to study RNA synthesis using RTCs iso-
lated form infected cells [236, 239, 240] resulted in barely detectable activities in vitro. 
Chapter 2 describes a robust assay to study nidovirus RNA synthesis in vitro. A crude 
cytoplasmic fraction from cells infected with the prototype arterivirus EAV, contained 
RTCs that were able to synthesise EAV genomic RNA and all sg mRNAs in vitro. Further 
subcellular fractionation yielded a membrane fraction that contained these functional 
RTCs. Strikingly, their RNA synthesising activity was strongly dependent on a cytosolic 
host factor that was not physically associated with the RTCs after their isolation. In paral-
lel to this study of the arterivirus RTCs, the same phenomenon was observed for RTCs 
isolated from SARS-CoV-infected cells [53]. This host factor could be partially purified 
from the cytosol of (uninfected) HeLa cells by size-exclusion chromatography and was 
found to have a native mass of 59-70 kDa. Several other chromatographic methods were 
applied in attempts to further purify and identify the host factor necessary for EAV RNA 
synthesis, and it still remains to be seen whether it is the same factor that is crucial 
for SARS-CoV replication. Its identification was hampered by the fact that all protein 
fractions purified need to be assayed for their ability to reconstitute the activity of 
pelleted (inactive) EAV RTCs, and that the preparation of these complexes is laborious 
and complicated, in particular since they lose their RNA-synthesising activity relatively 
quickly. Comparative quantitative mass spectrometry (in collaboration with the LUMC 
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Biomolecular Mass Spectrometry Facility) has now narrowed down the list of candidates 
to six proteins (de Wilde et al., unpublished data), but unfortunately the exact identity 
of this host protein remains to be established. Only a small amount of this factor is 
needed for EAV RTC activity, since a 50-fold diluted HeLa cell lysate or chromatography 
fractions containing almost undetectable amounts of protein can still reconstitute viral 
RNA synthesis (de Wilde et al., unpublished data). The need for a host factor that appar-
ently has no permanent physical interaction with the viral RTC was also observed for 
poliovirus RNA synthesis in a study by Barton et al. [264], and the identity of this factor is 
currently still unknown. I hypothesise that this factor modifies (by e.g. phosphorylation) 
and activates a host or viral protein within the RTC that is required for efficient RNA 
synthesis. Its unequivocal identification and functional characterisation, using siRNAs, 
chemical inhibitors and heterologous expression and purification is currently ongoing. 
Viral RNA synthesis is a logical target for developing antiviral strategies and inhibitors 
of this step of the replicative cycle have been successfully developed for several +RNA 
viruses (reviewed in [318, 408, 409]). In vitro assays have been used to analyse nidovirus 
RNA synthesis but also for screening for compounds that inhibit RNA synthesis, as exem-
plified by the identification of CsA (Chapter 3) and Zn2+ [159]. An advantage of screening 
for inhibitors in an in vitro system is that cellular uptake does not pose any limitations, 
which allows the identification of (cell-impermeable) lead compounds that would have 
been missed in cell-based screens. A disadvantage of this approach is that it would 
probably not identify inhibitors that need to be metabolised first, like Ribavirin. Another 
drawback is that potential cytotoxic effects caused by the compound are not detected 
at an early stage. It obviously remains important to test inhibitors that are identified in 
vitro, in cell-based assays to evaluate their toxicity and efficacy (see also Chapter 3).
In conclusion, the biochemical studies and in vitro activity assays provided more 
insight into the composition and characteristics of the nidovirus RTC and form a good 
basis for more in-depth studies, for example on their composition and the function 
and origin of the associated membranes. This would require more sophisticated – thus 
far unsuccessful – RTC purification strategies in combination with for example mass-
spectrometry. 
SYSTEMS VIROLOGY AND ITS POTENTIAL TO IDENTIFY HOST FACTORS 
INVOLVED IN CORONAVIRUS REPLICATION
The application of systems biology approaches in virology (systems virology) has pro-
vided a wealth of information on the role of individual proteins and cellular pathways 
in the replication of RNA viruses (for a recent review, see [410]). This relatively new, 







the cell or even in the whole organism and aims to provide an unbiased perspective. The 
applied techniques include transcriptomics (the analysis of gene expression profiles in 
infected cells), metabolomics (metabolic changes induced during infection), proteomics 
(to analyse changes in the cellular proteome caused by infection) and phenomics, which 
includes RNA interference (RNAi) screening. RNAi is a method that enables the specific 
degradation of cellular or viral mRNAs by transfecting small interfering RNA (siRNA) 
molecules that are complementary to the target RNA. This method is widely used to 
study virus-host interactions and it has identified numerous host genes involved in the 
replication of important human pathogens like WNV [334], DENV [335], HIV-1 [336], HCV 
[337-342] and influenza virus [338, 343, 344]. 
For coronaviruses a number of host proteins that affect the replicative cycle have 
been  described previously ([321] and reviewed in [65, 320]), but large(r)-scale siRNA 
screens to systematically identify such factors have not been reported thus far. Chapter 
5 describes an siRNA screen to identify host cell kinases that influence SARS-CoV replica-
tion. Protein kinases are key regulators in signal transduction and control a wide variety 
of cellular processes [411]. Consequently they have been the subject of many studies 
aiming to develop therapeutic strategies for the treatment of a variety of diseases, and 
indeed many registered drugs have cellular kinases as their target [412, 413]. In addition, 
kinases have been shown to play important roles in the replicative cycle of many +RNA 
viruses. 
The siRNA screen that is described in Chapter 5 yielded a relatively high proportion 
of antiviral hits (90 of 778 factors; ~12% of all factors) for SARS-CoV, compared to human 
kinome-directed screens that have been performed with other viruses [341, 414, 415]. 
This might indicate that compared to other viruses, SARS-CoV replication is more re-
stricted by cellular factors. However, differences in experimental set-up exist and should 
also be taken into account. 
Pathway analysis mapped multiple hits to cellular immune responses, like interleukin 
(IL) signalling. Within the IL signalling pathways, IL-6 and IL-8 signalling have previously 
been implicated in controlling coronavirus infection and coronavirus-induced inflamma-
tion (reviewed in [65]), and the results described in Chapter 5 (once again) emphasise 
their importance in SARS-CoV infection. 
Several hits of our siRNA screen are part of the p38 MAPK pathway, which has also 
been implicated in nidovirus replication previously, as it regulates IL-6-, IL-8- and IL-
10-mediated pro-inflammatory cytokine signalling [360, 361, 416]. This, for example, 
explains why MEK3, a key player in the p38 MAPK signalling pathway, was identified as 
antiviral hit for SARS-CoV. These results imply that activation of the p38 MAPK pathway 
limits SARS-CoV replication in cell culture and in vivo. Liao et al. showed that the avian 
coronavirus IBV induces IL-6 and IL-8 expression. Meanwhile, the same study showed 
that IBV has evolved a strategy to counteract IL-6 and IL-8 expression by inducing the 
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expression of dual-specificity phosphatase 1 (DUSP1), a negative regulator of p38 MAPK 
[362]. Although viral protein expression seemed not directly affected by IL-6 and IL-8, 
IBV apparently interferes with p38 MAPK signalling to limit expression of these pro-
inflammatory cytokines. In contrast to IBV, MHV infection activates p38 MAPK signalling 
and the increased IL-6 production actually promotes MHV-specific protein synthesis and 
virus production [363]. Follow-up studies on the role of MAPKs in SARS-CoV infection 
and their link with the immune response and other pathways should provide more in-
sight into the exact role of these pathways in coronavirus replication and pathogenesis, 
and in the apparently virus-specific (opposite) effects observed among coronaviruses.
The IL-17 signalling pathway that was identified as antiviral in the SARS-CoV siRNA 
screen, was recently found to be activated in epithelial cells during SARS-CoV and MERS-
CoV infection [417]. Since this pathway plays a pivotal role in host defence responses 
against microbial invaders, the authors suggested that this pathway might be an in-
teresting therapeutic target to limit coronavirus-induced cytopathicity and lung injury.
In parallel to the SARS-CoV siRNA screen described in Chapter 5, a similar screen us-
ing the same cell line was performed to identify cellular kinases that affect EAV replica-
tion [418]. For EAV, 38 proviral (40 for SARS-CoV) and 116 antiviral hits (90 for SARS-CoV) 
were identified. There was a remarkably small overlap between the hits identified for 
SARS-CoV and EAV, as only 5 common proviral (~12% of all hits) and 18 common antivi-
ral (20% of all hits) hits were found. Apparently, these distantly related nidoviruses differ 
significantly in their interactions with the host. Nonetheless, the few common factors 
that have been identified (diacylglycerol kinase epsilon, suppressor of cytokine signal-
ling 5, protein serine kinase H1, AarF domain containing kinase 4, and coatomer protein 
complex subunit beta-2) should be further evaluated as they could represent interesting 
targets for the development of broad-spectrum antiviral strategies against nidoviruses.
The application of RNAi screens was considered a revolution in genetics [419]. 
However, one should keep in mind that it also has drawbacks and that data must be 
interpreted with caution. This is illustrated, for example, by the fact that only three com-
mon hits were identified when data sets of three independent large-scale RNAi screens 
for host factors involved in HIV-1 replication were compared (reviewed in [420]). One 
of the major drawbacks of RNAi screening is that this method is relatively error prone 
and major concerns include the identification of false positive hits due to off-target ef-
fects, e.g. siRNAs might down-regulate multiple transcripts, siRNAs might stimulate the 
immune response, or exogenous siRNAs could saturate the RNAi machinery to block 
processing of essential cellular (mi)RNAs (reviewed in [421]). False negative hits could be 
observed due to insufficient knockdown of the factor that is being analysed [422]. Bear-
ing this in mind, one should consider hits from siRNA screens only as a starting point for 
further analysis rather than a definitive list of host factors involved in virus replication. 







for example using a deconvoluted set of siRNAs targeting the same gene, lentivirus-
expressed shRNAs and/or chemical inhibitors, if available for the target. A drawback of 
the use of chemical inhibitors is their potential lack of specificity. Overexpression stud-
ies of the identified proteins are generally expected to show an effect opposite of that 
found in the siRNA screen, although - depending on the endogenous level of the host 
factor - these effects might be limited or absent. However, the combined results of such 
follow-up/validation studies should increase the reliability of hit identification. 
The sets of pro- and antiviral host factors that were identified for SARS-CoV provides 
a good starting point for in-depth analysis of nidovirus-host interactions and the cellular 
pathways that influence replication, which might ultimately lead to the development of 
host factor-directed antiviral strategies. 
COP-I COATED VESICLES AND MEMBRANES IN CORONAVIRUS REPLICATION
COPB2 (or β’-COP), a subunit of the coatomer protein complex, was identified in our 
siRNA screen as a proviral factor for SARS-CoV, as its depletion strongly inhibited SARS-
CoV protein expression and progeny titres (Chapter 5). Other proteins involved in the 
formation of COP-I coated vesicles also play a role, as depletion of COPB1 and GBF1 
severely affected SARS-CoV replication. A schematic overview of (factors involved in) the 
formation of COP-I coated vesicles is shown in Fig. 1. 
There is some controversy on the role of COP-I coated vesicles and other membrane 
structures in coronavirus replication. Using advanced EM analyses, our group has shown 
that the SARS-CoV-induced reticulovesicular network (RVN) is derived from and continu-
ous with the ER [30, 208, 295]. In contrast, other studies implicated either the autophagic 
pathway [32, 54] or EDEMosomes [55] as the primary membrane source. Earlier work by 
our laboratory [295] and others [364-366] already suggested that (the integrity of ) the 
early secretory pathway is important for efficient SARS-CoV replication, but its exact role 
remained unclear since conflicting results have been reported. Knoops et al. have previ-
ously shown that Brefeldin A (BFA) treatment inhibits SARS-CoV replication, but does 
not completely block viral RNA synthesis, as ~20% of the activity remains in BFA-treated 
cells, compared to untreated infected cells. Furthermore, the lack of colocalisation of 
SARS-CoV replicase subunits with COP-I vesicles argues against a direct association 
of coronavirus RTCs with these COP-I-coated vesicles [295]. Using MHV-infected cells, 
Verheije et al. showed that depletion of Arf1 and GBF1, thus blocking COP-I coated 
vesicle formation, and BFA treatment almost completely abolishes replication of this 
distantly related coronavirus. In line with the work of Knoops et al., co-localisation of 
MHV RTCs with COP-I vesicles was not observed [365]. Our data from the siRNA screen 































































































Fig. 1. (A) Model depicting bidirectional transport between the ER and Golgi compartments. After 
translation and folding of nascent secretory proteins, membrane cargo and soluble secretory cargo are 
exported from the ER in COPII-formed transport vesicles. ER-derived vesicles traffic in an anterograde direc-
tion to fuse with or to form pre-Golgi compartments. COP-I coats bud retrograde-directed vesicles from 
pre-Golgi and Golgi compartments to recycle vesicle components and retrieve resident proteins (R) that 
have escaped the ER. This rapid cycling process allows anterograde transport of secretory cargo, whereas 
resident proteins remain dynamically localised to early secretory compartments. Reprinted with permis-
sion from [423]. (B) Schematic overview of COP-I coated vesicle formation. Arf1-GDP binds to the cytoplas-
mic tails of p23/p24 hetero-oligomers (1), and is subsequently activated by the GDP/GTP exchange that is 
mediated by GBF1. This activation step can be blocked by BFA (2). Coatomer subsequently binds both the 
p24 oligomer and Arf-GTP. Cargo can be captured by the α/β’-COP subunits (3) and after coat polymerisa-
tion (4), a COP-I vesicle can pinch off the donor membrane (5,6). These vesicles uncoat due to hydrolysis of 







for SARS-CoV replication, since we observed an almost complete inhibition of SARS-CoV 
replication upon depletion of COP-I coatomer components (Chapter 5). 
COP-I-coated vesicles have also been implicated in the replication of many other 
RNA viruses, such as poliovirus [367, 368], other enteroviruses [353, 369-371], VSV [372], 
Drosophila C virus [373], and influenza A virus [344, 374] and components of the early 
secretory pathway have also  been identified in siRNA screens for many RNA viruses [338, 
344, 373, 374, 425]. These data suggest that the secretory pathway or its components are 
commonly used by RNA viruses. A variety of mechanisms regarding the role of the early 
secretory pathway have been suggested. For example, replication of the enterovirus 
EV11 appeared to depend on the association of COP-I with membranes [369]. On the 
contrary, Belov et al. showed that GBF1, BIG1/2 and Arf proteins, but not COP-I coatomer 
components, are recruited to Golgi membranes to enable RC formation [367, 368]. Hsu 
et al. reported similar observations since Arf1 and GBF1 recruit PI4KB to membranes on 
which RCs associate to cause a change in lipid composition. This change is favourable for 
the binding of other components of the RC complex [353].
To date, there is no data that suggests a direct link between COP-I vesicles and coro-
navirus RNA synthesis, which supports the idea that these vesicles do not contain the 
viral RTC but have an indirect – still to be determined – effect on coronavirus replication. 
COP-I vesicles might transport cargo needed for the formation or activity of viral RTCs, 
or the observed effects might merely be due to a general disruption of cellular endocytic 
transport or cellular homeostasis.
TARGETING CYCLOPHILINS TO BLOCK +RNA VIRUS REPLICATION
Cyclosporin A is a well-known immunosuppressive drug that binds to cellular cyclophil-
ins (Cyps), yielding a Cyp-CsA complex that can inhibit calcineurin. Inhibition of calci-
neurin prevents the dephosphorylation and translocation of nuclear factor of activated 
T cells (NF-AT) from the cytosol into the nucleus (Fig. 2), which prevents the transcription 
of immune genes, such as IL-2 (reviewed in [279, 280, 426]). A total of 17 Cyps have been 
identified thus far, of which nine are targeted by CsA. Cyps are also known as peptidyl–
prolyl isomerases (PPIases) and many of them have chaperone and foldase activities 
[279, 427] that facilitate protein folding. Cyps are involved in various signalling pathways 
(reviewed in [280]), and processes such as apoptosis [428] and RNA splicing [429, 430]. 
CsA has been reported to block the replication of a variety of RNA viruses, like hepa-
titis C virus [274, 299], HIV-1 [272, 432] and several others [271, 273, 275, 433]. In line 
with the inhibitory effect of CsA treatment, Cyps and in particular the cytosolic CypA 
and the ER-associated CypB have been concluded to be essential host components in 
the replicative cycle of many RNA viruses [271, 273, 303, 306, 307, 309, 311, 434, 435]. 
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The work presented in this thesis shows that CsA also is a potent inhibitor of arteri-
virus (Chapter 3) and coronavirus replication (Chapters 4 and 6). MERS-CoV-induced 
cytopathology was severely reduced upon treatment with 9 µM of CsA (Chapter 6 and 
unpublished observations), and SARS-CoV replication was completely blocked upon 
treatment with 16 µM of CsA (Chapter 4). Similar results were obtained for the arteri-
virus PPRSV (IC50 of 5.5 µM; complete block at 16 µM), and EAV replication appeared 
even five-fold more sensitive to CsA treatment (IC50 of 0.95 µM). Similar results were 
reported for feline coronavirus (FCoV)-induced cytopathology, which was blocked at 
25 µM CsA. Pfefferle et al. have demonstrated that low micromolar concentrations of 
CsA block the replication of multiple coronaviruses, including SARS-CoV and HCoV-229E 
[277]. Noteworthy, Cyp levels may differ between test systems and therefore it is dif-
ficult to compare the sensitivities of different nidoviruses to CsA. Despite the apparently 
nidovirus-wide inhibitory effect of CsA, the exact mechanism by which the drug blocks 
nidovirus replication remains unclear. For SARS-CoV, we could not identify which spe-
cific (if any) Cyp was involved in CsA-mediated inhibition of virus replication (Chapter 
4). This might be due to the fact that Cyp expression could not be sufficiently depleted 
with specific siRNAs (~25% remaining expression). The replication of SARS-CoV was not 
blocked by a non-immunosuppressive CsA analogue (De Wilde et al., unpublished data) 
suggesting that PPIase activity and/or direct interaction with replicase subunits might 
not be involved in the proviral effect of Cyps. Pfefferle et al. suggested that SARS-CoV 
nsp1 is an activator of the NF-AT signalling pathway that induces a broad and systemic 
dysregulation of cytokine expression [277]. Combined with our data, this would argue 
against a direct role for Cyps in SARS-CoV replication, but suggests that the NF-AT path-
way is somehow (indirectly) involved. This model is not supported by the data obtained 
for FCoV replication in the feline cell line fcwf-4. The authors suggested that FCoV 
does not depend on a functional NF-AT signalling pathway since FCoV replication was 
blocked at CsA or FK506 concentrations that did not affect signalling in these cells [278]. 
However, these results should be interpreted with caution. At first, concentrations that 
were shown to block FCoV-induced cytopathicity were not tested, and secondly, the au-
thors do not show whether or not FCoV infection activates NF-AT signalling. Therefore, 
it would be interesting to investigate whether FCoV induces NF-AT nuclear translocation 
and whether FCoV replication is sensitive to treatment with non-immunosuppressive 
CsA analogues. More importantly, the role of the NF-AT pathway in SARS-CoV replication 
should be further investigated.
In contrast to coronaviruses, replication of the arteriviruses EAV and PRRSV is inhibited 
by the non-immunosuppressive CsA analogue Debio-064 (Chapter 3). Like Debio-025, 
NIM811, and SCY635, this compound has a higher affinity for Cyps than CsA and lacks its 
undesired immunosuppressive side-effect, since NF-AT signalling is not affected by this 







considered a promising class of antiviral compounds, and their potency was explored in 
phase III clinical trials, in combination with pegylated IFN and Ribavirin [436]. The non-
immunosuppressive CsA analogues are not only interesting because of their therapeutic 
potential, they are also valuable research tools for studying the proviral mode of action 
of Cyps. These compounds allow us to discriminate between the direct involvement of 
Cyps in viral replication and indirect effects involving e.g. (dysregulation) of the NF-AT 
signalling pathway.  
Mainly based on data obtained for HCV, different mechanisms have been proposed 
to explain the role(s) of Cyps in the viral replicative cycle [437]. First of all, Cyps are com-
ponents of the HCV replication complex and are important for the proper folding of the 
HCV polymerase (NS5B) [308]. Kaul et al. have shown that the development of resistance 
against the Cyp inhibitor Debio-025 involves mutations in HCV NS5B that are close to the 
NS5A/NS5B cleavage site. These are thought to delay processing of the NS5A/NS5B junc-
Fig. 2. The NF-AT signalling pathway. The calcineurin catalytic subunit (A), when bound to the regulatory 
subunit (B) and calmodulin–Ca2+ complex, dephosphorylates NF-AT in the cytoplasm, leading to nuclear 
translocation of this transcription factor and the subsequent activation of gene transcription. CsA binds to 
Cyps, and FK506 to FK506-binding proteins (FKBPs) and these Cyp-CsA or FK506-FKBP complexes inhibits 
Calcineurin activity, to reduce NF-AT dephosphorylation. Reprinted with permission from [431].
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tion, thus extending the time during which the CypA binding site in NS5B is accessible 
[308]. As a result, lower amounts of CypA would suffice to mediate the proper folding of 
NS5B and its incorporation into replication complexes. Others have postulated that the 
CsA treatment of infected cells leads to the depletion of CypA from the RC and that this 
interferes with the formation of these complexes [307, 332]. Finally, it was hypothesised 
that binding of the viral polymerase to the enzymatic pocket of CypA is essential for RNA 
synthesis [306]. Although the exact mechanism remains to be elucidated, Chatterji et al. 
suggested that the isomerase activity of CypA might be essential for NS5B function and 
thus for HCV replication [306], since CypA mutants that lack the PPIase activity showed 
a reduced binding to NS5B and PPIase-defective CypA reduced HCV replication. This 
hypothesis is supported by recent studies demonstrating that CsA resistance is linked to 
mutations in NS5B that increase its affinity for viral RNA, thus rendering the enzyme less 
dependent on CypA [438]. 
Chapter 4 describes that depletion of CypA affects EAV replication and that CypA 
cosediments with the membrane-associated viral RTCs. Furthermore, CsA treatment 
was able to prevent the cosedimentation of CypA and EAV RTCs. Although we were un-
able to show a direct interaction between CypA and any of the EAV nsps (unpublished 
observations), this suggests that the mechanism by which CypA associates with the 
viral RTC is sensitive to CsA. In addition, CsA completely blocked EAV RNA synthesis in 
vitro, presumably by targeting the functional association of CypA with preformed RTCs. 
Therefore, in the most likely model CypA is somehow directly involved in arterivirus RNA 
synthesis, by interacting with one of the key components of the EAV RTC. In this context, 
viral the helicase (nsp10) is of particular interest since it plays a role in RNA synthesis 
and contains several predicted CypA binding domains (Chapter 3). Previously, for SARS-
CoV it has been shown that CypA interacts with the RNA-binding N protein [312]. In the 
case of EAV, it is unlikely that an interaction between CypA and N is crucial for viral RNA 
synthesis, since the N protein was found to be completely dispensable for both genome 
replication and sg mRNA synthesis [270]. 
The different sensitivities to the non-immunosuppressive CsA analogue Debio-064 
suggest that mechanistic differences exist between corona- and arteriviruses with re-
spect to the role of Cyps in their replication. EAV and PRRSV replication was inhibited by 
Debio-064, while SARS-CoV replication was not affected by this compound. This notion 
is further supported by the fact that CypA or CypB knockdown did not affect SARS-CoV 
replication, whereas EAV replication was reduced upon CypA depletion. In line with 
the results of Pfefferle et al. [277] and a recent study by Carbajo-Lozoya et al. [439], this 
suggests that the NF-AT pathway is relevant for SARS-CoV replication. In contrast, the 
Cyps themselves probably directly affect EAV replication. Analysis of mutations acquired 







the viral proteins involved in functional interactions with CypA and on the mechanistic 
details of their role in nidovirus replication. 
ANTIVIRAL RESEARCH ON CURRENT AND FUTURE EMERGING 
CORONAVIRUSES
Vaccination was the basis for some of the greatest successes in the history of medicine, 
including the eradication of smallpox, the near-eradication of polio, and the prevention 
of considerable morbidity and mortality caused by viral infections. Vaccine development 
currently is a slow process that is not equipped to combat outbreaks of rapidly emerging 
viruses (see above), although this may improve in the longer run, for example due better 
production platforms and vaccine engineering on the basis of viral reverse genetics. 
An alternative way to combat, or at least slow down, emerging infections is the use of 
antiviral compounds. Thus far, global research efforts to develop antiviral drugs  have 
resulted in treatments for only a handful of human pathogens, i.e. herpesviruses (herpes 
simplex virus, varicella zoster virus, Epstein-Barr virus, cytomegalovirus), HIV-1, influenza 
virus and HCV, the only +RNA virus for which approved antiviral therapy  is available. 
Antiviral drugs can be divided in two main classes: direct-acting antivirals (DAA) and 
host-directed antivirals (HDA). DAAs directly target (the function of ) viral proteins, dur-
ing entry, replication or assembly of the virus. In general, due to their specificity, these 
compounds are very potent viral inhibitors, however the quick rise of viral resistance 
remains a major issue. Successful antiviral therapies are therefore commonly based on 
the use of a combination of antiviral drugs, in order to increase the barrier of resistance. 
To reduce this problem of resistance, the development of HDAs is current receiving more 
attention, especially for the treatment of HCV. Registered antiviral therapies for HCV are 
based on targeting the viral protease with Telaprevir or Boceprevir, in combination with 
stimulation of the antiviral response by treatment with IFNs and using the nucleoside 
analogue Ribavirin [440-442]. This treatment accomplishes a sustained viral response, 
which means no detectable virus in the blood for six months after the end of treat-
ment, in up to 75%-85% of the cases [443]. This example illustrates the high potential 
of combined treatment with DAAs (nucleosides and/or protease inhibitors) and HDAs 
(IFN). However, adverse effects are common during the current anti-HCV therapy, with 
half of the patients exhibiting flu-like symptoms and a third experiencing emotional 
problems. These adverse effects are mainly attributed to the use of IFN. For HCV treat-
ment, the effect of Cyp inhibitors, in combination with Ribavirin and pegylated IFN, is 
currently being explored in phase III clinical trials [436, 444], although these have been 
(temporarily) put on hold by the FDA due to safety concerns since a patient died from 
pancreas failure. 
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As discussed at the start of this chapter, vaccines that need to be developed at 
the start are not very suitable against outbreaks that only last for a few months, and 
a more promising approach is to develop treatments with (broad-spectrum) antiviral 
drugs. In the case of SARS-CoV infection, the gap of ~10 days between the onset of 
early symptoms and the peak of viral load provides a good window of opportunity for 
antiviral treatment [445]. A variety of coronavirus inhibitors has been identified in in vitro 
systems and in cell culture (for an overview, see Chapter 1). To evaluate the efficacy of 
these compounds in vivo and to study SARS-CoV pathogenesis, multiple animal models 
have been developed. Mouse-adapted SARS-CoV strain MA15 [446], transgenic mice 
expressing the human ACE2 receptor [447], and a SARS-CoV ferret model [190] have all 
been used to study SARS-CoV infection [399]. However, a well-tolerated and effective 
treatment of SARS-CoV infection is still not available [187]. It therefore remains very 
important to continue identifying and optimizing SARS-CoV inhibitors or preferentially 
pan-coronavirus inhibitors and to keep evaluating those in the available animal models. 
Since the start of the MERS outbreak in June 2012, the search for antivirals and the 
development of convenient animal models have been ongoing in many institutes. So 
far, virus replication was only observed in rhesus macaques [448] and the lack of (cost-
effective) small animal models hampers antiviral studies and is one of the reasons to 
evaluate already registered drugs for their potential to inhibit MERS-CoV [449]. These 
drugs have already been evaluated in clinical trials and have well-documented safety 
and pharmacokinetic profiles in patients. Therefore, using these drugs would greatly 
accelerate the development of antiviral therapy for MERS infections. We (Chapter 6) and 
others [395, 450-452] have reported that MERS-CoV replication was very sensitive to 
several FDA approved drugs. Especially IFN treatment strongly inhibited MERS infec-
tion, and MERS-CoV was up to 100 times more sensitive to type-I IFNs than SARS-CoV. In 
cell culture, MERS-CoV replication was inhibited by CsA (Chapter 6) and the registered 
drugs lopinavir and chloroquine (de Wilde et al, unpublished observations), which 
provides a promising starting point for the development of intervention strategies for 
MERS infections. These antivirals would be desperately needed if the MERS outbreak 
increases in magnitude and severity and could be a treatment option for other zoonotic 
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Ten gevolge van de Severe Acute Respiratory Syndrome-coronavirus (SARS-CoV) uitbraak 
in 2003 zijn wereldwijd ruim 8000 besmettingen en ongeveer 800 sterfgevallen geregis-
treerd. Er waren geen antivirale middelen of vaccins tegen SARS-CoV voorhanden en de 
uitbraak werd na 4 maanden uiteindelijk onder controle gebracht met behulp van tradi-
tionele maatregelen, zoals opsporing en quarantaine van patiënten, en controle van hun 
contacten. Tien jaar na de SARS-epidemie, in de zomer van 2012, dook in Saoedi-Arabië 
een onbekend coronavirus op: Middle East Respiratory Syndrome-coronavirus (MERS-
CoV). Tot september 2013 werden meer dan 100 besmettingen formeel vastgesteld en 
ongeveer de helft van deze patiënten is overleden. Hoewel er officieel relatief weinig 
gevallen geregistreerd zijn, wordt aangenomen dat mogelijk (tien)duizenden mensen 
(ongemerkt) besmet zijn met dit virus. De recente MERS-uitbraak maakt duidelijk dat 
er 10 jaar na de SARS-epidemie nog steeds geen specifieke behandelmethoden zijn 
voor patiënten die besmet zijn met dit soort coronavirussen. Voor de ontwikkeling van 
antivirale strategieën is het noodzakelijk om de virale levenscyclus beter te begrijpen 
om zo aangrijpingspunten te vinden voor gerichte antivirale therapie. 
Dit proefschrift verschaft meer inzicht in de vermenigvuldiging (replicatie) van nido-
virussen, de groep waartoe ook de coronavirussen MERS-CoV en SARS-CoV behoren. Het 
genetisch materiaal van nidovirussen bestaat net als voor veel andere belangrijke hu-
mane ziekteverwekkers (pathogenen) uit een zogenaamd positiefstrengig RNA (+RNA) 
genoom. Dit genoom kan na infectie direct door de gastheercel vertaald worden in virale 
eiwitten. Deze virale eiwitten (niet-structurele eiwitten; nsps) vormen de replicatie- en 
transcriptiecomplexen (RTCs) die vervolgens het virale genetisch materiaal kopiëren 
en zorgen dat de structurele eiwitten tot expressie komen. Samen met het virale RNA 
genoom vormen deze eiwitten nieuwe virusdeeltjes die omhuld zijn met een mem-
braan. Nidovirus RTCs  zijn, net als de replicatiecomplexen van andere +RNA virussen, 
geassocieerd met speciale, viraal geïnduceerde intracellulaire membraanstructuren. 
Het onderzoek beschreven in dit proefschrift is gedaan om meer inzicht te verkrijgen in 
nidovirus RTCs en het samenspel tussen nidovirussen en de gastheercel. In het bijzonder 
is gekeken naar de rol van  gastheerfactoren betrokken bij nidovirusreplicatie.
Voor dit onderzoek is in eerste instantie gebruik gemaakt van het paardenvirus 
Equine arteritis virus (EAV), een voor de mens ongevaarlijk maar goed gekarakteriseerd 
modelvirus. In hoofdstuk 2 wordt een methode beschreven voor het isoleren van ac-
tieve RTCs uit EAV-geïnfecteerde cellen. Met deze methode kan de RNA-synthetiserende 
activiteit van deze RTCs in vitro in detail bestudeerd worden. Het bleek dat diverse nsps 
geassocieerd zijn met cellulaire membranen. Een van deze nsps is het RNA-afhankelijke 
RNA polymerase (RdRp) dat het virale RNA kopieert. Deze membranen leken het com-
plex te beschermen en waren cruciaal voor virale RNA synthese. Bovendien bleek de 
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RNA synthese activiteit absoluut afhankelijk te zijn van een gastheereiwit met een 
massa van 60-70 kDa, dat opmerkelijk genoeg niet permanent geassocieerd is met de 
membraangebonden complexen. De identificatie van dit eiwit is gaande. 
Hoofdstuk 3 beschrijft het remmende effect van Cyclosporine A (CsA) op de replica-
tie van de arterivirussen EAV en het varkensvirus Porcine Reproductive and Respiratory 
Syndrome Virus. Behandeling van geïnfecteerde cellen met CsA blokkeert de aanmaak 
van virale eiwitten en ook de productie van nieuwe virusdeeltjes. De in hoofdstuk 2 be-
schreven in vitro methode werd gebruikt om aan te tonen dat CsA een direct effect heeft 
op de synthese van het EAV RNA. Van CsA is bekend dat het de activiteit remt van een 
specifieke groep van cellulaire eiwitten: de cyclophilins (Cyps). Het belang van enkele 
van deze Cyps, voornamelijk cyclophilin A (CypA) en CypB, is al eerder beschreven voor 
o.a. hepatitis C virus (HCV). Door gebruik te maken van een techniek (RNA interferentie) 
om het expressieniveau van specifieke eiwitten in de cel te verlagen, kon worden aange-
toond dat CypA belangrijk is voor EAV replicatie. Verder zijn er aanwijzingen gevonden 
dat dit eiwit aanwezig is in EAV replicatiecomplexen en daar mogelijk een essentiële 
rol speelt. CsA is een onderdrukker van het immuunsysteem en is daardoor niet direct 
geschikt als antiviraal middel. Er bestaan echter varianten van CsA die wel de activiteit 
van Cyps blokkeren maar het immuunsysteem niet onderdrukken. Verscheidene van 
deze moleculen zijn al in klinische studies geëvalueerd voor de behandeling van HCV 
infecties. Eén van deze niet-immuunsuppressieve CsA-varianten, Debio-064, remt de 
EAV infectie. Dit bevestigt de betrokkenheid van Cyps bij arterivirus replicatie en sug-
gereert dat deze klasse van middelen in de toekomst mogelijk ook ingezet kan worden 
als antivirale therapie tegen arterivirussen.
In hoofdstuk 4 wordt aangetoond dat ook de replicatie van SARS-CoV, humaan 
coronavirus 229E (HCoV-229E), en het modelcoronavirus muizenhepatitis virus (MHV) 
wordt geremd door CsA. Echter kon geen duidelijke betrokkenheid van één of meer 
specifieke Cyps bij de SARS-CoV replicatie worden vastgesteld, wat erop zou kunnen wij-
zen dat de remming van de replicatie van SARS-CoV en EAV door CsA op verschillende 
mechanismen gebaseerd is. Dit verklaart ook mogelijk het verschil in gevoeligheid van 
deze virussen voor deze gastheercelgerichte remmer.
Om inzicht te krijgen in de rol van gastheerfactoren in de virale levenscyclus zijn voor 
een aantal virussen zogenaamde siRNA screens uitgevoerd, waarbij op systematische 
wijze de hoeveelheid van een bepaald gastheereiwit in de cel wordt verminderd, waarna 
het effect daarvan op virusreplicatie wordt gemeten. Op deze manier kunnen zowel 
provirale factoren (nodig voor virusreplicatie) als antivirale factoren (die virusreplicatie 
remmen) worden geïdentificeerd. Hoofdstuk 5 beschrijft een dergelijke RNAi screen 
naar de rol van kinasen - eiwitten die vele cellulaire processen reguleren – in de SARS-
CoV levenscyclus. Van de ~800 onderzochte eiwitten bleken er 90 een antiviraal effect te 









het immuunsysteem. Verder werden 40 provirale factoren geïdentificeerd, waaronder 
enkele die betrokken (kunnen) zijn bij de virus-geïnduceerde membraanveranderingen. 
De rol van twee van de gevonden factoren – de antivirale factor PKR en de provirale factor 
COPB2 - is vervolgens in meer detail bestudeerd. PKR is eerder beschreven als antivirale 
factor voor andere virussen, en depletie van dit eiwit bleek inderdaad een stimulerend 
effect op SARS-CoV replicatie te hebben. COPB2 is een component van COPI-gecoate 
blaasjes die het transport vanuit het Golgi-complex regelen. Vermindering van COPB2 
expressie resulteerde in een vermindering van SARS-CoV eiwit- en virusproductie. Niet 
alleen COPB2, maar ook andere componenten die betrokken zijn bij de vorming van 
de COPI-gecoate blaasjes, zoals COPB1 en GBF1, bleken een proviraal effect te hebben. 
Deze resultaten wijzen erop dat de vorming en/of aanwezigheid van deze blaasjes es-
sentieel is voor efficiënte SARS-CoV replicatie. De resultaten van de RNAi experimenten 
vormen een goede basis voor het onderzoeken van de rol van gastheerfactoren in de 
SARS-CoV replicatie.
In hoofdstuk 6 wordt inzicht verschaft in MERS-CoV replicatie. Verschillende cellen, 
waaronder Vero, VeroE6, Huh7 en Calu3 cellen, bleken met dit virus geïnfecteerd te kun-
nen worden. Met behulp van elektronenmicroscopie konden in MERS-CoV-geïnfecteerde 
Vero cellen blaasjes met een dubbel membraan (double-membrane vesicles; DMVs) en 
“in elkaar gedraaide” membranen (convoluted membranes; CM) worden waargenomen. 
Deze structuren zijn typerend voor coronavirusgeïnfecteerde cellen. In dezelfde studie 
wordt aangetoond dat MERS-CoV snelle celdood induceert in Vero en Huh7 cellen. Dit 
fenomeen is gebruikt om een methode te ontwikkelen voor de identificatie van anti-
virale middelen, waarin het remmen van MERS-CoV-geïnduceerde celdood door deze 
middelen kwantitatief kan worden bepaald. CsA is gebruikt als “proof-of-principle” anti-
viraal middel en bleek inderdaad MERS-CoV te remmen bij vergelijkbare concentraties 
als gevonden voor SARS-CoV. Verder bleek interferon-α een potente remmer van MERS-
CoV-geïnduceerde celdood en virus productie. Interessant is dat MERS-CoV ongeveer 
50-100 keer gevoeliger is voor interferon-α behandeling dan SARS-CoV. Een mogelijke 
(deel)verklaring voor dit verschil is dat MERS-CoV geen homoloog van het SARS-CoV 
ORF6 eiwit heeft, zodat dit virus de immuunrespons van de gastheer mogelijk minder 
efficiënt onderdrukt. Deze bevindingen bieden mogelijk een aangrijpingspunt voor de 
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